id	sid	tid	token	lemma	pos
dpc-4050	1	1	dermatology	dermatology	NOUN
dpc-4050	1	2	:	:	PUNCT
dpc-4050	1	3	practical	practical	ADJ
dpc-4050	1	4	and	and	CCONJ
dpc-4050	1	5	conceptual	conceptual	ADJ
dpc-4050	1	6	original	original	ADJ
dpc-4050	1	7	article	article	NOUN
dpc-4050	1	8	|	|	ADV
dpc-4050	1	9	dermatol	dermatol	ADJ
dpc-4050	1	10	pract	pract	NOUN
dpc-4050	1	11	concept	concept	NOUN
dpc-4050	1	12	.	.	PUNCT
dpc-4050	2	1	2024;14(3):e2024166	2024;14(3):e2024166	NUM
dpc-4050	2	2	1	1	NUM
dpc-4050	2	3	effectiveness	effectiveness	NOUN
dpc-4050	2	4	of	of	ADP
dpc-4050	2	5	ixekizumab	ixekizumab	NOUN
dpc-4050	2	6	in	in	ADP
dpc-4050	2	7	elderly	elderly	ADJ
dpc-4050	2	8	patients	patient	NOUN
dpc-4050	2	9	for	for	ADP
dpc-4050	2	10	the	the	DET
dpc-4050	2	11	treatment	treatment	NOUN
dpc-4050	2	12	of	of	ADP
dpc-4050	2	13	moderate	moderate	ADJ
dpc-4050	2	14	-	-	PUNCT
dpc-4050	2	15	to	to	ADP
dpc-4050	2	16	-	-	PUNCT
dpc-4050	2	17	severe	severe	ADJ
dpc-4050	2	18	psoriasis	psoriasis	NOUN
dpc-4050	2	19	:	:	PUNCT
dpc-4050	2	20	results	result	VERB
dpc-4050	2	21	from	from	ADP
dpc-4050	2	22	a	a	DET
dpc-4050	2	23	multicenter	multicenter	NOUN
dpc-4050	2	24	,	,	PUNCT
dpc-4050	2	25	retrospective	retrospective	ADJ
dpc-4050	2	26	real	real	ADJ
dpc-4050	2	27	-	-	PUNCT
dpc-4050	2	28	life	life	NOUN
dpc-4050	2	29	study	study	NOUN
dpc-4050	2	30	in	in	ADP
dpc-4050	2	31	the	the	DET
dpc-4050	2	32	lazio	lazio	PROPN
dpc-4050	2	33	region	region	PROPN
dpc-4050	2	34	annunziata	annunziata	VERB
dpc-4050	2	35	dattola1	dattola1	PROPN
dpc-4050	2	36	,	,	PUNCT
dpc-4050	2	37	nicoletta	nicoletta	PROPN
dpc-4050	2	38	bernardini2	bernardini2	PROPN
dpc-4050	2	39	,	,	PUNCT
dpc-4050	2	40	giacomo	giacomo	PROPN
dpc-4050	2	41	caldarola3,4	caldarola3,4	PROPN
dpc-4050	2	42	,	,	PUNCT
dpc-4050	2	43	rosa	rosa	PROPN
dpc-4050	2	44	coppola5	coppola5	PROPN
dpc-4050	2	45	,	,	PUNCT
dpc-4050	2	46	clara	clara	PROPN
dpc-4050	2	47	de	de	PROPN
dpc-4050	2	48	simone3,4	simone3,4	PROPN
dpc-4050	2	49	,	,	PUNCT
dpc-4050	2	50	domenico	domenico	PROPN
dpc-4050	2	51	giordano6	giordano6	PROPN
dpc-4050	2	52	,	,	PUNCT
dpc-4050	2	53	alessandro	alessandro	PROPN
dpc-4050	2	54	giunta7	giunta7	PROPN
dpc-4050	2	55	,	,	PUNCT
dpc-4050	2	56	gaia	gaia	PROPN
dpc-4050	2	57	moretta8	moretta8	PROPN
dpc-4050	2	58	,	,	PUNCT
dpc-4050	2	59	gianluca	gianluca	PROPN
dpc-4050	2	60	pagnanelli8	pagnanelli8	PROPN
dpc-4050	2	61	,	,	PUNCT
dpc-4050	2	62	vincenzo	vincenzo	PROPN
dpc-4050	2	63	panasiti4,8	panasiti4,8	PROPN
dpc-4050	2	64	,	,	PUNCT
dpc-4050	2	65	severino	severino	PROPN
dpc-4050	2	66	persechino6	persechino6	PROPN
dpc-4050	2	67	,	,	PUNCT
dpc-4050	2	68	concetta	concetta	PROPN
dpc-4050	2	69	potenza2	potenza2	PROPN
dpc-4050	2	70	,	,	PUNCT
dpc-4050	2	71	federica	federica	PROPN
dpc-4050	2	72	trovato1	trovato1	PROPN
dpc-4050	2	73	,	,	PUNCT
dpc-4050	2	74	arianna	arianna	PROPN
dpc-4050	2	75	zangrilli7	zangrilli7	PROPN
dpc-4050	2	76	,	,	PUNCT
dpc-4050	2	77	luca	luca	PROPN
dpc-4050	2	78	bianchi7	bianchi7	PROPN
dpc-4050	2	79	,	,	PUNCT
dpc-4050	2	80	giovanni	giovanni	PROPN
dpc-4050	2	81	pellacani1	pellacani1	NOUN
dpc-4050	2	82	,	,	PUNCT
dpc-4050	2	83	ketty	ketty	PROPN
dpc-4050	2	84	peris3,4	peris3,4	PROPN
dpc-4050	2	85	,	,	PUNCT
dpc-4050	2	86	antonio	antonio	PROPN
dpc-4050	2	87	giovanni	giovanni	PROPN
dpc-4050	2	88	richetta1	richetta1	PROPN
dpc-4050	2	89	1	1	NUM
dpc-4050	2	90	dermatology	dermatology	NOUN
dpc-4050	2	91	unit	unit	NOUN
dpc-4050	2	92	,	,	PUNCT
dpc-4050	2	93	department	department	NOUN
dpc-4050	2	94	of	of	ADP
dpc-4050	2	95	clinical	clinical	ADJ
dpc-4050	2	96	internal	internal	ADJ
dpc-4050	2	97	,	,	PUNCT
dpc-4050	2	98	anesthesiological	anesthesiological	ADJ
dpc-4050	2	99	and	and	CCONJ
dpc-4050	2	100	cardiovascular	cardiovascular	ADJ
dpc-4050	2	101	science	science	NOUN
dpc-4050	2	102	,	,	PUNCT
dpc-4050	2	103	university	university	NOUN
dpc-4050	2	104	of	of	ADP
dpc-4050	2	105	la	la	PROPN
dpc-4050	2	106	sapienza	sapienza	PROPN
dpc-4050	2	107	,	,	PUNCT
dpc-4050	2	108	rome	rome	PROPN
dpc-4050	2	109	,	,	PUNCT
dpc-4050	2	110	italy	italy	PROPN
dpc-4050	2	111	2	2	NUM
dpc-4050	2	112	department	department	NOUN
dpc-4050	2	113	of	of	ADP
dpc-4050	2	114	medico	medico	PROPN
dpc-4050	2	115	-	-	PUNCT
dpc-4050	2	116	surgical	surgical	ADJ
dpc-4050	2	117	sciences	science	NOUN
dpc-4050	2	118	and	and	CCONJ
dpc-4050	2	119	biotechnologies	biotechnology	NOUN
dpc-4050	2	120	,	,	PUNCT
dpc-4050	2	121	sapienza	sapienza	PROPN
dpc-4050	2	122	university	university	PROPN
dpc-4050	2	123	of	of	ADP
dpc-4050	2	124	rome	rome	PROPN
dpc-4050	2	125	polo	polo	PROPN
dpc-4050	2	126	pontino	pontino	PROPN
dpc-4050	2	127	,	,	PUNCT
dpc-4050	2	128	asl	asl	PROPN
dpc-4050	2	129	latina	latina	PROPN
dpc-4050	2	130	 	 	SPACE
dpc-4050	2	131	,	,	PUNCT
dpc-4050	2	132	latina	latina	PROPN
dpc-4050	2	133	,	,	PUNCT
dpc-4050	2	134	italy	italy	PROPN
dpc-4050	2	135	3	3	NUM
dpc-4050	2	136	section	section	NOUN
dpc-4050	2	137	of	of	ADP
dpc-4050	2	138	dermatology	dermatology	NOUN
dpc-4050	2	139	,	,	PUNCT
dpc-4050	2	140	department	department	NOUN
dpc-4050	2	141	of	of	ADP
dpc-4050	2	142	translational	translational	ADJ
dpc-4050	2	143	medicine	medicine	NOUN
dpc-4050	2	144	and	and	CCONJ
dpc-4050	2	145	surgery	surgery	NOUN
dpc-4050	2	146	,	,	PUNCT
dpc-4050	2	147	catholic	catholic	PROPN
dpc-4050	2	148	university	university	PROPN
dpc-4050	2	149	of	of	ADP
dpc-4050	2	150	the	the	DET
dpc-4050	2	151	s.	s.	PROPN
dpc-4050	2	152	heart	heart	PROPN
dpc-4050	2	153	;	;	PUNCT
dpc-4050	2	154	rome	rome	PROPN
dpc-4050	2	155	,	,	PUNCT
dpc-4050	2	156	italy	italy	PROPN
dpc-4050	2	157	4	4	NUM
dpc-4050	2	158	dermatology	dermatology	NOUN
dpc-4050	2	159	unit	unit	NOUN
dpc-4050	2	160	,	,	PUNCT
dpc-4050	2	161	policlinico	policlinico	PROPN
dpc-4050	2	162	a.	a.	NOUN
dpc-4050	2	163	gemelli	gemelli	PROPN
dpc-4050	2	164	,	,	PUNCT
dpc-4050	2	165	irccs	irccs	PROPN
dpc-4050	2	166	,	,	PUNCT
dpc-4050	2	167	rome	rome	PROPN
dpc-4050	2	168	,	,	PUNCT
dpc-4050	2	169	italy	italy	PROPN
dpc-4050	2	170	5	5	NUM
dpc-4050	2	171	fondazione	fondazione	NOUN
dpc-4050	2	172	policlinico	policlinico	PROPN
dpc-4050	2	173	universitario	universitario	PROPN
dpc-4050	2	174	campus	campus	PROPN
dpc-4050	2	175	bio	bio	PROPN
dpc-4050	2	176	medico	medico	PROPN
dpc-4050	2	177	,	,	PUNCT
dpc-4050	2	178	rome	rome	PROPN
dpc-4050	2	179	,	,	PUNCT
dpc-4050	2	180	italy	italy	PROPN
dpc-4050	2	181	6	6	NUM
dpc-4050	2	182	department	department	NOUN
dpc-4050	2	183	of	of	ADP
dpc-4050	2	184	neurosciences	neuroscience	NOUN
dpc-4050	2	185	,	,	PUNCT
dpc-4050	2	186	mental	mental	ADJ
dpc-4050	2	187	health	health	NOUN
dpc-4050	2	188	and	and	CCONJ
dpc-4050	2	189	sensory	sensory	ADJ
dpc-4050	2	190	organs	organ	NOUN
dpc-4050	2	191	,	,	PUNCT
dpc-4050	2	192	“	"	PUNCT
dpc-4050	2	193	sapienza	sapienza	ADJ
dpc-4050	2	194	”	"	PUNCT
dpc-4050	2	195	university	university	PROPN
dpc-4050	2	196	of	of	ADP
dpc-4050	2	197	rome	rome	PROPN
dpc-4050	2	198	,	,	PUNCT
dpc-4050	2	199	rome	rome	PROPN
dpc-4050	2	200	,	,	PUNCT
dpc-4050	2	201	italy	italy	PROPN
dpc-4050	2	202	7	7	NUM
dpc-4050	2	203	dermatology	dermatology	NOUN
dpc-4050	2	204	unit	unit	NOUN
dpc-4050	2	205	,	,	PUNCT
dpc-4050	2	206	university	university	PROPN
dpc-4050	2	207	of	of	ADP
dpc-4050	2	208	rome	rome	PROPN
dpc-4050	2	209	“	"	PUNCT
dpc-4050	2	210	tor	tor	PROPN
dpc-4050	2	211	vergata	vergata	NOUN
dpc-4050	2	212	”	"	PUNCT
dpc-4050	2	213	,	,	PUNCT
dpc-4050	2	214	rome	rome	PROPN
dpc-4050	2	215	,	,	PUNCT
dpc-4050	2	216	italy	italy	PROPN
dpc-4050	2	217	8	8	NUM
dpc-4050	2	218	department	department	PROPN
dpc-4050	2	219	of	of	ADP
dpc-4050	2	220	dermatology	dermatology	NOUN
dpc-4050	2	221	,	,	PUNCT
dpc-4050	2	222	istituto	istituto	X
dpc-4050	2	223	dermopatico	dermopatico	PROPN
dpc-4050	2	224	dell’immacolata	dell’immacolata	PROPN
dpc-4050	2	225	idi	idi	PROPN
dpc-4050	2	226	irccs	irccs	PROPN
dpc-4050	2	227	,	,	PUNCT
dpc-4050	2	228	rome	rome	PROPN
dpc-4050	2	229	,	,	PUNCT
dpc-4050	2	230	italy	italy	PROPN
dpc-4050	2	231	key	key	ADJ
dpc-4050	2	232	words	word	NOUN
dpc-4050	2	233	:	:	PUNCT
dpc-4050	2	234	psoriasis	psoriasis	NOUN
dpc-4050	2	235	,	,	PUNCT
dpc-4050	2	236	interleukin-17	interleukin-17	NOUN
dpc-4050	2	237	,	,	PUNCT
dpc-4050	2	238	ixekizumab	ixekizumab	NOUN
dpc-4050	2	239	,	,	PUNCT
dpc-4050	2	240	real	real	ADJ
dpc-4050	2	241	-	-	PUNCT
dpc-4050	2	242	life	life	NOUN
dpc-4050	2	243	,	,	PUNCT
dpc-4050	2	244	elderly	elderly	ADJ
dpc-4050	2	245	citation	citation	NOUN
dpc-4050	2	246	:	:	PUNCT
dpc-4050	2	247	dattola	dattola	PROPN
dpc-4050	2	248	a	a	PRON
dpc-4050	2	249	,	,	PUNCT
dpc-4050	2	250	bernardini	bernardini	PROPN
dpc-4050	2	251	n	n	CCONJ
dpc-4050	2	252	,	,	PUNCT
dpc-4050	2	253	caldarola	caldarola	PROPN
dpc-4050	2	254	g	g	PROPN
dpc-4050	2	255	,	,	PUNCT
dpc-4050	2	256	et	et	PROPN
dpc-4050	2	257	al	al	PROPN
dpc-4050	2	258	.	.	PROPN
dpc-4050	3	1	effectiveness	effectiveness	NOUN
dpc-4050	3	2	of	of	ADP
dpc-4050	3	3	ixekizumab	ixekizumab	NOUN
dpc-4050	3	4	in	in	ADP
dpc-4050	3	5	elderly	elderly	ADJ
dpc-4050	3	6	patients	patient	NOUN
dpc-4050	3	7	for	for	ADP
dpc-4050	3	8	the	the	DET
dpc-4050	3	9	treatment	treatment	NOUN
dpc-4050	3	10	of	of	ADP
dpc-4050	3	11	moderateto	moderateto	NOUN
dpc-4050	3	12	-	-	PUNCT
dpc-4050	3	13	severe	severe	ADJ
dpc-4050	3	14	psoriasis	psoriasis	NOUN
dpc-4050	3	15	:	:	PUNCT
dpc-4050	3	16	results	result	VERB
dpc-4050	3	17	from	from	ADP
dpc-4050	3	18	a	a	DET
dpc-4050	3	19	multicenter	multicenter	NOUN
dpc-4050	3	20	,	,	PUNCT
dpc-4050	3	21	retrospective	retrospective	ADJ
dpc-4050	3	22	real	real	ADJ
dpc-4050	3	23	-	-	PUNCT
dpc-4050	3	24	life	life	NOUN
dpc-4050	3	25	study	study	NOUN
dpc-4050	3	26	in	in	ADP
dpc-4050	3	27	the	the	DET
dpc-4050	3	28	lazio	lazio	PROPN
dpc-4050	3	29	region	region	NOUN
dpc-4050	3	30	.	.	PUNCT
dpc-4050	4	1	dermatol	dermatol	NOUN
dpc-4050	4	2	pract	pract	PROPN
dpc-4050	4	3	concept	concept	NOUN
dpc-4050	4	4	.	.	PUNCT
dpc-4050	5	1	2024;14(3):e2024166	2024;14(3):e2024166	NUM
dpc-4050	5	2	.	.	PUNCT
dpc-4050	5	3	doi	doi	NOUN
dpc-4050	5	4	:	:	PUNCT
dpc-4050	5	5	https://doi.org/10.5826/dpc.1403a166	https://doi.org/10.5826/dpc.1403a166	PROPN
dpc-4050	5	6	accepted	accept	VERB
dpc-4050	5	7	:	:	PUNCT
dpc-4050	5	8	march	march	PROPN
dpc-4050	5	9	14	14	NUM
dpc-4050	5	10	,	,	PUNCT
dpc-4050	5	11	2024	2024	NUM
dpc-4050	5	12	;	;	PUNCT
dpc-4050	5	13	published	publish	VERB
dpc-4050	5	14	:	:	PUNCT
dpc-4050	6	1	july	july	PROPN
dpc-4050	6	2	2024	2024	NUM
dpc-4050	6	3	copyright	copyright	NOUN
dpc-4050	6	4	:	:	PUNCT
dpc-4050	6	5	©	©	PROPN
dpc-4050	6	6	2024	2024	NUM
dpc-4050	6	7	dattola	dattola	PROPN
dpc-4050	6	8	et	et	PROPN
dpc-4050	6	9	al	al	PROPN
dpc-4050	6	10	.	.	PUNCT
dpc-4050	7	1	this	this	PRON
dpc-4050	7	2	is	be	AUX
dpc-4050	7	3	an	an	DET
dpc-4050	7	4	open	open	ADJ
dpc-4050	7	5	-	-	PUNCT
dpc-4050	7	6	access	access	NOUN
dpc-4050	7	7	article	article	NOUN
dpc-4050	7	8	distributed	distribute	VERB
dpc-4050	7	9	under	under	ADP
dpc-4050	7	10	the	the	DET
dpc-4050	7	11	terms	term	NOUN
dpc-4050	7	12	of	of	ADP
dpc-4050	7	13	the	the	DET
dpc-4050	7	14	creative	creative	ADJ
dpc-4050	7	15	commons	common	NOUN
dpc-4050	7	16	attributionnoncommercial	attributionnoncommercial	ADJ
dpc-4050	7	17	license	license	NOUN
dpc-4050	7	18	(	(	PUNCT
dpc-4050	7	19	by	by	ADP
dpc-4050	7	20	-	-	PUNCT
dpc-4050	7	21	nc-4.0	nc-4.0	NOUN
dpc-4050	7	22	)	)	PUNCT
dpc-4050	7	23	,	,	PUNCT
dpc-4050	7	24	https://creativecommons.org/licenses/by-nc/4.0/	https://creativecommons.org/licenses/by-nc/4.0/	PROPN
dpc-4050	7	25	,	,	PUNCT
dpc-4050	7	26	which	which	PRON
dpc-4050	7	27	permits	permit	VERB
dpc-4050	7	28	unrestricted	unrestricted	ADJ
dpc-4050	7	29	noncommercial	noncommercial	ADJ
dpc-4050	7	30	use	use	NOUN
dpc-4050	7	31	,	,	PUNCT
dpc-4050	7	32	distribution	distribution	NOUN
dpc-4050	7	33	,	,	PUNCT
dpc-4050	7	34	and	and	CCONJ
dpc-4050	7	35	reproduction	reproduction	NOUN
dpc-4050	7	36	in	in	ADP
dpc-4050	7	37	any	any	DET
dpc-4050	7	38	medium	medium	NOUN
dpc-4050	7	39	,	,	PUNCT
dpc-4050	7	40	provided	provide	VERB
dpc-4050	7	41	the	the	DET
dpc-4050	7	42	original	original	ADJ
dpc-4050	7	43	authors	author	NOUN
dpc-4050	7	44	and	and	CCONJ
dpc-4050	7	45	source	source	NOUN
dpc-4050	7	46	are	be	AUX
dpc-4050	7	47	credited	credit	VERB
dpc-4050	7	48	.	.	PUNCT
dpc-4050	8	1	funding	funding	NOUN
dpc-4050	8	2	:	:	PUNCT
dpc-4050	8	3	none	none	NOUN
dpc-4050	8	4	.	.	PUNCT
dpc-4050	9	1	competing	compete	VERB
dpc-4050	9	2	interests	interest	NOUN
dpc-4050	9	3	:	:	PUNCT
dpc-4050	9	4	ad	ad	NOUN
dpc-4050	9	5	:	:	PUNCT
dpc-4050	9	6	has	have	AUX
dpc-4050	9	7	served	serve	VERB
dpc-4050	9	8	as	as	ADP
dpc-4050	9	9	a	a	DET
dpc-4050	9	10	speaker	speaker	NOUN
dpc-4050	9	11	,	,	PUNCT
dpc-4050	9	12	consultant	consultant	NOUN
dpc-4050	9	13	or	or	CCONJ
dpc-4050	9	14	advisory	advisory	ADJ
dpc-4050	9	15	board	board	NOUN
dpc-4050	9	16	member	member	NOUN
dpc-4050	9	17	from	from	ADP
dpc-4050	9	18	abbvie	abbvie	PROPN
dpc-4050	9	19	,	,	PUNCT
dpc-4050	9	20	almirall	almirall	PROPN
dpc-4050	9	21	,	,	PUNCT
dpc-4050	9	22	amgen	amgen	PROPN
dpc-4050	9	23	,	,	PUNCT
dpc-4050	9	24	eli	eli	PROPN
dpc-4050	9	25	lilly	lilly	PROPN
dpc-4050	9	26	,	,	PUNCT
dpc-4050	9	27	leo	leo	PROPN
dpc-4050	9	28	pharma	pharma	PROPN
dpc-4050	9	29	,	,	PUNCT
dpc-4050	9	30	janssen	janssen	PROPN
dpc-4050	9	31	,	,	PUNCT
dpc-4050	9	32	novartis	novartis	PROPN
dpc-4050	9	33	,	,	PUNCT
dpc-4050	9	34	boehringer	boehringer	PROPN
dpc-4050	9	35	ingelheim	ingelheim	PROPN
dpc-4050	9	36	and	and	CCONJ
dpc-4050	9	37	ucb	ucb	PROPN
dpc-4050	9	38	pharma	pharma	PROPN
dpc-4050	9	39	.	.	PUNCT
dpc-4050	10	1	nb	nb	PROPN
dpc-4050	10	2	:	:	PUNCT
dpc-4050	10	3	served	serve	VERB
dpc-4050	10	4	as	as	ADP
dpc-4050	10	5	consultant	consultant	NOUN
dpc-4050	10	6	for	for	ADP
dpc-4050	10	7	amgen	amgen	PROPN
dpc-4050	10	8	,	,	PUNCT
dpc-4050	10	9	abbvie	abbvie	PROPN
dpc-4050	10	10	,	,	PUNCT
dpc-4050	10	11	janssen	janssen	PROPN
dpc-4050	10	12	,	,	PUNCT
dpc-4050	10	13	eli	eli	PROPN
dpc-4050	10	14	lilly	lilly	PROPN
dpc-4050	10	15	,	,	PUNCT
dpc-4050	10	16	leo	leo	PROPN
dpc-4050	10	17	-	-	PUNCT
dpc-4050	10	18	pharma	pharma	PROPN
dpc-4050	10	19	,	,	PUNCT
dpc-4050	10	20	novartis	novartis	PROPN
dpc-4050	10	21	,	,	PUNCT
dpc-4050	10	22	bristol	bristol	PROPN
dpc-4050	10	23	,	,	PUNCT
dpc-4050	10	24	sanofi	sanofi	PROPN
dpc-4050	10	25	,	,	PUNCT
dpc-4050	10	26	pfizer	pfizer	NOUN
dpc-4050	10	27	,	,	PUNCT
dpc-4050	10	28	pierre	pierre	PROPN
dpc-4050	10	29	fabre	fabre	PROPN
dpc-4050	10	30	,	,	PUNCT
dpc-4050	10	31	rilastil	rilastil	NOUN
dpc-4050	10	32	.	.	PUNCT
dpc-4050	11	1	gc	gc	PROPN
dpc-4050	11	2	:	:	PUNCT
dpc-4050	11	3	has	have	AUX
dpc-4050	11	4	served	serve	VERB
dpc-4050	11	5	as	as	ADP
dpc-4050	11	6	a	a	DET
dpc-4050	11	7	speaker	speaker	NOUN
dpc-4050	11	8	,	,	PUNCT
dpc-4050	11	9	consultant	consultant	NOUN
dpc-4050	11	10	or	or	CCONJ
dpc-4050	11	11	advisory	advisory	ADJ
dpc-4050	11	12	board	board	NOUN
dpc-4050	11	13	member	member	NOUN
dpc-4050	11	14	and	and	CCONJ
dpc-4050	11	15	has	have	AUX
dpc-4050	11	16	received	receive	VERB
dpc-4050	11	17	honoraria	honoraria	NOUN
dpc-4050	11	18	from	from	ADP
dpc-4050	11	19	abbvie	abbvie	NOUN
dpc-4050	11	20	,	,	PUNCT
dpc-4050	11	21	almirall	almirall	PROPN
dpc-4050	11	22	,	,	PUNCT
dpc-4050	11	23	amgen	amgen	PROPN
dpc-4050	11	24	,	,	PUNCT
dpc-4050	11	25	eli	eli	PROPN
dpc-4050	11	26	lilly	lilly	PROPN
dpc-4050	11	27	,	,	PUNCT
dpc-4050	11	28	leo	leo	PROPN
dpc-4050	11	29	pharma	pharma	PROPN
dpc-4050	11	30	,	,	PUNCT
dpc-4050	11	31	janssen	janssen	PROPN
dpc-4050	11	32	,	,	PUNCT
dpc-4050	11	33	novartis	novartis	PROPN
dpc-4050	11	34	,	,	PUNCT
dpc-4050	11	35	and	and	CCONJ
dpc-4050	11	36	ucb	ucb	PROPN
dpc-4050	11	37	pharma	pharma	PROPN
dpc-4050	11	38	.	.	PUNCT
dpc-4050	12	1	cds	cds	PROPN
dpc-4050	12	2	:	:	PUNCT
dpc-4050	12	3	has	have	AUX
dpc-4050	12	4	served	serve	VERB
dpc-4050	12	5	as	as	ADP
dpc-4050	12	6	a	a	DET
dpc-4050	12	7	speaker	speaker	NOUN
dpc-4050	12	8	,	,	PUNCT
dpc-4050	12	9	consultant	consultant	NOUN
dpc-4050	12	10	or	or	CCONJ
dpc-4050	12	11	advisory	advisory	ADJ
dpc-4050	12	12	board	board	NOUN
dpc-4050	12	13	member	member	NOUN
dpc-4050	12	14	and	and	CCONJ
dpc-4050	12	15	has	have	AUX
dpc-4050	12	16	received	receive	VERB
dpc-4050	12	17	honoraria	honoraria	NOUN
dpc-4050	12	18	from	from	ADP
dpc-4050	12	19	abbvie	abbvie	NOUN
dpc-4050	12	20	,	,	PUNCT
dpc-4050	12	21	almirall	almirall	PROPN
dpc-4050	12	22	,	,	PUNCT
dpc-4050	12	23	amgen	amgen	PROPN
dpc-4050	12	24	,	,	PUNCT
dpc-4050	12	25	eli	eli	PROPN
dpc-4050	12	26	lilly	lilly	PROPN
dpc-4050	12	27	,	,	PUNCT
dpc-4050	12	28	leo	leo	PROPN
dpc-4050	12	29	pharma	pharma	PROPN
dpc-4050	12	30	,	,	PUNCT
dpc-4050	12	31	janssen	janssen	PROPN
dpc-4050	12	32	,	,	PUNCT
dpc-4050	12	33	novartis	novartis	PROPN
dpc-4050	12	34	,	,	PUNCT
dpc-4050	12	35	and	and	CCONJ
dpc-4050	12	36	ucb	ucb	PROPN
dpc-4050	12	37	pharma	pharma	PROPN
dpc-4050	12	38	.	.	PUNCT
dpc-4050	13	1	gm	gm	PROPN
dpc-4050	13	2	consultant	consultant	NOUN
dpc-4050	13	3	for	for	ADP
dpc-4050	13	4	abbvie	abbvie	PROPN
dpc-4050	13	5	,	,	PUNCT
dpc-4050	13	6	leo	leo	PROPN
dpc-4050	13	7	pharma	pharma	PROPN
dpc-4050	13	8	,	,	PUNCT
dpc-4050	13	9	sanofi	sanofi	PROPN
dpc-4050	13	10	,	,	PUNCT
dpc-4050	13	11	ely	ely	NOUN
dpc-4050	13	12	-	-	PUNCT
dpc-4050	13	13	lilly	lilly	NOUN
dpc-4050	13	14	.	.	PUNCT
dpc-4050	14	1	dg	dg	PROPN
dpc-4050	14	2	:	:	PUNCT
dpc-4050	14	3	 	 	SPACE
dpc-4050	14	4	consultant	consultant	NOUN
dpc-4050	14	5	for	for	ADP
dpc-4050	14	6	abbvie	abbvie	PROPN
dpc-4050	14	7	,	,	PUNCT
dpc-4050	14	8	almirall	almirall	PROPN
dpc-4050	14	9	,	,	PUNCT
dpc-4050	14	10	amgen	amgen	PROPN
dpc-4050	14	11	,	,	PUNCT
dpc-4050	14	12	difa	difa	PROPN
dpc-4050	14	13	cooper	cooper	PROPN
dpc-4050	14	14	,	,	PUNCT
dpc-4050	14	15	eli	eli	PROPN
dpc-4050	14	16	lilly	lilly	PROPN
dpc-4050	14	17	,	,	PUNCT
dpc-4050	14	18	fresenius	fresenius	PROPN
dpc-4050	14	19	kabi	kabi	PROPN
dpc-4050	14	20	,	,	PUNCT
dpc-4050	14	21	janssen	janssen	PROPN
dpc-4050	14	22	-	-	PUNCT
dpc-4050	14	23	cileg	cileg	PROPN
dpc-4050	14	24	,	,	PUNCT
dpc-4050	14	25	novartis	novartis	PROPN
dpc-4050	14	26	,	,	PUNCT
dpc-4050	14	27	sanofi	sanofi	PROPN
dpc-4050	14	28	.	.	PUNCT
dpc-4050	15	1	sp	sp	ADP
dpc-4050	15	2	consultant	consultant	NOUN
dpc-4050	15	3	for	for	ADP
dpc-4050	15	4	abbvie	abbvie	PROPN
dpc-4050	15	5	,	,	PUNCT
dpc-4050	15	6	almirall	almirall	PROPN
dpc-4050	15	7	,	,	PUNCT
dpc-4050	15	8	eli	eli	PROPN
dpc-4050	15	9	lilly	lilly	PROPN
dpc-4050	15	10	,	,	PUNCT
dpc-4050	15	11	janssen	janssen	PROPN
dpc-4050	15	12	-	-	PUNCT
dpc-4050	15	13	cileg	cileg	PROPN
dpc-4050	15	14	,	,	PUNCT
dpc-4050	15	15	novartis	novartis	PROPN
dpc-4050	15	16	,	,	PUNCT
dpc-4050	15	17	sanofi	sanofi	PROPN
dpc-4050	15	18	.	.	PUNCT
dpc-4050	16	1	gp	gp	PROPN
dpc-4050	16	2	has	have	AUX
dpc-4050	16	3	served	serve	VERB
dpc-4050	16	4	as	as	ADP
dpc-4050	16	5	a	a	DET
dpc-4050	16	6	speaker	speaker	NOUN
dpc-4050	16	7	,	,	PUNCT
dpc-4050	16	8	consultant	consultant	NOUN
dpc-4050	16	9	or	or	CCONJ
dpc-4050	16	10	advisory	advisory	ADJ
dpc-4050	16	11	board	board	NOUN
dpc-4050	16	12	member	member	NOUN
dpc-4050	16	13	from	from	ADP
dpc-4050	16	14	abbvie	abbvie	PROPN
dpc-4050	16	15	,	,	PUNCT
dpc-4050	16	16	almirall	almirall	PROPN
dpc-4050	16	17	,	,	PUNCT
dpc-4050	16	18	amgen	amgen	PROPN
dpc-4050	16	19	,	,	PUNCT
dpc-4050	16	20	eli	eli	PROPN
dpc-4050	16	21	lilly	lilly	PROPN
dpc-4050	16	22	,	,	PUNCT
dpc-4050	16	23	leo	leo	PROPN
dpc-4050	16	24	pharma	pharma	PROPN
dpc-4050	16	25	,	,	PUNCT
dpc-4050	16	26	janssen	janssen	PROPN
dpc-4050	16	27	,	,	PUNCT
dpc-4050	16	28	novartis	novartis	PROPN
dpc-4050	16	29	,	,	PUNCT
dpc-4050	16	30	boehringer	boehringer	PROPN
dpc-4050	16	31	ingelheim	ingelheim	PROPN
dpc-4050	16	32	,	,	PUNCT
dpc-4050	16	33	loreàl	loreàl	PROPN
dpc-4050	16	34	,	,	PUNCT
dpc-4050	16	35	pierre	pierre	NOUN
dpc-4050	16	36	fabbre	fabbre	NOUN
dpc-4050	16	37	,	,	PUNCT
dpc-4050	16	38	eucerin	eucerin	NOUN
dpc-4050	16	39	and	and	CCONJ
dpc-4050	16	40	ucb	ucb	PROPN
dpc-4050	16	41	pharma	pharma	PROPN
dpc-4050	16	42	.	.	PUNCT
dpc-4050	17	1	all	all	DET
dpc-4050	17	2	other	other	ADJ
dpc-4050	17	3	authors	author	NOUN
dpc-4050	17	4	reports	report	VERB
dpc-4050	17	5	no	no	DET
dpc-4050	17	6	conflict	conflict	NOUN
dpc-4050	17	7	of	of	ADP
dpc-4050	17	8	interest	interest	NOUN
dpc-4050	17	9	.	.	PUNCT
dpc-4050	18	1	authorship	authorship	NOUN
dpc-4050	18	2	:	:	PUNCT
dpc-4050	18	3	all	all	DET
dpc-4050	18	4	authors	author	NOUN
dpc-4050	18	5	have	have	AUX
dpc-4050	18	6	contributed	contribute	VERB
dpc-4050	18	7	significantly	significantly	ADV
dpc-4050	18	8	to	to	ADP
dpc-4050	18	9	this	this	DET
dpc-4050	18	10	publication	publication	NOUN
dpc-4050	18	11	.	.	PUNCT
dpc-4050	19	1	corresponding	correspond	VERB
dpc-4050	19	2	author	author	NOUN
dpc-4050	19	3	:	:	PUNCT
dpc-4050	19	4	annunziata	annunziata	PROPN
dpc-4050	19	5	dattola	dattola	PROPN
dpc-4050	19	6	,	,	PUNCT
dpc-4050	19	7	md	md	PROPN
dpc-4050	19	8	,	,	PUNCT
dpc-4050	19	9	phd	phd	NOUN
dpc-4050	19	10	,	,	PUNCT
dpc-4050	19	11	dermatology	dermatology	NOUN
dpc-4050	19	12	clinic	clinic	NOUN
dpc-4050	19	13	,	,	PUNCT
dpc-4050	19	14	department	department	NOUN
dpc-4050	19	15	of	of	ADP
dpc-4050	19	16	clinical	clinical	ADJ
dpc-4050	19	17	internal	internal	ADJ
dpc-4050	19	18	,	,	PUNCT
dpc-4050	19	19	anesthesiological	anesthesiological	ADJ
dpc-4050	19	20	and	and	CCONJ
dpc-4050	19	21	cardiovascular	cardiovascular	ADJ
dpc-4050	19	22	sciences	science	NOUN
dpc-4050	19	23	,	,	PUNCT
dpc-4050	19	24	sapienza	sapienza	PROPN
dpc-4050	19	25	university	university	PROPN
dpc-4050	19	26	of	of	ADP
dpc-4050	19	27	rome	rome	PROPN
dpc-4050	19	28	,	,	PUNCT
dpc-4050	19	29	rome	rome	PROPN
dpc-4050	19	30	,	,	PUNCT
dpc-4050	19	31	italy	italy	PROPN
dpc-4050	19	32	.	.	PUNCT
dpc-4050	20	1	email	email	NOUN
dpc-4050	20	2	:	:	PUNCT
dpc-4050	21	1	nancydattola@gmail.com	nancydattola@gmail.com	X
dpc-4050	21	2	2	2	NUM
dpc-4050	21	3	original	original	ADJ
dpc-4050	21	4	article	article	NOUN
dpc-4050	21	5	|	|	ADV
dpc-4050	21	6	dermatol	dermatol	ADJ
dpc-4050	21	7	pract	pract	NOUN
dpc-4050	21	8	concept	concept	NOUN
dpc-4050	21	9	.	.	PUNCT
dpc-4050	22	1	2024;14(3):e2024166	2024;14(3):e2024166	NUM
dpc-4050	22	2	introduction	introduction	NOUN
dpc-4050	22	3	psoriasis	psoriasis	NOUN
dpc-4050	22	4	is	be	AUX
dpc-4050	22	5	a	a	DET
dpc-4050	22	6	chronic	chronic	ADJ
dpc-4050	22	7	inflammatory	inflammatory	ADJ
dpc-4050	22	8	dermatosis	dermatosis	NOUN
dpc-4050	22	9	with	with	ADP
dpc-4050	22	10	a	a	DET
dpc-4050	22	11	multifactorial	multifactorial	ADJ
dpc-4050	22	12	pathogenesis	pathogenesis	NOUN
dpc-4050	22	13	and	and	CCONJ
dpc-4050	22	14	a	a	DET
dpc-4050	22	15	relapsing	relapse	VERB
dpc-4050	22	16	trend	trend	NOUN
dpc-4050	22	17	[	[	X
dpc-4050	22	18	1	1	NUM
dpc-4050	22	19	]	]	PUNCT
dpc-4050	22	20	.	.	PUNCT
dpc-4050	23	1	it	it	PRON
dpc-4050	23	2	is	be	AUX
dpc-4050	23	3	currently	currently	ADV
dpc-4050	23	4	estimated	estimate	VERB
dpc-4050	23	5	that	that	SCONJ
dpc-4050	23	6	around	around	ADV
dpc-4050	23	7	120	120	NUM
dpc-4050	23	8	million	million	NUM
dpc-4050	23	9	individuals	individual	NOUN
dpc-4050	23	10	are	be	AUX
dpc-4050	23	11	affected	affect	VERB
dpc-4050	23	12	worldwide	worldwide	ADV
dpc-4050	23	13	,	,	PUNCT
dpc-4050	23	14	with	with	ADP
dpc-4050	23	15	a	a	DET
dpc-4050	23	16	prevalence	prevalence	NOUN
dpc-4050	23	17	around	around	ADP
dpc-4050	23	18	2%-3	2%-3	NUM
dpc-4050	23	19	%	%	NOUN
dpc-4050	23	20	of	of	ADP
dpc-4050	23	21	the	the	DET
dpc-4050	23	22	adult	adult	NOUN
dpc-4050	23	23	population	population	NOUN
dpc-4050	23	24	and	and	CCONJ
dpc-4050	23	25	0.5%-1	0.5%-1	NUM
dpc-4050	23	26	%	%	NOUN
dpc-4050	23	27	of	of	ADP
dpc-4050	23	28	children	child	NOUN
dpc-4050	23	29	.	.	PUNCT
dpc-4050	24	1	psoriasis	psoriasis	NOUN
dpc-4050	24	2	shows	show	VERB
dpc-4050	24	3	a	a	DET
dpc-4050	24	4	bi	bi	ADJ
dpc-4050	24	5	-	-	ADJ
dpc-4050	24	6	modal	modal	ADJ
dpc-4050	24	7	distribution	distribution	NOUN
dpc-4050	24	8	with	with	ADP
dpc-4050	24	9	a	a	DET
dpc-4050	24	10	main	main	ADJ
dpc-4050	24	11	onset	onset	NOUN
dpc-4050	24	12	peak	peak	NOUN
dpc-4050	24	13	around	around	ADV
dpc-4050	24	14	20	20	NUM
dpc-4050	24	15	-	-	SYM
dpc-4050	24	16	30	30	NUM
dpc-4050	24	17	years	year	NOUN
dpc-4050	24	18	and	and	CCONJ
dpc-4050	24	19	a	a	DET
dpc-4050	24	20	second	second	ADJ
dpc-4050	24	21	peak	peak	NOUN
dpc-4050	24	22	after	after	ADP
dpc-4050	24	23	50	50	NUM
dpc-4050	24	24	-	-	SYM
dpc-4050	24	25	60	60	NUM
dpc-4050	24	26	years	year	NOUN
dpc-4050	24	27	,	,	PUNCT
dpc-4050	24	28	with	with	ADP
dpc-4050	24	29	a	a	DET
dpc-4050	24	30	worse	bad	ADJ
dpc-4050	24	31	prognosis	prognosis	NOUN
dpc-4050	24	32	if	if	SCONJ
dpc-4050	24	33	the	the	DET
dpc-4050	24	34	onset	onset	NOUN
dpc-4050	24	35	occurs	occur	VERB
dpc-4050	24	36	at	at	ADP
dpc-4050	24	37	a	a	DET
dpc-4050	24	38	young	young	ADJ
dpc-4050	24	39	age	age	NOUN
dpc-4050	24	40	compared	compare	VERB
dpc-4050	24	41	to	to	ADP
dpc-4050	24	42	a	a	DET
dpc-4050	24	43	development	development	NOUN
dpc-4050	24	44	in	in	ADP
dpc-4050	24	45	adulthood	adulthood	NOUN
dpc-4050	25	1	[	[	X
dpc-4050	25	2	2	2	NUM
dpc-4050	25	3	]	]	PUNCT
dpc-4050	25	4	.	.	PUNCT
dpc-4050	26	1	skin	skin	NOUN
dpc-4050	26	2	lesions	lesion	NOUN
dpc-4050	26	3	and	and	CCONJ
dpc-4050	26	4	the	the	DET
dpc-4050	26	5	chronic	chronic	NOUN
dpc-4050	26	6	and	and	CCONJ
dpc-4050	26	7	relapsing	relapse	VERB
dpc-4050	26	8	course	course	NOUN
dpc-4050	26	9	of	of	ADP
dpc-4050	26	10	the	the	DET
dpc-4050	26	11	disease	disease	NOUN
dpc-4050	26	12	deeply	deeply	ADV
dpc-4050	26	13	and	and	CCONJ
dpc-4050	26	14	negatively	negatively	ADV
dpc-4050	26	15	undermine	undermine	VERB
dpc-4050	26	16	the	the	DET
dpc-4050	26	17	quality	quality	NOUN
dpc-4050	26	18	of	of	ADP
dpc-4050	26	19	life	life	NOUN
dpc-4050	26	20	of	of	ADP
dpc-4050	26	21	patients	patient	NOUN
dpc-4050	26	22	.	.	PUNCT
dpc-4050	27	1	furthermore	furthermore	ADV
dpc-4050	27	2	,	,	PUNCT
dpc-4050	27	3	these	these	DET
dpc-4050	27	4	patients	patient	NOUN
dpc-4050	27	5	have	have	VERB
dpc-4050	27	6	an	an	DET
dpc-4050	27	7	increased	increase	VERB
dpc-4050	27	8	risk	risk	NOUN
dpc-4050	27	9	of	of	ADP
dpc-4050	27	10	developing	develop	VERB
dpc-4050	27	11	other	other	ADJ
dpc-4050	27	12	serious	serious	ADJ
dpc-4050	27	13	comorbidities	comorbiditie	NOUN
dpc-4050	27	14	,	,	PUNCT
dpc-4050	27	15	such	such	ADJ
dpc-4050	27	16	as	as	ADP
dpc-4050	27	17	psoriatic	psoriatic	ADJ
dpc-4050	27	18	arthritis	arthritis	NOUN
dpc-4050	27	19	,	,	PUNCT
dpc-4050	27	20	metabolic	metabolic	NOUN
dpc-4050	27	21	syndrome	syndrome	NOUN
dpc-4050	27	22	,	,	PUNCT
dpc-4050	27	23	cardiovascular	cardiovascular	ADJ
dpc-4050	27	24	diseases	disease	NOUN
dpc-4050	27	25	,	,	PUNCT
dpc-4050	27	26	crohn	crohn	PROPN
dpc-4050	27	27	disease	disease	NOUN
dpc-4050	27	28	,	,	PUNCT
dpc-4050	27	29	psychiatric	psychiatric	ADJ
dpc-4050	27	30	disorders	disorder	NOUN
dpc-4050	27	31	,	,	PUNCT
dpc-4050	27	32	such	such	ADJ
dpc-4050	27	33	as	as	ADP
dpc-4050	27	34	anxiety	anxiety	NOUN
dpc-4050	27	35	and	and	CCONJ
dpc-4050	27	36	depression	depression	NOUN
dpc-4050	27	37	[	[	X
dpc-4050	27	38	3	3	NUM
dpc-4050	27	39	-	-	SYM
dpc-4050	27	40	5	5	NUM
dpc-4050	27	41	]	]	PUNCT
dpc-4050	27	42	.	.	PUNCT
dpc-4050	28	1	the	the	DET
dpc-4050	28	2	pathogenesis	pathogenesis	NOUN
dpc-4050	28	3	of	of	ADP
dpc-4050	28	4	psoriasis	psoriasis	NOUN
dpc-4050	28	5	involves	involve	VERB
dpc-4050	28	6	antimicrobial	antimicrobial	ADJ
dpc-4050	28	7	peptides	peptide	NOUN
dpc-4050	28	8	(	(	PUNCT
dpc-4050	28	9	amps	amp	NOUN
dpc-4050	28	10	)	)	PUNCT
dpc-4050	28	11	,	,	PUNCT
dpc-4050	28	12	dendritic	dendritic	ADJ
dpc-4050	28	13	cells	cell	NOUN
dpc-4050	28	14	(	(	PUNCT
dpc-4050	28	15	dcs	dcs	PROPN
dpc-4050	28	16	)	)	PUNCT
dpc-4050	28	17	,	,	PUNCT
dpc-4050	28	18	tumor	tumor	NOUN
dpc-4050	28	19	necrosis	necrosis	NOUN
dpc-4050	28	20	factor	factor	NOUN
dpc-4050	28	21	(	(	PUNCT
dpc-4050	28	22	tnf)α	tnf)α	PROPN
dpc-4050	28	23	,	,	PUNCT
dpc-4050	28	24	interleukin	interleukin	NOUN
dpc-4050	28	25	(	(	PUNCT
dpc-4050	28	26	il	il	PROPN
dpc-4050	28	27	)	)	PUNCT
dpc-4050	28	28	23	23	NUM
dpc-4050	28	29	,	,	PUNCT
dpc-4050	28	30	th17	th17	PROPN
dpc-4050	28	31	,	,	PUNCT
dpc-4050	28	32	il17	il17	PROPN
dpc-4050	28	33	,	,	PUNCT
dpc-4050	28	34	il22	il22	PROPN
dpc-4050	28	35	,	,	PUNCT
dpc-4050	28	36	and	and	CCONJ
dpc-4050	28	37	signal	signal	ADJ
dpc-4050	28	38	transducer	transducer	NOUN
dpc-4050	28	39	and	and	CCONJ
dpc-4050	28	40	activator	activator	NOUN
dpc-4050	28	41	of	of	ADP
dpc-4050	28	42	transcription	transcription	NOUN
dpc-4050	28	43	(	(	PUNCT
dpc-4050	28	44	stat)3	stat)3	NOUN
dpc-4050	28	45	.	.	PUNCT
dpc-4050	29	1	the	the	DET
dpc-4050	29	2	il-23	il-23	NOUN
dpc-4050	29	3	/	/	SYM
dpc-4050	29	4	th17	th17	NOUN
dpc-4050	29	5	immune	immune	ADJ
dpc-4050	29	6	axis	axis	NOUN
dpc-4050	29	7	is	be	AUX
dpc-4050	29	8	now	now	ADV
dpc-4050	29	9	thought	think	VERB
dpc-4050	29	10	to	to	PART
dpc-4050	29	11	be	be	AUX
dpc-4050	29	12	central	central	ADJ
dpc-4050	29	13	to	to	ADP
dpc-4050	29	14	the	the	DET
dpc-4050	29	15	pathogenesis	pathogenesis	NOUN
dpc-4050	29	16	of	of	ADP
dpc-4050	29	17	psoriasis	psoriasis	NOUN
dpc-4050	29	18	.	.	PUNCT
dpc-4050	30	1	the	the	DET
dpc-4050	30	2	main	main	ADJ
dpc-4050	30	3	cytokines	cytokine	NOUN
dpc-4050	30	4	involved	involve	VERB
dpc-4050	30	5	in	in	ADP
dpc-4050	30	6	psoriasis	psoriasis	NOUN
dpc-4050	30	7	pathogenesis	pathogenesis	NOUN
dpc-4050	30	8	,	,	PUNCT
dpc-4050	30	9	il-23	il-23	NOUN
dpc-4050	30	10	,	,	PUNCT
dpc-4050	30	11	tnf	tnf	PROPN
dpc-4050	30	12	and	and	CCONJ
dpc-4050	30	13	il-17	il-17	X
dpc-4050	30	14	,	,	PUNCT
dpc-4050	30	15	can	can	AUX
dpc-4050	30	16	be	be	AUX
dpc-4050	30	17	subdivided	subdivide	VERB
dpc-4050	30	18	into	into	ADP
dpc-4050	30	19	regulatory	regulatory	ADJ
dpc-4050	30	20	and	and	CCONJ
dpc-4050	30	21	effector	effector	NOUN
dpc-4050	30	22	cytokines	cytokine	NOUN
dpc-4050	30	23	based	base	VERB
dpc-4050	30	24	on	on	ADP
dpc-4050	30	25	their	their	PRON
dpc-4050	30	26	mode	mode	NOUN
dpc-4050	30	27	of	of	ADP
dpc-4050	30	28	action	action	NOUN
dpc-4050	30	29	.	.	PUNCT
dpc-4050	31	1	il-23	il-23	PUNCT
dpc-4050	31	2	exerts	exert	VERB
dpc-4050	31	3	regulatory	regulatory	ADJ
dpc-4050	31	4	effects	effect	NOUN
dpc-4050	31	5	on	on	ADP
dpc-4050	31	6	the	the	DET
dpc-4050	31	7	maintenance	maintenance	NOUN
dpc-4050	31	8	of	of	ADP
dpc-4050	31	9	th17	th17	NOUN
dpc-4050	31	10	cells	cell	NOUN
dpc-4050	31	11	,	,	PUNCT
dpc-4050	31	12	whereas	whereas	SCONJ
dpc-4050	31	13	il-17	il-17	ADV
dpc-4050	31	14	and	and	CCONJ
dpc-4050	31	15	tnf	tnf	PROPN
dpc-4050	31	16	mediate	mediate	PROPN
dpc-4050	31	17	effector	effector	NOUN
dpc-4050	31	18	functions	function	NOUN
dpc-4050	31	19	of	of	ADP
dpc-4050	31	20	innate	innate	ADJ
dpc-4050	31	21	(	(	PUNCT
dpc-4050	31	22	tnf	tnf	PROPN
dpc-4050	31	23	)	)	PUNCT
dpc-4050	31	24	and	and	CCONJ
dpc-4050	31	25	adaptive	adaptive	ADJ
dpc-4050	31	26	(	(	PUNCT
dpc-4050	31	27	tnf	tnf	PROPN
dpc-4050	31	28	,	,	PUNCT
dpc-4050	31	29	il-17	il-17	NUM
dpc-4050	31	30	)	)	PUNCT
dpc-4050	31	31	immune	immune	ADJ
dpc-4050	31	32	cells	cell	NOUN
dpc-4050	31	33	.	.	PUNCT
dpc-4050	32	1	il-23	il-23	NOUN
dpc-4050	32	2	was	be	AUX
dpc-4050	32	3	identified	identify	VERB
dpc-4050	32	4	in	in	ADP
dpc-4050	32	5	2000	2000	NUM
dpc-4050	32	6	as	as	ADP
dpc-4050	32	7	a	a	DET
dpc-4050	32	8	heterodimer	heterodimer	NOUN
dpc-4050	32	9	composed	compose	VERB
dpc-4050	32	10	of	of	ADP
dpc-4050	32	11	the	the	DET
dpc-4050	32	12	il-12/23p40	il-12/23p40	PROPN
dpc-4050	32	13	subunit	subunit	NOUN
dpc-4050	32	14	and	and	CCONJ
dpc-4050	32	15	a	a	DET
dpc-4050	32	16	newly	newly	ADV
dpc-4050	32	17	discovered	discover	VERB
dpc-4050	32	18	p19	p19	ADJ
dpc-4050	32	19	subunit	subunit	NOUN
dpc-4050	32	20	that	that	PRON
dpc-4050	32	21	is	be	AUX
dpc-4050	32	22	exclusive	exclusive	ADJ
dpc-4050	32	23	to	to	PART
dpc-4050	32	24	il-23	il-23	VERB
dpc-4050	32	25	[	[	X
dpc-4050	32	26	6	6	NUM
dpc-4050	32	27	]	]	PUNCT
dpc-4050	32	28	il-23	il-23	NOUN
dpc-4050	32	29	signals	signal	NOUN
dpc-4050	32	30	through	through	ADP
dpc-4050	32	31	a	a	DET
dpc-4050	32	32	heterodimeric	heterodimeric	ADJ
dpc-4050	32	33	receptor	receptor	NOUN
dpc-4050	32	34	complex	complex	NOUN
dpc-4050	32	35	composed	compose	VERB
dpc-4050	32	36	of	of	ADP
dpc-4050	32	37	two	two	NUM
dpc-4050	32	38	subunits	subunit	NOUN
dpc-4050	32	39	,	,	PUNCT
dpc-4050	32	40	il-23r	il-23r	NOUN
dpc-4050	32	41	and	and	CCONJ
dpc-4050	32	42	il-12rb1	il-12rb1	PROPN
dpc-4050	32	43	.	.	PUNCT
dpc-4050	33	1	this	this	DET
dpc-4050	33	2	complex	complex	NOUN
dpc-4050	33	3	predominantly	predominantly	ADV
dpc-4050	33	4	activates	activate	VERB
dpc-4050	33	5	signal	signal	NOUN
dpc-4050	33	6	transducer	transducer	NOUN
dpc-4050	33	7	and	and	CCONJ
dpc-4050	33	8	activator	activator	NOUN
dpc-4050	33	9	of	of	ADP
dpc-4050	33	10	transcription	transcription	NOUN
dpc-4050	33	11	3	3	NUM
dpc-4050	33	12	(	(	PUNCT
dpc-4050	33	13	stat3	stat3	NOUN
dpc-4050	33	14	)	)	PUNCT
dpc-4050	33	15	,	,	PUNCT
dpc-4050	33	16	leading	lead	VERB
dpc-4050	33	17	to	to	ADP
dpc-4050	33	18	il-23	il-23	NOUN
dpc-4050	33	19	–	–	PUNCT
dpc-4050	33	20	dependent	dependent	ADJ
dpc-4050	33	21	gene	gene	NOUN
dpc-4050	33	22	expression	expression	NOUN
dpc-4050	33	23	.	.	PUNCT
dpc-4050	34	1	il-23	il-23	NOUN
dpc-4050	34	2	is	be	AUX
dpc-4050	34	3	an	an	DET
dpc-4050	34	4	upstream	upstream	ADJ
dpc-4050	34	5	regulatory	regulatory	ADJ
dpc-4050	34	6	cytokine	cytokine	NOUN
dpc-4050	34	7	that	that	PRON
dpc-4050	34	8	acts	act	VERB
dpc-4050	34	9	early	early	ADV
dpc-4050	34	10	in	in	ADP
dpc-4050	34	11	the	the	DET
dpc-4050	34	12	inflammatory	inflammatory	ADJ
dpc-4050	34	13	cascade	cascade	NOUN
dpc-4050	34	14	in	in	ADP
dpc-4050	34	15	psoriasis	psoriasis	NOUN
dpc-4050	34	16	to	to	PART
dpc-4050	34	17	maintain	maintain	VERB
dpc-4050	34	18	the	the	DET
dpc-4050	34	19	th17	th17	PROPN
dpc-4050	34	20	cell	cell	NOUN
dpc-4050	34	21	phenotype	phenotype	NOUN
dpc-4050	34	22	and	and	CCONJ
dpc-4050	34	23	is	be	AUX
dpc-4050	34	24	critical	critical	ADJ
dpc-4050	34	25	in	in	ADP
dpc-4050	34	26	the	the	DET
dpc-4050	34	27	production	production	NOUN
dpc-4050	34	28	of	of	ADP
dpc-4050	34	29	downstream	downstream	ADJ
dpc-4050	34	30	effector	effector	NOUN
dpc-4050	34	31	cytokines	cytokine	NOUN
dpc-4050	34	32	,	,	PUNCT
dpc-4050	34	33	such	such	ADJ
dpc-4050	34	34	as	as	ADP
dpc-4050	34	35	il-17a	il-17a	PROPN
dpc-4050	34	36	,	,	PUNCT
dpc-4050	34	37	il-17f	il-17f	PROPN
dpc-4050	34	38	and	and	CCONJ
dpc-4050	34	39	tnf	tnf	PROPN
dpc-4050	34	40	.	.	PUNCT
dpc-4050	35	1	the	the	DET
dpc-4050	35	2	il-17	il-17	NUM
dpc-4050	35	3	cytokine	cytokine	ADJ
dpc-4050	35	4	family	family	NOUN
dpc-4050	35	5	consists	consist	VERB
dpc-4050	35	6	of	of	ADP
dpc-4050	35	7	six	six	NUM
dpc-4050	35	8	isoforms	isoform	NOUN
dpc-4050	35	9	termed	term	VERB
dpc-4050	35	10	il-17	il-17	ADP
dpc-4050	35	11	a	a	PRON
dpc-4050	35	12	–	–	PUNCT
dpc-4050	35	13	f.	f.	PROPN
dpc-4050	35	14	il-17a	il-17a	PROPN
dpc-4050	35	15	shows	show	VERB
dpc-4050	35	16	similarities	similarity	NOUN
dpc-4050	35	17	with	with	ADP
dpc-4050	35	18	il-17f	il-17f	NOUN
dpc-4050	35	19	and	and	CCONJ
dpc-4050	35	20	both	both	DET
dpc-4050	35	21	cytokines	cytokine	VERB
dpc-4050	35	22	bind	bind	VERB
dpc-4050	35	23	to	to	ADP
dpc-4050	35	24	the	the	DET
dpc-4050	35	25	same	same	ADJ
dpc-4050	35	26	receptor	receptor	NOUN
dpc-4050	35	27	il-17ra	il-17ra	PROPN
dpc-4050	35	28	.	.	PUNCT
dpc-4050	36	1	the	the	DET
dpc-4050	36	2	biologically	biologically	ADV
dpc-4050	36	3	active	active	ADJ
dpc-4050	36	4	form	form	NOUN
dpc-4050	36	5	of	of	ADP
dpc-4050	36	6	il-17a	il-17a	PROPN
dpc-4050	36	7	comprises	comprise	VERB
dpc-4050	36	8	either	either	CCONJ
dpc-4050	36	9	an	an	DET
dpc-4050	36	10	il-17a	il-17a	PROPN
dpc-4050	36	11	homodimer	homodimer	NOUN
dpc-4050	36	12	or	or	CCONJ
dpc-4050	36	13	an	an	DET
dpc-4050	36	14	il-17a	il-17a	PROPN
dpc-4050	36	15	-	-	PUNCT
dpc-4050	36	16	il-17f	il-17f	ADJ
dpc-4050	36	17	heterodimer	heterodimer	NOUN
dpc-4050	36	18	,	,	PUNCT
dpc-4050	36	19	although	although	SCONJ
dpc-4050	36	20	the	the	DET
dpc-4050	36	21	first	first	ADJ
dpc-4050	36	22	one	one	NOUN
dpc-4050	36	23	has	have	VERB
dpc-4050	36	24	greater	great	ADJ
dpc-4050	36	25	biological	biological	ADJ
dpc-4050	36	26	activity	activity	NOUN
dpc-4050	36	27	increased	increase	VERB
dpc-4050	36	28	expression	expression	NOUN
dpc-4050	36	29	of	of	ADP
dpc-4050	36	30	il-17a	il-17a	PROPN
dpc-4050	36	31	,	,	PUNCT
dpc-4050	36	32	e	e	PROPN
dpc-4050	36	33	and	and	CCONJ
dpc-4050	36	34	f	f	PROPN
dpc-4050	36	35	in	in	ADP
dpc-4050	36	36	psoriatic	psoriatic	ADJ
dpc-4050	36	37	lesions	lesion	NOUN
dpc-4050	36	38	has	have	AUX
dpc-4050	36	39	been	be	AUX
dpc-4050	36	40	described	describe	VERB
dpc-4050	36	41	[	[	PUNCT
dpc-4050	36	42	7	7	NUM
dpc-4050	36	43	]	]	X
dpc-4050	36	44	.	.	PUNCT
dpc-4050	37	1	th17	th17	NOUN
dpc-4050	37	2	(	(	PUNCT
dpc-4050	37	3	cd4	cd4	PROPN
dpc-4050	37	4	+	+	NOUN
dpc-4050	37	5	)	)	PUNCT
dpc-4050	37	6	cells	cell	NOUN
dpc-4050	37	7	are	be	AUX
dpc-4050	37	8	a	a	DET
dpc-4050	37	9	major	major	ADJ
dpc-4050	37	10	source	source	NOUN
dpc-4050	37	11	of	of	ADP
dpc-4050	37	12	il-17a	il-17a	PROPN
dpc-4050	37	13	,	,	PUNCT
dpc-4050	37	14	although	although	SCONJ
dpc-4050	37	15	this	this	DET
dpc-4050	37	16	cytokine	cytokine	NOUN
dpc-4050	37	17	can	can	AUX
dpc-4050	37	18	also	also	ADV
dpc-4050	37	19	be	be	AUX
dpc-4050	37	20	produced	produce	VERB
dpc-4050	37	21	by	by	ADP
dpc-4050	37	22	cd8	cd8	PROPN
dpc-4050	37	23	+	+	PROPN
dpc-4050	37	24	t	t	PROPN
dpc-4050	37	25	cells	cell	NOUN
dpc-4050	37	26	and	and	CCONJ
dpc-4050	37	27	cd	cd	PROPN
dpc-4050	37	28	t	t	PROPN
dpc-4050	37	29	cells	cell	NOUN
dpc-4050	37	30	,	,	PUNCT
dpc-4050	37	31	natural	natural	ADJ
dpc-4050	37	32	killer	killer	NOUN
dpc-4050	37	33	t	t	PROPN
dpc-4050	37	34	cells	cell	NOUN
dpc-4050	37	35	,	,	PUNCT
dpc-4050	37	36	mast	mast	NOUN
dpc-4050	37	37	cells	cell	NOUN
dpc-4050	37	38	and	and	CCONJ
dpc-4050	37	39	neutrophils	neutrophil	NOUN
dpc-4050	37	40	.	.	PUNCT
dpc-4050	38	1	il-17	il-17	X
dpc-4050	38	2	is	be	AUX
dpc-4050	38	3	an	an	DET
dpc-4050	38	4	effector	effector	NOUN
dpc-4050	38	5	cytokine	cytokine	NOUN
dpc-4050	38	6	downstream	downstream	ADV
dpc-4050	38	7	of	of	ADP
dpc-4050	38	8	il-23	il-23	NOUN
dpc-4050	38	9	that	that	PRON
dpc-4050	38	10	mediates	mediate	VERB
dpc-4050	38	11	psoriatic	psoriatic	ADJ
dpc-4050	38	12	inflammation	inflammation	NOUN
dpc-4050	38	13	.	.	PUNCT
dpc-4050	39	1	il-17	il-17	PROPN
dpc-4050	39	2	induces	induce	VERB
dpc-4050	39	3	il-17	il-17	AUX
dpc-4050	39	4	receptor	receptor	NOUN
dpc-4050	39	5	–	–	PUNCT
dpc-4050	39	6	dependent	dependent	ADJ
dpc-4050	39	7	proliferation	proliferation	NOUN
dpc-4050	39	8	of	of	ADP
dpc-4050	39	9	keratinocytes	keratinocyte	NOUN
dpc-4050	39	10	and	and	CCONJ
dpc-4050	39	11	production	production	NOUN
dpc-4050	39	12	of	of	ADP
dpc-4050	39	13	pro	pro	ADJ
dpc-4050	39	14	-	-	ADJ
dpc-4050	39	15	inflammatory	inflammatory	ADJ
dpc-4050	39	16	cytokines	cytokine	NOUN
dpc-4050	39	17	,	,	PUNCT
dpc-4050	39	18	including	include	VERB
dpc-4050	39	19	il-1b	il-1b	PROPN
dpc-4050	39	20	,	,	PUNCT
dpc-4050	39	21	il-6	il-6	NUM
dpc-4050	39	22	and	and	CCONJ
dpc-4050	39	23	tnf	tnf	PROPN
dpc-4050	39	24	,	,	PUNCT
dpc-4050	39	25	and	and	CCONJ
dpc-4050	39	26	antimicrobial	antimicrobial	ADJ
dpc-4050	39	27	peptides	peptide	NOUN
dpc-4050	39	28	,	,	PUNCT
dpc-4050	39	29	including	include	VERB
dpc-4050	39	30	b	b	NOUN
dpc-4050	39	31	-	-	PUNCT
dpc-4050	39	32	defensin	defensin	NOUN
dpc-4050	39	33	and	and	CCONJ
dpc-4050	39	34	matrix	matrix	NOUN
dpc-4050	39	35	metalloproteinase	metalloproteinase	NOUN
dpc-4050	39	36	9.82–85,87	9.82–85,87	NUM
dpc-4050	39	37	.	.	PUNCT
dpc-4050	40	1	blockade	blockade	NOUN
dpc-4050	40	2	of	of	ADP
dpc-4050	40	3	either	either	CCONJ
dpc-4050	40	4	il-17a	il-17a	PROPN
dpc-4050	40	5	or	or	CCONJ
dpc-4050	40	6	the	the	DET
dpc-4050	40	7	il-17	il-17	NUM
dpc-4050	40	8	receptor	receptor	NOUN
dpc-4050	40	9	has	have	AUX
dpc-4050	40	10	been	be	AUX
dpc-4050	40	11	shown	show	VERB
dpc-4050	40	12	to	to	PART
dpc-4050	40	13	be	be	AUX
dpc-4050	40	14	an	an	DET
dpc-4050	40	15	effective	effective	ADJ
dpc-4050	40	16	therapy	therapy	NOUN
dpc-4050	40	17	in	in	ADP
dpc-4050	40	18	plaque	plaque	NOUN
dpc-4050	40	19	psoriasis	psoriasis	NOUN
dpc-4050	40	20	[	[	X
dpc-4050	40	21	8	8	NUM
dpc-4050	40	22	]	]	PUNCT
dpc-4050	40	23	.	.	PUNCT
dpc-4050	41	1	anti	anti	ADJ
dpc-4050	41	2	-	-	ADJ
dpc-4050	41	3	il17	il17	ADJ
dpc-4050	41	4	biologics	biologic	NOUN
dpc-4050	41	5	drugs	drug	NOUN
dpc-4050	41	6	(	(	PUNCT
dpc-4050	41	7	including	include	VERB
dpc-4050	41	8	secukinumab	secukinumab	NOUN
dpc-4050	41	9	,	,	PUNCT
dpc-4050	41	10	ixekizumab	ixekizumab	NOUN
dpc-4050	41	11	,	,	PUNCT
dpc-4050	41	12	brodalumab	brodalumab	NOUN
dpc-4050	41	13	and	and	CCONJ
dpc-4050	41	14	bimekizumab	bimekizumab	NOUN
dpc-4050	41	15	)	)	PUNCT
dpc-4050	41	16	are	be	AUX
dpc-4050	41	17	effectice	effectice	NOUN
dpc-4050	41	18	in	in	ADP
dpc-4050	41	19	introduction	introduction	NOUN
dpc-4050	41	20	:	:	PUNCT
dpc-4050	41	21	this	this	PRON
dpc-4050	41	22	was	be	AUX
dpc-4050	41	23	an	an	DET
dpc-4050	41	24	observational	observational	ADJ
dpc-4050	41	25	,	,	PUNCT
dpc-4050	41	26	retrospective	retrospective	ADJ
dpc-4050	41	27	,	,	PUNCT
dpc-4050	41	28	multicenter	multicenter	ADJ
dpc-4050	41	29	study	study	NOUN
dpc-4050	41	30	,	,	PUNCT
dpc-4050	41	31	enrolling	enrol	VERB
dpc-4050	41	32	elderly	elderly	ADJ
dpc-4050	41	33	patients	patient	NOUN
dpc-4050	41	34	(	(	PUNCT
dpc-4050	41	35	>	>	SYM
dpc-4050	41	36	65	65	NUM
dpc-4050	41	37	years	year	NOUN
dpc-4050	41	38	old	old	ADJ
dpc-4050	41	39	)	)	PUNCT
dpc-4050	41	40	treated	treat	VERB
dpc-4050	41	41	with	with	ADP
dpc-4050	41	42	ixekizumab	ixekizumab	NOUN
dpc-4050	41	43	with	with	ADP
dpc-4050	41	44	a	a	DET
dpc-4050	41	45	diagnosis	diagnosis	NOUN
dpc-4050	41	46	of	of	ADP
dpc-4050	41	47	psoriasis	psoriasis	NOUN
dpc-4050	41	48	(	(	PUNCT
dpc-4050	41	49	pso	pso	NOUN
dpc-4050	41	50	)	)	PUNCT
dpc-4050	41	51	and/or	and/or	CCONJ
dpc-4050	41	52	psoriatic	psoriatic	ADJ
dpc-4050	41	53	arthritis	arthritis	NOUN
dpc-4050	41	54	(	(	PUNCT
dpc-4050	41	55	psa	psa	NOUN
dpc-4050	41	56	)	)	PUNCT
dpc-4050	41	57	during	during	ADP
dpc-4050	41	58	the	the	DET
dpc-4050	41	59	period	period	NOUN
dpc-4050	41	60	2020	2020	NUM
dpc-4050	41	61	to	to	ADP
dpc-4050	41	62	2023	2023	NUM
dpc-4050	41	63	.	.	PUNCT
dpc-4050	42	1	objectives	objective	NOUN
dpc-4050	42	2	:	:	PUNCT
dpc-4050	42	3	efficacy	efficacy	NOUN
dpc-4050	42	4	of	of	ADP
dpc-4050	42	5	ixekizumab	ixekizumab	NOUN
dpc-4050	42	6	in	in	ADP
dpc-4050	42	7	elderly	elderly	ADJ
dpc-4050	42	8	patients	patient	NOUN
dpc-4050	42	9	in	in	ADP
dpc-4050	42	10	the	the	DET
dpc-4050	42	11	treatment	treatment	NOUN
dpc-4050	42	12	of	of	ADP
dpc-4050	42	13	moderate	moderate	ADJ
dpc-4050	42	14	to	to	ADP
dpc-4050	42	15	severe	severe	ADJ
dpc-4050	42	16	psoriasis	psoriasis	NOUN
dpc-4050	42	17	.	.	PUNCT
dpc-4050	43	1	methods	method	NOUN
dpc-4050	43	2	:	:	PUNCT
dpc-4050	43	3	we	we	PRON
dpc-4050	43	4	included	include	VERB
dpc-4050	43	5	73	73	NUM
dpc-4050	43	6	patients	patient	NOUN
dpc-4050	43	7	with	with	ADP
dpc-4050	43	8	psoriasis	psoriasis	NOUN
dpc-4050	43	9	(	(	PUNCT
dpc-4050	43	10	32.9	32.9	NUM
dpc-4050	43	11	%	%	NOUN
dpc-4050	43	12	)	)	PUNCT
dpc-4050	43	13	,	,	PUNCT
dpc-4050	43	14	psoriatic	psoriatic	ADJ
dpc-4050	43	15	arthritis	arthritis	NOUN
dpc-4050	43	16	(	(	PUNCT
dpc-4050	43	17	1.4	1.4	NUM
dpc-4050	43	18	%	%	NOUN
dpc-4050	43	19	)	)	PUNCT
dpc-4050	43	20	and	and	CCONJ
dpc-4050	43	21	both	both	PRON
dpc-4050	43	22	of	of	ADP
dpc-4050	43	23	them	they	PRON
dpc-4050	43	24	(	(	PUNCT
dpc-4050	43	25	pso	pso	NOUN
dpc-4050	43	26	-	-	PUNCT
dpc-4050	43	27	psa	psa	NOUN
dpc-4050	43	28	65.8	65.8	NUM
dpc-4050	43	29	%	%	NOUN
dpc-4050	43	30	)	)	PUNCT
dpc-4050	43	31	,	,	PUNCT
dpc-4050	43	32	attending	attend	VERB
dpc-4050	43	33	the	the	DET
dpc-4050	43	34	outpatient	outpatient	NOUN
dpc-4050	43	35	clinics	clinic	NOUN
dpc-4050	43	36	of	of	ADP
dpc-4050	43	37	seven	seven	NUM
dpc-4050	43	38	italian	italian	ADJ
dpc-4050	43	39	referral	referral	ADJ
dpc-4050	43	40	center	center	NOUN
dpc-4050	43	41	for	for	ADP
dpc-4050	43	42	psoriasis	psoriasis	NOUN
dpc-4050	43	43	in	in	ADP
dpc-4050	43	44	lazio	lazio	PROPN
dpc-4050	43	45	region	region	NOUN
dpc-4050	43	46	:	:	PUNCT
dpc-4050	43	47	policlinico	policlinico	NOUN
dpc-4050	43	48	umberto	umberto	NOUN
dpc-4050	43	49	i	i	PRON
dpc-4050	43	50	università	università	PROPN
dpc-4050	43	51	roma	roma	PROPN
dpc-4050	43	52	la	la	PROPN
dpc-4050	43	53	sapienza	sapienza	PROPN
dpc-4050	43	54	,	,	PUNCT
dpc-4050	43	55	sant’andrea	sant’andrea	PROPN
dpc-4050	43	56	università	università	PROPN
dpc-4050	43	57	di	di	PROPN
dpc-4050	43	58	roma	roma	PROPN
dpc-4050	43	59	la	la	PROPN
dpc-4050	43	60	sapienza	sapienza	PROPN
dpc-4050	43	61	,	,	PUNCT
dpc-4050	43	62	polo	polo	NOUN
dpc-4050	43	63	pontino	pontino	PROPN
dpc-4050	43	64	università	università	PROPN
dpc-4050	43	65	roma	roma	PROPN
dpc-4050	43	66	la	la	PROPN
dpc-4050	43	67	sapienza	sapienza	PROPN
dpc-4050	43	68	,	,	PUNCT
dpc-4050	43	69	fondazione	fondazione	PROPN
dpc-4050	43	70	policlinico	policlinico	PROPN
dpc-4050	43	71	universitario	universitario	PROPN
dpc-4050	43	72	a.	a.	PROPN
dpc-4050	43	73	gemelli	gemelli	PROPN
dpc-4050	43	74	,	,	PUNCT
dpc-4050	43	75	università	università	PROPN
dpc-4050	43	76	campus	campus	NOUN
dpc-4050	43	77	biomedico	biomedico	PROPN
dpc-4050	43	78	roma	roma	PROPN
dpc-4050	43	79	,	,	PUNCT
dpc-4050	43	80	istituto	istituto	X
dpc-4050	43	81	dermopatico	dermopatico	NOUN
dpc-4050	43	82	dell’immacolata	dell’immacolata	NOUN
dpc-4050	43	83	–	–	PUNCT
dpc-4050	43	84	idi	idi	NOUN
dpc-4050	43	85	and	and	CCONJ
dpc-4050	43	86	policlinico	policlinico	NOUN
dpc-4050	43	87	tor	tor	NOUN
dpc-4050	43	88	vergata	vergata	NOUN
dpc-4050	43	89	.	.	PUNCT
dpc-4050	44	1	we	we	PRON
dpc-4050	44	2	collected	collect	VERB
dpc-4050	44	3	data	datum	NOUN
dpc-4050	44	4	related	relate	VERB
dpc-4050	44	5	to	to	ADP
dpc-4050	44	6	the	the	DET
dpc-4050	44	7	characteristics	characteristic	NOUN
dpc-4050	44	8	of	of	ADP
dpc-4050	44	9	the	the	DET
dpc-4050	44	10	patients	patient	NOUN
dpc-4050	44	11	(	(	PUNCT
dpc-4050	44	12	age	age	NOUN
dpc-4050	44	13	,	,	PUNCT
dpc-4050	44	14	sex	sex	NOUN
dpc-4050	44	15	,	,	PUNCT
dpc-4050	44	16	body	body	NOUN
dpc-4050	44	17	mass	mass	NOUN
dpc-4050	44	18	index	index	PROPN
dpc-4050	44	19	)	)	PUNCT
dpc-4050	44	20	and	and	CCONJ
dpc-4050	44	21	of	of	ADP
dpc-4050	44	22	the	the	DET
dpc-4050	44	23	disease	disease	NOUN
dpc-4050	44	24	(	(	PUNCT
dpc-4050	44	25	age	age	NOUN
dpc-4050	44	26	at	at	ADP
dpc-4050	44	27	onset	onset	NOUN
dpc-4050	44	28	,	,	PUNCT
dpc-4050	44	29	duration	duration	NOUN
dpc-4050	44	30	of	of	ADP
dpc-4050	44	31	psoriasis	psoriasis	NOUN
dpc-4050	44	32	,	,	PUNCT
dpc-4050	44	33	previous	previous	ADJ
dpc-4050	44	34	treatments	treatment	NOUN
dpc-4050	44	35	)	)	PUNCT
dpc-4050	44	36	.	.	PUNCT
dpc-4050	45	1	the	the	DET
dpc-4050	45	2	severity	severity	NOUN
dpc-4050	45	3	of	of	ADP
dpc-4050	45	4	psoriasis	psoriasis	NOUN
dpc-4050	45	5	was	be	AUX
dpc-4050	45	6	measured	measure	VERB
dpc-4050	45	7	with	with	ADP
dpc-4050	45	8	the	the	DET
dpc-4050	45	9	psoriasis	psoriasis	NOUN
dpc-4050	45	10	area	area	NOUN
dpc-4050	45	11	and	and	CCONJ
dpc-4050	45	12	severity	severity	NOUN
dpc-4050	45	13	index	index	NOUN
dpc-4050	45	14	(	(	PUNCT
dpc-4050	45	15	pasi	pasi	NOUN
dpc-4050	45	16	)	)	PUNCT
dpc-4050	45	17	score	score	NOUN
dpc-4050	45	18	at	at	ADP
dpc-4050	45	19	baseline	baseline	NOUN
dpc-4050	45	20	and	and	CCONJ
dpc-4050	45	21	after	after	ADP
dpc-4050	45	22	16	16	NUM
dpc-4050	45	23	,	,	PUNCT
dpc-4050	45	24	24	24	NUM
dpc-4050	45	25	,	,	PUNCT
dpc-4050	45	26	52	52	NUM
dpc-4050	45	27	,	,	PUNCT
dpc-4050	45	28	104	104	NUM
dpc-4050	45	29	and	and	CCONJ
dpc-4050	45	30	156	156	NUM
dpc-4050	45	31	weeks	week	NOUN
dpc-4050	45	32	of	of	ADP
dpc-4050	45	33	treatment	treatment	NOUN
dpc-4050	45	34	.	.	PUNCT
dpc-4050	46	1	results	result	NOUN
dpc-4050	46	2	:	:	PUNCT
dpc-4050	46	3	pasi90	pasi90	NOUN
dpc-4050	46	4	was	be	AUX
dpc-4050	46	5	achieved	achieve	VERB
dpc-4050	46	6	by	by	ADP
dpc-4050	46	7	all	all	DET
dpc-4050	46	8	the	the	DET
dpc-4050	46	9	patients	patient	NOUN
dpc-4050	46	10	in	in	ADP
dpc-4050	46	11	week	week	NOUN
dpc-4050	46	12	16	16	NUM
dpc-4050	46	13	and	and	CCONJ
dpc-4050	46	14	remained	remain	VERB
dpc-4050	46	15	stable	stable	ADJ
dpc-4050	46	16	until	until	ADP
dpc-4050	46	17	the	the	DET
dpc-4050	46	18	end	end	NOUN
dpc-4050	46	19	of	of	ADP
dpc-4050	46	20	the	the	DET
dpc-4050	46	21	study	study	NOUN
dpc-4050	46	22	.	.	PUNCT
dpc-4050	47	1	pasi100	pasi100	PROPN
dpc-4050	47	2	has	have	AUX
dpc-4050	47	3	been	be	AUX
dpc-4050	47	4	achieved	achieve	VERB
dpc-4050	47	5	by	by	ADP
dpc-4050	47	6	55.1	55.1	NUM
dpc-4050	47	7	%	%	NOUN
dpc-4050	47	8	of	of	ADP
dpc-4050	47	9	patients	patient	NOUN
dpc-4050	47	10	at	at	ADP
dpc-4050	47	11	weeks	week	NOUN
dpc-4050	47	12	16	16	NUM
dpc-4050	47	13	and	and	CCONJ
dpc-4050	47	14	by	by	ADP
dpc-4050	47	15	81.3	81.3	NUM
dpc-4050	47	16	%	%	NOUN
dpc-4050	47	17	at	at	ADP
dpc-4050	47	18	week	week	NOUN
dpc-4050	47	19	104	104	NUM
dpc-4050	47	20	.	.	PUNCT
dpc-4050	48	1	a	a	DET
dpc-4050	48	2	statistically	statistically	ADV
dpc-4050	48	3	significant	significant	ADJ
dpc-4050	48	4	difference	difference	NOUN
dpc-4050	48	5	has	have	AUX
dpc-4050	48	6	been	be	AUX
dpc-4050	48	7	showed	show	VERB
dpc-4050	48	8	between	between	ADP
dpc-4050	48	9	baseline	baseline	NOUN
dpc-4050	48	10	and	and	CCONJ
dpc-4050	48	11	all	all	DET
dpc-4050	48	12	the	the	DET
dpc-4050	48	13	other	other	ADJ
dpc-4050	48	14	time	time	NOUN
dpc-4050	48	15	points	point	NOUN
dpc-4050	48	16	(	(	PUNCT
dpc-4050	48	17	p	p	X
dpc-4050	48	18	<	<	X
dpc-4050	48	19	0.0001	0.0001	NUM
dpc-4050	48	20	)	)	PUNCT
dpc-4050	48	21	for	for	ADP
dpc-4050	48	22	pasi	pasi	NOUN
dpc-4050	48	23	score	score	NOUN
dpc-4050	48	24	.	.	PUNCT
dpc-4050	49	1	a	a	DET
dpc-4050	49	2	similar	similar	ADJ
dpc-4050	49	3	trend	trend	NOUN
dpc-4050	49	4	was	be	AUX
dpc-4050	49	5	observed	observe	VERB
dpc-4050	49	6	for	for	ADP
dpc-4050	49	7	visual	visual	ADJ
dpc-4050	49	8	analogue	analogue	NOUN
dpc-4050	49	9	scale	scale	NOUN
dpc-4050	49	10	score	score	NOUN
dpc-4050	49	11	and	and	CCONJ
dpc-4050	49	12	dermatology	dermatology	NOUN
dpc-4050	49	13	life	life	NOUN
dpc-4050	49	14	quality	quality	NOUN
dpc-4050	49	15	index	index	NOUN
dpc-4050	49	16	score	score	NOUN
dpc-4050	49	17	.	.	PUNCT
dpc-4050	50	1	conclusions	conclusion	NOUN
dpc-4050	50	2	:	:	PUNCT
dpc-4050	50	3	ixekizumab	ixekizumab	NOUN
dpc-4050	50	4	was	be	AUX
dpc-4050	50	5	effective	effective	ADJ
dpc-4050	50	6	and	and	CCONJ
dpc-4050	50	7	with	with	ADP
dpc-4050	50	8	a	a	DET
dpc-4050	50	9	good	good	ADJ
dpc-4050	50	10	safety	safety	NOUN
dpc-4050	50	11	profile	profile	NOUN
dpc-4050	50	12	in	in	ADP
dpc-4050	50	13	psoriatic	psoriatic	ADJ
dpc-4050	50	14	patients	patient	NOUN
dpc-4050	50	15	over	over	ADP
dpc-4050	50	16	65	65	NUM
dpc-4050	50	17	years	year	NOUN
dpc-4050	50	18	.	.	PUNCT
dpc-4050	51	1	no	no	DET
dpc-4050	51	2	significant	significant	ADJ
dpc-4050	51	3	adverse	adverse	ADJ
dpc-4050	51	4	events	event	NOUN
dpc-4050	51	5	were	be	AUX
dpc-4050	51	6	reported	report	VERB
dpc-4050	51	7	.	.	PUNCT
dpc-4050	52	1	abstract	abstract	ADJ
dpc-4050	52	2	original	original	ADJ
dpc-4050	52	3	article	article	NOUN
dpc-4050	52	4	|	|	ADV
dpc-4050	52	5	dermatol	dermatol	ADJ
dpc-4050	52	6	pract	pract	NOUN
dpc-4050	52	7	concept	concept	NOUN
dpc-4050	52	8	.	.	PUNCT
dpc-4050	53	1	2024;14(3):e2024166	2024;14(3):e2024166	NUM
dpc-4050	53	2	3	3	NUM
dpc-4050	53	3	the	the	DET
dpc-4050	53	4	treatment	treatment	NOUN
dpc-4050	53	5	of	of	ADP
dpc-4050	53	6	psoriasis	psoriasis	NOUN
dpc-4050	53	7	that	that	PRON
dpc-4050	53	8	act	act	VERB
dpc-4050	53	9	by	by	ADP
dpc-4050	53	10	neutralizing	neutralize	VERB
dpc-4050	53	11	il-17a	il-17a	PROPN
dpc-4050	53	12	,	,	PUNCT
dpc-4050	53	13	a	a	DET
dpc-4050	53	14	key	key	ADJ
dpc-4050	53	15	cytokine	cytokine	NOUN
dpc-4050	53	16	in	in	ADP
dpc-4050	53	17	the	the	DET
dpc-4050	53	18	pathogenesis	pathogenesis	NOUN
dpc-4050	53	19	of	of	ADP
dpc-4050	53	20	the	the	DET
dpc-4050	53	21	disease	disease	NOUN
dpc-4050	53	22	.	.	PUNCT
dpc-4050	54	1	there	there	PRON
dpc-4050	54	2	are	be	VERB
dpc-4050	54	3	three	three	NUM
dpc-4050	54	4	large	large	ADJ
dpc-4050	54	5	prospective	prospective	ADJ
dpc-4050	54	6	,	,	PUNCT
dpc-4050	54	7	double	double	ADJ
dpc-4050	54	8	-	-	PUNCT
dpc-4050	54	9	blind	blind	ADJ
dpc-4050	54	10	,	,	PUNCT
dpc-4050	54	11	multicenter	multicenter	NOUN
dpc-4050	54	12	,	,	PUNCT
dpc-4050	54	13	phase	phase	NOUN
dpc-4050	54	14	iii	iii	NUM
dpc-4050	54	15	studies	study	NOUN
dpc-4050	54	16	(	(	PUNCT
dpc-4050	54	17	uncover-1	uncover-1	PROPN
dpc-4050	54	18	,	,	PUNCT
dpc-4050	54	19	-2	-2	NOUN
dpc-4050	54	20	and	and	CCONJ
dpc-4050	54	21	-3	-3	PUNCT
dpc-4050	54	22	)	)	PUNCT
dpc-4050	54	23	that	that	PRON
dpc-4050	54	24	evaluated	evaluate	VERB
dpc-4050	54	25	ixekizumab	ixekizumab	NOUN
dpc-4050	54	26	efficacy	efficacy	NOUN
dpc-4050	54	27	and	and	CCONJ
dpc-4050	54	28	safety	safety	NOUN
dpc-4050	55	1	[	[	X
dpc-4050	55	2	9	9	NUM
dpc-4050	55	3	]	]	PUNCT
dpc-4050	55	4	.	.	PUNCT
dpc-4050	56	1	objectives	objective	VERB
dpc-4050	56	2	our	our	PRON
dpc-4050	56	3	study	study	NOUN
dpc-4050	56	4	was	be	AUX
dpc-4050	56	5	designed	design	VERB
dpc-4050	56	6	to	to	PART
dpc-4050	56	7	evaluate	evaluate	VERB
dpc-4050	56	8	,	,	PUNCT
dpc-4050	56	9	in	in	ADP
dpc-4050	56	10	a	a	DET
dpc-4050	56	11	real	real	ADJ
dpc-4050	56	12	-	-	PUNCT
dpc-4050	56	13	world	world	NOUN
dpc-4050	56	14	setting	setting	NOUN
dpc-4050	56	15	,	,	PUNCT
dpc-4050	56	16	the	the	DET
dpc-4050	56	17	effectiveness	effectiveness	NOUN
dpc-4050	56	18	and	and	CCONJ
dpc-4050	56	19	safety	safety	NOUN
dpc-4050	56	20	of	of	ADP
dpc-4050	56	21	ixekizumab	ixekizumab	NOUN
dpc-4050	56	22	in	in	ADP
dpc-4050	56	23	elderly	elderly	ADJ
dpc-4050	56	24	patients	patient	NOUN
dpc-4050	56	25	(	(	PUNCT
dpc-4050	56	26	>	>	SYM
dpc-4050	56	27	65	65	NUM
dpc-4050	56	28	years	year	NOUN
dpc-4050	56	29	old	old	ADJ
dpc-4050	56	30	)	)	PUNCT
dpc-4050	56	31	with	with	ADP
dpc-4050	56	32	psoriasis	psoriasis	NOUN
dpc-4050	56	33	(	(	PUNCT
dpc-4050	56	34	pso	pso	NOUN
dpc-4050	56	35	)	)	PUNCT
dpc-4050	56	36	and/or	and/or	CCONJ
dpc-4050	56	37	psoriatic	psoriatic	ADJ
dpc-4050	56	38	arthritis	arthritis	NOUN
dpc-4050	56	39	(	(	PUNCT
dpc-4050	56	40	psa	psa	NOUN
dpc-4050	56	41	)	)	PUNCT
dpc-4050	57	1	[	[	X
dpc-4050	57	2	10	10	NUM
dpc-4050	57	3	]	]	PUNCT
dpc-4050	57	4	.	.	PUNCT
dpc-4050	58	1	the	the	DET
dpc-4050	58	2	main	main	ADJ
dpc-4050	58	3	objective	objective	NOUN
dpc-4050	58	4	was	be	AUX
dpc-4050	58	5	to	to	PART
dpc-4050	58	6	evaluate	evaluate	VERB
dpc-4050	58	7	the	the	DET
dpc-4050	58	8	effectiveness	effectiveness	NOUN
dpc-4050	58	9	and	and	CCONJ
dpc-4050	58	10	safety	safety	NOUN
dpc-4050	58	11	of	of	ADP
dpc-4050	58	12	ixekizumab	ixekizumab	NOUN
dpc-4050	58	13	in	in	ADP
dpc-4050	58	14	a	a	DET
dpc-4050	58	15	cohort	cohort	NOUN
dpc-4050	58	16	of	of	ADP
dpc-4050	58	17	real	real	ADJ
dpc-4050	58	18	-	-	PUNCT
dpc-4050	58	19	life	life	NOUN
dpc-4050	58	20	psoriasis	psoriasis	NOUN
dpc-4050	58	21	patients	patient	NOUN
dpc-4050	58	22	.	.	PUNCT
dpc-4050	59	1	methods	method	NOUN
dpc-4050	59	2	we	we	PRON
dpc-4050	59	3	performed	perform	VERB
dpc-4050	59	4	a	a	DET
dpc-4050	59	5	multicenter	multicenter	NOUN
dpc-4050	59	6	,	,	PUNCT
dpc-4050	59	7	retrospective	retrospective	ADJ
dpc-4050	59	8	,	,	PUNCT
dpc-4050	59	9	observational	observational	ADJ
dpc-4050	59	10	analysis	analysis	NOUN
dpc-4050	59	11	in	in	ADP
dpc-4050	59	12	patients	patient	NOUN
dpc-4050	59	13	with	with	ADP
dpc-4050	59	14	chronic	chronic	ADJ
dpc-4050	59	15	plaque	plaque	NOUN
dpc-4050	59	16	psoriasis	psoriasis	NOUN
dpc-4050	59	17	and	and	CCONJ
dpc-4050	59	18	psoriatic	psoriatic	ADJ
dpc-4050	59	19	arthritis	arthritis	NOUN
dpc-4050	59	20	in	in	ADP
dpc-4050	59	21	real	real	ADJ
dpc-4050	59	22	life	life	NOUN
dpc-4050	59	23	of	of	ADP
dpc-4050	59	24	elderly	elderly	ADJ
dpc-4050	59	25	patients	patient	NOUN
dpc-4050	59	26	treated	treat	VERB
dpc-4050	59	27	with	with	ADP
dpc-4050	59	28	ixekizumab	ixekizumab	NOUN
dpc-4050	59	29	.	.	PUNCT
dpc-4050	60	1	we	we	PRON
dpc-4050	60	2	included	include	VERB
dpc-4050	60	3	males	male	NOUN
dpc-4050	60	4	and	and	CCONJ
dpc-4050	60	5	females	female	NOUN
dpc-4050	60	6	attending	attend	VERB
dpc-4050	60	7	the	the	DET
dpc-4050	60	8	outpatient	outpatient	NOUN
dpc-4050	60	9	clinics	clinic	NOUN
dpc-4050	60	10	of	of	ADP
dpc-4050	60	11	seven	seven	NUM
dpc-4050	60	12	italian	italian	ADJ
dpc-4050	60	13	referral	referral	ADJ
dpc-4050	60	14	center	center	NOUN
dpc-4050	60	15	for	for	ADP
dpc-4050	60	16	psoriasis	psoriasis	NOUN
dpc-4050	60	17	in	in	ADP
dpc-4050	60	18	lazio	lazio	PROPN
dpc-4050	60	19	region	region	NOUN
dpc-4050	60	20	:	:	PUNCT
dpc-4050	60	21	policlinico	policlinico	NOUN
dpc-4050	60	22	umberto	umberto	NOUN
dpc-4050	61	1	i	i	PRON
dpc-4050	61	2	università	università	PROPN
dpc-4050	61	3	roma	roma	PROPN
dpc-4050	61	4	la	la	PROPN
dpc-4050	61	5	sapienza	sapienza	PROPN
dpc-4050	61	6	,	,	PUNCT
dpc-4050	61	7	sant’andrea	sant’andrea	PROPN
dpc-4050	61	8	università	università	PROPN
dpc-4050	61	9	di	di	PROPN
dpc-4050	61	10	roma	roma	PROPN
dpc-4050	61	11	la	la	PROPN
dpc-4050	61	12	sapienza	sapienza	PROPN
dpc-4050	61	13	,	,	PUNCT
dpc-4050	61	14	polo	polo	NOUN
dpc-4050	61	15	pontino	pontino	PROPN
dpc-4050	61	16	università	università	PROPN
dpc-4050	61	17	roma	roma	PROPN
dpc-4050	61	18	la	la	PROPN
dpc-4050	61	19	sapienza	sapienza	PROPN
dpc-4050	61	20	,	,	PUNCT
dpc-4050	61	21	fondazione	fondazione	PROPN
dpc-4050	61	22	policlinico	policlinico	PROPN
dpc-4050	61	23	universitario	universitario	PROPN
dpc-4050	61	24	a.	a.	PROPN
dpc-4050	61	25	gemelli	gemelli	PROPN
dpc-4050	61	26	,	,	PUNCT
dpc-4050	61	27	università	università	PROPN
dpc-4050	61	28	campus	campus	NOUN
dpc-4050	61	29	biomedico	biomedico	PROPN
dpc-4050	61	30	roma	roma	PROPN
dpc-4050	61	31	;	;	PUNCT
dpc-4050	61	32	istituto	istituto	X
dpc-4050	61	33	dermopatico	dermopatico	NOUN
dpc-4050	61	34	dell’immacolata	dell’immacolata	NOUN
dpc-4050	61	35	–	–	PUNCT
dpc-4050	61	36	idi	idi	NOUN
dpc-4050	61	37	;	;	PUNCT
dpc-4050	61	38	policlinico	policlinico	NOUN
dpc-4050	61	39	tor	tor	NOUN
dpc-4050	61	40	vergata	vergata	NOUN
dpc-4050	61	41	.	.	PUNCT
dpc-4050	62	1	all	all	DET
dpc-4050	62	2	patients	patient	NOUN
dpc-4050	62	3	were	be	AUX
dpc-4050	62	4	treated	treat	VERB
dpc-4050	62	5	with	with	ADP
dpc-4050	62	6	ixekizumab	ixekizumab	NOUN
dpc-4050	62	7	at	at	ADP
dpc-4050	62	8	the	the	DET
dpc-4050	62	9	european	european	PROPN
dpc-4050	62	10	medical	medical	ADJ
dpc-4050	62	11	agency	agency	PROPN
dpc-4050	62	12	(	(	PUNCT
dpc-4050	62	13	ema	ema	PROPN
dpc-4050	62	14	)	)	PUNCT
dpc-4050	62	15	approved	approve	VERB
dpc-4050	62	16	dosage	dosage	NOUN
dpc-4050	62	17	(	(	PUNCT
dpc-4050	62	18	80	80	NUM
dpc-4050	62	19	mg	mg	NOUN
dpc-4050	62	20	x2	x2	NOUN
dpc-4050	62	21	administered	administer	VERB
dpc-4050	62	22	by	by	ADP
dpc-4050	62	23	subcutaneous	subcutaneous	ADJ
dpc-4050	62	24	injection	injection	NOUN
dpc-4050	62	25	at	at	ADP
dpc-4050	62	26	week	week	NOUN
dpc-4050	62	27	0	0	NUM
dpc-4050	62	28	,	,	PUNCT
dpc-4050	62	29	and	and	CCONJ
dpc-4050	62	30	80	80	NUM
dpc-4050	62	31	mg	mg	NOUN
dpc-4050	62	32	at	at	ADP
dpc-4050	62	33	weeks	week	NOUN
dpc-4050	62	34	2	2	NUM
dpc-4050	62	35	,	,	PUNCT
dpc-4050	62	36	4	4	NUM
dpc-4050	62	37	,	,	PUNCT
dpc-4050	62	38	8	8	NUM
dpc-4050	62	39	,	,	PUNCT
dpc-4050	62	40	12	12	NUM
dpc-4050	62	41	,	,	PUNCT
dpc-4050	62	42	and	and	CCONJ
dpc-4050	62	43	every	every	DET
dpc-4050	62	44	4	4	NUM
dpc-4050	62	45	weeks	week	NOUN
dpc-4050	62	46	thereafter	thereafter	ADV
dpc-4050	62	47	)	)	PUNCT
dpc-4050	62	48	.	.	PUNCT
dpc-4050	63	1	we	we	PRON
dpc-4050	63	2	collected	collect	VERB
dpc-4050	63	3	data	datum	NOUN
dpc-4050	63	4	related	relate	VERB
dpc-4050	63	5	to	to	ADP
dpc-4050	63	6	the	the	DET
dpc-4050	63	7	characteristics	characteristic	NOUN
dpc-4050	63	8	of	of	ADP
dpc-4050	63	9	the	the	DET
dpc-4050	63	10	patients	patient	NOUN
dpc-4050	63	11	(	(	PUNCT
dpc-4050	63	12	age	age	NOUN
dpc-4050	63	13	,	,	PUNCT
dpc-4050	63	14	sex	sex	NOUN
dpc-4050	63	15	,	,	PUNCT
dpc-4050	63	16	bmi	bmi	NOUN
dpc-4050	63	17	)	)	PUNCT
dpc-4050	63	18	and	and	CCONJ
dpc-4050	63	19	of	of	ADP
dpc-4050	63	20	disease	disease	NOUN
dpc-4050	63	21	(	(	PUNCT
dpc-4050	63	22	age	age	NOUN
dpc-4050	63	23	at	at	ADP
dpc-4050	63	24	onset	onset	NOUN
dpc-4050	63	25	,	,	PUNCT
dpc-4050	63	26	severity	severity	NOUN
dpc-4050	63	27	and	and	CCONJ
dpc-4050	63	28	duration	duration	NOUN
dpc-4050	63	29	of	of	ADP
dpc-4050	63	30	psoriasis	psoriasis	NOUN
dpc-4050	63	31	,	,	PUNCT
dpc-4050	63	32	previous	previous	ADJ
dpc-4050	63	33	treatments	treatment	NOUN
dpc-4050	63	34	)	)	PUNCT
dpc-4050	63	35	.	.	PUNCT
dpc-4050	64	1	the	the	DET
dpc-4050	64	2	severity	severity	NOUN
dpc-4050	64	3	of	of	ADP
dpc-4050	64	4	psoriasis	psoriasis	NOUN
dpc-4050	64	5	was	be	AUX
dpc-4050	64	6	measured	measure	VERB
dpc-4050	64	7	with	with	ADP
dpc-4050	64	8	the	the	DET
dpc-4050	64	9	psoriasis	psoriasis	NOUN
dpc-4050	64	10	area	area	NOUN
dpc-4050	64	11	and	and	CCONJ
dpc-4050	64	12	severity	severity	NOUN
dpc-4050	64	13	index	index	NOUN
dpc-4050	64	14	(	(	PUNCT
dpc-4050	64	15	pasi	pasi	NOUN
dpc-4050	64	16	)	)	PUNCT
dpc-4050	64	17	score	score	NOUN
dpc-4050	64	18	at	at	ADP
dpc-4050	64	19	baseline	baseline	NOUN
dpc-4050	64	20	and	and	CCONJ
dpc-4050	64	21	after	after	ADP
dpc-4050	64	22	16	16	NUM
dpc-4050	64	23	,	,	PUNCT
dpc-4050	64	24	24	24	NUM
dpc-4050	64	25	,	,	PUNCT
dpc-4050	64	26	52	52	NUM
dpc-4050	64	27	,	,	PUNCT
dpc-4050	64	28	104	104	NUM
dpc-4050	64	29	and	and	CCONJ
dpc-4050	64	30	156	156	NUM
dpc-4050	64	31	weeks	week	NOUN
dpc-4050	64	32	of	of	ADP
dpc-4050	64	33	treatment	treatment	NOUN
dpc-4050	64	34	.	.	PUNCT
dpc-4050	65	1	study	study	NOUN
dpc-4050	65	2	design	design	NOUN
dpc-4050	65	3	and	and	CCONJ
dpc-4050	65	4	patients	patient	NOUN
dpc-4050	65	5	this	this	PRON
dpc-4050	65	6	was	be	AUX
dpc-4050	65	7	an	an	DET
dpc-4050	65	8	observational	observational	ADJ
dpc-4050	65	9	,	,	PUNCT
dpc-4050	65	10	retrospective	retrospective	ADJ
dpc-4050	65	11	,	,	PUNCT
dpc-4050	65	12	multicenter	multicenter	ADJ
dpc-4050	65	13	study	study	NOUN
dpc-4050	65	14	performed	perform	VERB
dpc-4050	65	15	in	in	ADP
dpc-4050	65	16	seven	seven	NUM
dpc-4050	65	17	centers	center	NOUN
dpc-4050	65	18	in	in	ADP
dpc-4050	65	19	italy	italy	PROPN
dpc-4050	65	20	in	in	ADP
dpc-4050	65	21	lazio	lazio	PROPN
dpc-4050	65	22	region	region	PROPN
dpc-4050	65	23	,	,	PUNCT
dpc-4050	65	24	enrolling	enrol	VERB
dpc-4050	65	25	elderly	elderly	ADJ
dpc-4050	65	26	patients	patient	NOUN
dpc-4050	65	27	with	with	ADP
dpc-4050	65	28	a	a	DET
dpc-4050	65	29	diagnosis	diagnosis	NOUN
dpc-4050	65	30	pso	pso	NOUN
dpc-4050	65	31	and/or	and/or	CCONJ
dpc-4050	65	32	psa	psa	VERB
dpc-4050	65	33	during	during	ADP
dpc-4050	65	34	the	the	DET
dpc-4050	65	35	period	period	NOUN
dpc-4050	65	36	from	from	ADP
dpc-4050	65	37	2020	2020	NUM
dpc-4050	65	38	to	to	ADP
dpc-4050	65	39	2023	2023	NUM
dpc-4050	65	40	.	.	PUNCT
dpc-4050	66	1	inclusion	inclusion	NOUN
dpc-4050	66	2	criteria	criterion	NOUN
dpc-4050	66	3	patients	patient	NOUN
dpc-4050	66	4	over	over	ADP
dpc-4050	66	5	65	65	NUM
dpc-4050	66	6	years	year	NOUN
dpc-4050	66	7	old	old	ADJ
dpc-4050	66	8	,	,	PUNCT
dpc-4050	66	9	affected	affect	VERB
dpc-4050	66	10	by	by	ADP
dpc-4050	66	11	pso	pso	NOUN
dpc-4050	66	12	and/or	and/or	CCONJ
dpc-4050	66	13	psa	psa	VERB
dpc-4050	66	14	and	and	CCONJ
dpc-4050	66	15	currently	currently	ADV
dpc-4050	66	16	treated	treat	VERB
dpc-4050	66	17	with	with	ADP
dpc-4050	66	18	ixekizumab	ixekizumab	NOUN
dpc-4050	66	19	were	be	AUX
dpc-4050	66	20	included	include	VERB
dpc-4050	66	21	in	in	ADP
dpc-4050	66	22	the	the	DET
dpc-4050	66	23	study	study	NOUN
dpc-4050	66	24	.	.	PUNCT
dpc-4050	67	1	procedures	procedure	NOUN
dpc-4050	67	2	baseline	baseline	VERB
dpc-4050	67	3	clinical	clinical	ADJ
dpc-4050	67	4	and	and	CCONJ
dpc-4050	67	5	demographic	demographic	ADJ
dpc-4050	67	6	characteristics	characteristic	NOUN
dpc-4050	67	7	of	of	ADP
dpc-4050	67	8	the	the	DET
dpc-4050	67	9	patients	patient	NOUN
dpc-4050	67	10	have	have	AUX
dpc-4050	67	11	been	be	AUX
dpc-4050	67	12	collected	collect	VERB
dpc-4050	67	13	from	from	ADP
dpc-4050	67	14	hospital	hospital	NOUN
dpc-4050	67	15	records	record	NOUN
dpc-4050	67	16	.	.	PUNCT
dpc-4050	68	1	results	result	NOUN
dpc-4050	68	2	from	from	ADP
dpc-4050	68	3	the	the	DET
dpc-4050	68	4	pasi	pasi	NOUN
dpc-4050	68	5	and	and	CCONJ
dpc-4050	68	6	visual	visual	ADJ
dpc-4050	68	7	analogue	analogue	NOUN
dpc-4050	68	8	scale	scale	NOUN
dpc-4050	68	9	(	(	PUNCT
dpc-4050	68	10	vas	vas	X
dpc-4050	68	11	)	)	PUNCT
dpc-4050	68	12	have	have	AUX
dpc-4050	68	13	been	be	AUX
dpc-4050	68	14	collected	collect	VERB
dpc-4050	68	15	for	for	ADP
dpc-4050	68	16	6	6	NUM
dpc-4050	68	17	time	time	NOUN
dpc-4050	68	18	points	point	NOUN
dpc-4050	68	19	:	:	PUNCT
dpc-4050	68	20	baseline	baseline	NOUN
dpc-4050	68	21	,	,	PUNCT
dpc-4050	68	22	16	16	NUM
dpc-4050	68	23	,	,	PUNCT
dpc-4050	68	24	24	24	NUM
dpc-4050	68	25	,	,	PUNCT
dpc-4050	68	26	52	52	NUM
dpc-4050	68	27	,	,	PUNCT
dpc-4050	68	28	104	104	NUM
dpc-4050	68	29	and	and	CCONJ
dpc-4050	68	30	156	156	NUM
dpc-4050	68	31	weeks	week	NOUN
dpc-4050	68	32	.	.	PUNCT
dpc-4050	69	1	results	result	NOUN
dpc-4050	69	2	from	from	ADP
dpc-4050	69	3	dermatology	dermatology	NOUN
dpc-4050	69	4	life	life	NOUN
dpc-4050	69	5	quality	quality	NOUN
dpc-4050	69	6	index	index	NOUN
dpc-4050	69	7	(	(	PUNCT
dpc-4050	69	8	dlqi	dlqi	PROPN
dpc-4050	69	9	)	)	PUNCT
dpc-4050	69	10	have	have	AUX
dpc-4050	69	11	been	be	AUX
dpc-4050	69	12	collected	collect	VERB
dpc-4050	69	13	at	at	ADP
dpc-4050	69	14	baseline	baseline	NOUN
dpc-4050	69	15	and	and	CCONJ
dpc-4050	69	16	at	at	ADP
dpc-4050	69	17	52	52	NUM
dpc-4050	69	18	weeks	week	NOUN
dpc-4050	69	19	.	.	PUNCT
dpc-4050	70	1	patients	patient	NOUN
dpc-4050	70	2	have	have	AUX
dpc-4050	70	3	been	be	AUX
dpc-4050	70	4	diagnosed	diagnose	VERB
dpc-4050	70	5	with	with	ADP
dpc-4050	70	6	pso	pso	NOUN
dpc-4050	70	7	,	,	PUNCT
dpc-4050	70	8	psa	psa	NOUN
dpc-4050	70	9	,	,	PUNCT
dpc-4050	70	10	or	or	CCONJ
dpc-4050	70	11	both	both	DET
dpc-4050	70	12	(	(	PUNCT
dpc-4050	70	13	psopsa	psopsa	NOUN
dpc-4050	70	14	)	)	PUNCT
dpc-4050	70	15	.	.	PUNCT
dpc-4050	71	1	concerning	concern	VERB
dpc-4050	71	2	the	the	DET
dpc-4050	71	3	body	body	NOUN
dpc-4050	71	4	areas	area	NOUN
dpc-4050	71	5	affected	affect	VERB
dpc-4050	71	6	by	by	ADP
dpc-4050	71	7	the	the	DET
dpc-4050	71	8	disease	disease	NOUN
dpc-4050	71	9	,	,	PUNCT
dpc-4050	71	10	pso	pso	NOUN
dpc-4050	71	11	presentation	presentation	NOUN
dpc-4050	71	12	has	have	AUX
dpc-4050	71	13	been	be	AUX
dpc-4050	71	14	classified	classify	VERB
dpc-4050	71	15	in	in	ADP
dpc-4050	71	16	“	"	PUNCT
dpc-4050	71	17	difficult	difficult	ADJ
dpc-4050	71	18	areas	area	NOUN
dpc-4050	71	19	”	"	PUNCT
dpc-4050	71	20	(	(	PUNCT
dpc-4050	71	21	head	head	NOUN
dpc-4050	71	22	,	,	PUNCT
dpc-4050	71	23	nails	nail	NOUN
dpc-4050	71	24	,	,	PUNCT
dpc-4050	71	25	hands	hand	NOUN
dpc-4050	71	26	,	,	PUNCT
dpc-4050	71	27	feet	foot	NOUN
dpc-4050	71	28	,	,	PUNCT
dpc-4050	71	29	genital	genital	ADJ
dpc-4050	71	30	area	area	NOUN
dpc-4050	71	31	)	)	PUNCT
dpc-4050	71	32	and	and	CCONJ
dpc-4050	71	33	“	"	PUNCT
dpc-4050	71	34	widespread	widespread	ADJ
dpc-4050	71	35	”	"	PUNCT
dpc-4050	71	36	(	(	PUNCT
dpc-4050	71	37	all	all	DET
dpc-4050	71	38	the	the	DET
dpc-4050	71	39	remaining	remain	VERB
dpc-4050	71	40	areas	area	NOUN
dpc-4050	71	41	not	not	PART
dpc-4050	71	42	included	include	VERB
dpc-4050	71	43	in	in	ADP
dpc-4050	71	44	the	the	DET
dpc-4050	71	45	first	first	ADJ
dpc-4050	71	46	group	group	NOUN
dpc-4050	71	47	)	)	PUNCT
dpc-4050	71	48	.	.	PUNCT
dpc-4050	72	1	statistics	statistic	NOUN
dpc-4050	72	2	the	the	DET
dpc-4050	72	3	sample	sample	NOUN
dpc-4050	72	4	has	have	AUX
dpc-4050	72	5	been	be	AUX
dpc-4050	72	6	described	describe	VERB
dpc-4050	72	7	in	in	ADP
dpc-4050	72	8	its	its	PRON
dpc-4050	72	9	clinical	clinical	ADJ
dpc-4050	72	10	and	and	CCONJ
dpc-4050	72	11	demographic	demographic	ADJ
dpc-4050	72	12	characteristics	characteristic	NOUN
dpc-4050	72	13	applying	apply	VERB
dpc-4050	72	14	descriptive	descriptive	ADJ
dpc-4050	72	15	statistics	statistic	NOUN
dpc-4050	72	16	techniques	technique	NOUN
dpc-4050	72	17	.	.	PUNCT
dpc-4050	73	1	qualitative	qualitative	ADJ
dpc-4050	73	2	variables	variable	NOUN
dpc-4050	73	3	have	have	AUX
dpc-4050	73	4	been	be	AUX
dpc-4050	73	5	described	describe	VERB
dpc-4050	73	6	with	with	ADP
dpc-4050	73	7	absolute	absolute	ADJ
dpc-4050	73	8	frequencies	frequency	NOUN
dpc-4050	73	9	and	and	CCONJ
dpc-4050	73	10	percentage	percentage	NOUN
dpc-4050	73	11	;	;	PUNCT
dpc-4050	73	12	quantitative	quantitative	ADJ
dpc-4050	73	13	variables	variable	NOUN
dpc-4050	73	14	have	have	AUX
dpc-4050	73	15	been	be	AUX
dpc-4050	73	16	summarized	summarize	VERB
dpc-4050	73	17	with	with	ADP
dpc-4050	73	18	mean	mean	ADJ
dpc-4050	73	19	and	and	CCONJ
dpc-4050	73	20	standard	standard	ADJ
dpc-4050	73	21	deviation	deviation	NOUN
dpc-4050	73	22	.	.	PUNCT
dpc-4050	74	1	comparisons	comparison	NOUN
dpc-4050	74	2	between	between	ADP
dpc-4050	74	3	groups	group	NOUN
dpc-4050	74	4	of	of	ADP
dpc-4050	74	5	patients	patient	NOUN
dpc-4050	74	6	have	have	AUX
dpc-4050	74	7	been	be	AUX
dpc-4050	74	8	performed	perform	VERB
dpc-4050	74	9	applying	apply	VERB
dpc-4050	74	10	the	the	DET
dpc-4050	74	11	chi	chi	PROPN
dpc-4050	74	12	square	square	PROPN
dpc-4050	74	13	test	test	NOUN
dpc-4050	74	14	(	(	PUNCT
dpc-4050	74	15	or	or	CCONJ
dpc-4050	74	16	the	the	DET
dpc-4050	74	17	fisher	fisher	PROPN
dpc-4050	74	18	exact	exact	ADJ
dpc-4050	74	19	test	test	NOUN
dpc-4050	74	20	)	)	PUNCT
dpc-4050	74	21	for	for	ADP
dpc-4050	74	22	categorical	categorical	ADJ
dpc-4050	74	23	variables	variable	NOUN
dpc-4050	74	24	;	;	PUNCT
dpc-4050	74	25	for	for	ADP
dpc-4050	74	26	continuous	continuous	ADJ
dpc-4050	74	27	,	,	PUNCT
dpc-4050	74	28	not	not	PART
dpc-4050	74	29	normally	normally	ADV
dpc-4050	74	30	distributed	distribute	VERB
dpc-4050	74	31	,	,	PUNCT
dpc-4050	74	32	variables	variable	VERB
dpc-4050	74	33	the	the	DET
dpc-4050	74	34	mann	mann	PROPN
dpc-4050	74	35	whitney	whitney	PROPN
dpc-4050	74	36	test	test	NOUN
dpc-4050	74	37	have	have	AUX
dpc-4050	74	38	been	be	AUX
dpc-4050	74	39	applied	apply	VERB
dpc-4050	74	40	.	.	PUNCT
dpc-4050	75	1	to	to	PART
dpc-4050	75	2	evaluate	evaluate	VERB
dpc-4050	75	3	the	the	DET
dpc-4050	75	4	effectiveness	effectiveness	NOUN
dpc-4050	75	5	of	of	ADP
dpc-4050	75	6	ixekizumab	ixekizumab	NOUN
dpc-4050	75	7	pasi	pasi	PROPN
dpc-4050	75	8	score	score	PROPN
dpc-4050	75	9	,	,	PUNCT
dpc-4050	75	10	vas	vas	PROPN
dpc-4050	75	11	and	and	CCONJ
dpc-4050	75	12	dlqi	dlqi	PROPN
dpc-4050	75	13	have	have	AUX
dpc-4050	75	14	been	be	AUX
dpc-4050	75	15	considered	consider	VERB
dpc-4050	75	16	.	.	PUNCT
dpc-4050	76	1	results	result	NOUN
dpc-4050	76	2	from	from	ADP
dpc-4050	76	3	the	the	DET
dpc-4050	76	4	three	three	NUM
dpc-4050	76	5	questionnaires	questionnaire	NOUN
dpc-4050	76	6	have	have	AUX
dpc-4050	76	7	been	be	AUX
dpc-4050	76	8	described	describe	VERB
dpc-4050	76	9	for	for	ADP
dpc-4050	76	10	each	each	DET
dpc-4050	76	11	time	time	NOUN
dpc-4050	76	12	points	point	NOUN
dpc-4050	76	13	,	,	PUNCT
dpc-4050	76	14	applying	apply	VERB
dpc-4050	76	15	the	the	DET
dpc-4050	76	16	already	already	ADV
dpc-4050	76	17	mentioned	mention	VERB
dpc-4050	76	18	descriptive	descriptive	ADJ
dpc-4050	76	19	statistics	statistic	NOUN
dpc-4050	76	20	techniques	technique	NOUN
dpc-4050	76	21	.	.	PUNCT
dpc-4050	77	1	moreover	moreover	ADV
dpc-4050	77	2	,	,	PUNCT
dpc-4050	77	3	the	the	DET
dpc-4050	77	4	percentages	percentage	NOUN
dpc-4050	77	5	of	of	ADP
dpc-4050	77	6	patients	patient	NOUN
dpc-4050	77	7	achieving	achieve	VERB
dpc-4050	77	8	pasi90	pasi90	NOUN
dpc-4050	77	9	and	and	CCONJ
dpc-4050	77	10	pasi100	pasi100	PROPN
dpc-4050	77	11	improvement	improvement	NOUN
dpc-4050	77	12	have	have	AUX
dpc-4050	77	13	been	be	AUX
dpc-4050	77	14	calculated	calculate	VERB
dpc-4050	77	15	at	at	ADP
dpc-4050	77	16	each	each	DET
dpc-4050	77	17	time	time	NOUN
dpc-4050	77	18	point	point	NOUN
dpc-4050	77	19	not	not	PART
dpc-4050	77	20	considering	consider	VERB
dpc-4050	77	21	the	the	DET
dpc-4050	77	22	loss	loss	NOUN
dpc-4050	77	23	to	to	PART
dpc-4050	77	24	follow	follow	VERB
dpc-4050	77	25	-	-	PUNCT
dpc-4050	77	26	up	up	ADP
dpc-4050	77	27	patients	patient	NOUN
dpc-4050	77	28	.	.	PUNCT
dpc-4050	78	1	to	to	PART
dpc-4050	78	2	evaluate	evaluate	VERB
dpc-4050	78	3	the	the	DET
dpc-4050	78	4	changes	change	NOUN
dpc-4050	78	5	over	over	ADP
dpc-4050	78	6	times	time	NOUN
dpc-4050	78	7	a	a	DET
dpc-4050	78	8	one	one	NUM
dpc-4050	78	9	-	-	PUNCT
dpc-4050	78	10	way	way	NOUN
dpc-4050	78	11	repeated	repeat	VERB
dpc-4050	78	12	measures	measure	NOUN
dpc-4050	78	13	anova	anova	X
dpc-4050	78	14	has	have	AUX
dpc-4050	78	15	been	be	AUX
dpc-4050	78	16	performed	perform	VERB
dpc-4050	78	17	for	for	ADP
dpc-4050	78	18	pasi	pasi	NOUN
dpc-4050	78	19	and	and	CCONJ
dpc-4050	78	20	vas	vas	X
dpc-4050	78	21	over	over	ADP
dpc-4050	78	22	a	a	DET
dpc-4050	78	23	total	total	NOUN
dpc-4050	78	24	of	of	ADP
dpc-4050	78	25	6	6	NUM
dpc-4050	78	26	time	time	NOUN
dpc-4050	78	27	points	point	NOUN
dpc-4050	78	28	.	.	PUNCT
dpc-4050	79	1	a	a	DET
dpc-4050	79	2	wilcoxon	wilcoxon	PROPN
dpc-4050	79	3	signed	sign	VERB
dpc-4050	79	4	rank	rank	NOUN
dpc-4050	79	5	test	test	NOUN
dpc-4050	79	6	has	have	AUX
dpc-4050	79	7	been	be	AUX
dpc-4050	79	8	performed	perform	VERB
dpc-4050	79	9	for	for	ADP
dpc-4050	79	10	the	the	DET
dpc-4050	79	11	evaluation	evaluation	NOUN
dpc-4050	79	12	of	of	ADP
dpc-4050	79	13	changes	change	NOUN
dpc-4050	79	14	in	in	ADP
dpc-4050	79	15	dlqi	dlqi	VERB
dpc-4050	79	16	over	over	ADP
dpc-4050	79	17	two	two	NUM
dpc-4050	79	18	timepoints	timepoint	NOUN
dpc-4050	79	19	(	(	PUNCT
dpc-4050	79	20	baseline	baseline	NOUN
dpc-4050	79	21	and	and	CCONJ
dpc-4050	79	22	week	week	NOUN
dpc-4050	79	23	52	52	NUM
dpc-4050	79	24	)	)	PUNCT
dpc-4050	79	25	.	.	PUNCT
dpc-4050	80	1	a	a	DET
dpc-4050	80	2	subgroup	subgroup	NOUN
dpc-4050	80	3	analysis	analysis	NOUN
dpc-4050	80	4	(	(	PUNCT
dpc-4050	80	5	male	male	ADJ
dpc-4050	80	6	vs	vs	ADP
dpc-4050	80	7	female	female	NOUN
dpc-4050	80	8	;	;	PUNCT
dpc-4050	80	9	bio	bio	NOUN
dpc-4050	80	10	naive	naive	ADJ
dpc-4050	80	11	vs	vs	ADP
dpc-4050	80	12	not	not	PART
dpc-4050	80	13	bio	bio	NOUN
dpc-4050	80	14	naive	naive	ADJ
dpc-4050	80	15	;	;	PUNCT
dpc-4050	80	16	pso	pso	NOUN
dpc-4050	80	17	-	-	PUNCT
dpc-4050	80	18	psa	psa	NOUN
dpc-4050	80	19	versus	versus	ADP
dpc-4050	80	20	pso	pso	NOUN
dpc-4050	80	21	;	;	PUNCT
dpc-4050	80	22	bmi<25	bmi<25	PROPN
dpc-4050	80	23	vs	vs	ADP
dpc-4050	80	24	bmi	bmi	X
dpc-4050	80	25	≥25	≥25	PROPN
dpc-4050	80	26	)	)	PUNCT
dpc-4050	80	27	for	for	ADP
dpc-4050	80	28	pasi	pasi	NOUN
dpc-4050	80	29	,	,	PUNCT
dpc-4050	80	30	vas	vas	X
dpc-4050	80	31	(	(	PUNCT
dpc-4050	80	32	100	100	NUM
dpc-4050	80	33	points	point	NOUN
dpc-4050	80	34	score	score	NOUN
dpc-4050	80	35	)	)	PUNCT
dpc-4050	80	36	and	and	CCONJ
dpc-4050	80	37	dlqi	dlqi	PROPN
dpc-4050	80	38	data	datum	NOUN
dpc-4050	80	39	,	,	PUNCT
dpc-4050	80	40	has	have	AUX
dpc-4050	80	41	been	be	AUX
dpc-4050	80	42	performed	perform	VERB
dpc-4050	80	43	applying	apply	VERB
dpc-4050	80	44	an	an	DET
dpc-4050	80	45	anova	anova	PROPN
dpc-4050	80	46	mixed	mixed	ADJ
dpc-4050	80	47	model	model	NOUN
dpc-4050	80	48	for	for	ADP
dpc-4050	80	49	repeated	repeat	VERB
dpc-4050	80	50	measures	measure	NOUN
dpc-4050	80	51	.	.	PUNCT
dpc-4050	81	1	due	due	ADP
dpc-4050	81	2	to	to	ADP
dpc-4050	81	3	subgroup	subgroup	NOUN
dpc-4050	81	4	dimension	dimension	NOUN
dpc-4050	81	5	,	,	PUNCT
dpc-4050	81	6	only	only	ADV
dpc-4050	81	7	pso	pso	NOUN
dpc-4050	81	8	-	-	PUNCT
dpc-4050	81	9	psa	psa	NOUN
dpc-4050	81	10	and	and	CCONJ
dpc-4050	81	11	pso	pso	NOUN
dpc-4050	81	12	patients	patient	NOUN
dpc-4050	81	13	have	have	AUX
dpc-4050	81	14	been	be	AUX
dpc-4050	81	15	considered	consider	VERB
dpc-4050	81	16	(	(	PUNCT
dpc-4050	81	17	in	in	ADP
dpc-4050	81	18	the	the	DET
dpc-4050	81	19	sample	sample	NOUN
dpc-4050	81	20	there	there	PRON
dpc-4050	81	21	was	be	VERB
dpc-4050	81	22	only	only	ADV
dpc-4050	81	23	one	one	NUM
dpc-4050	81	24	psa	psa	NOUN
dpc-4050	81	25	patient	patient	NOUN
dpc-4050	81	26	)	)	PUNCT
dpc-4050	81	27	.	.	PUNCT
dpc-4050	82	1	before	before	ADP
dpc-4050	82	2	performing	perform	VERB
dpc-4050	82	3	the	the	DET
dpc-4050	82	4	anova	anova	PROPN
dpc-4050	82	5	mixed	mixed	ADJ
dpc-4050	82	6	model	model	NOUN
dpc-4050	82	7	for	for	ADP
dpc-4050	82	8	repeated	repeat	VERB
dpc-4050	82	9	measures	measure	NOUN
dpc-4050	82	10	,	,	PUNCT
dpc-4050	82	11	some	some	DET
dpc-4050	82	12	preliminary	preliminary	ADJ
dpc-4050	82	13	tests	test	NOUN
dpc-4050	82	14	were	be	AUX
dpc-4050	82	15	carried	carry	VERB
dpc-4050	82	16	out	out	ADP
dpc-4050	82	17	to	to	PART
dpc-4050	82	18	verify	verify	VERB
dpc-4050	82	19	that	that	SCONJ
dpc-4050	82	20	groups	group	NOUN
dpc-4050	82	21	were	be	AUX
dpc-4050	82	22	not	not	PART
dpc-4050	82	23	significantly	significantly	ADV
dpc-4050	82	24	different	different	ADJ
dpc-4050	82	25	at	at	ADP
dpc-4050	82	26	the	the	DET
dpc-4050	82	27	baseline	baseline	NOUN
dpc-4050	82	28	in	in	ADP
dpc-4050	82	29	relation	relation	NOUN
dpc-4050	82	30	to	to	ADP
dpc-4050	82	31	some	some	DET
dpc-4050	82	32	selected	select	VERB
dpc-4050	82	33	variables	variable	NOUN
dpc-4050	82	34	that	that	PRON
dpc-4050	82	35	could	could	AUX
dpc-4050	82	36	influence	influence	VERB
dpc-4050	82	37	the	the	DET
dpc-4050	82	38	results	result	NOUN
dpc-4050	82	39	.	.	PUNCT
dpc-4050	83	1	ixekizumab	ixekizumab	NOUN
dpc-4050	83	2	safety	safety	NOUN
dpc-4050	83	3	has	have	AUX
dpc-4050	83	4	been	be	AUX
dpc-4050	83	5	evaluated	evaluate	VERB
dpc-4050	83	6	investigating	investigate	VERB
dpc-4050	83	7	the	the	DET
dpc-4050	83	8	frequency	frequency	NOUN
dpc-4050	83	9	and	and	CCONJ
dpc-4050	83	10	the	the	DET
dpc-4050	83	11	severity	severity	NOUN
dpc-4050	83	12	of	of	ADP
dpc-4050	83	13	adverse	adverse	ADJ
dpc-4050	83	14	events	event	NOUN
dpc-4050	83	15	.	.	PUNCT
dpc-4050	84	1	a	a	DET
dpc-4050	84	2	p	p	NOUN
dpc-4050	84	3	-value	-value	PROPN
dpc-4050	84	4	<	<	NOUN
dpc-4050	84	5	0.05	0.05	NUM
dpc-4050	84	6	has	have	AUX
dpc-4050	84	7	been	be	AUX
dpc-4050	84	8	considered	consider	VERB
dpc-4050	84	9	as	as	ADP
dpc-4050	84	10	significant	significant	ADJ
dpc-4050	84	11	.	.	PUNCT
dpc-4050	85	1	all	all	DET
dpc-4050	85	2	the	the	DET
dpc-4050	85	3	statistical	statistical	ADJ
dpc-4050	85	4	analyses	analysis	NOUN
dpc-4050	85	5	were	be	AUX
dpc-4050	85	6	performed	perform	VERB
dpc-4050	85	7	using	use	VERB
dpc-4050	85	8	r	r	NOUN
dpc-4050	85	9	(	(	PUNCT
dpc-4050	85	10	4.3.0	4.3.0	NUM
dpc-4050	85	11	)	)	PUNCT
dpc-4050	85	12	.	.	PUNCT
dpc-4050	86	1	results	result	VERB
dpc-4050	86	2	a	a	DET
dpc-4050	86	3	total	total	NOUN
dpc-4050	86	4	of	of	ADP
dpc-4050	86	5	73	73	NUM
dpc-4050	86	6	patients	patient	NOUN
dpc-4050	86	7	,	,	PUNCT
dpc-4050	86	8	56.2	56.2	NUM
dpc-4050	86	9	%	%	NOUN
dpc-4050	86	10	males	male	NOUN
dpc-4050	86	11	and	and	CCONJ
dpc-4050	86	12	43.8	43.8	NUM
dpc-4050	86	13	%	%	NOUN
dpc-4050	86	14	females	female	NOUN
dpc-4050	86	15	,	,	PUNCT
dpc-4050	86	16	with	with	ADP
dpc-4050	86	17	mean	mean	ADJ
dpc-4050	86	18	age	age	NOUN
dpc-4050	86	19	of	of	ADP
dpc-4050	86	20	71.5	71.5	NUM
dpc-4050	86	21	years	year	NOUN
dpc-4050	86	22	(	(	PUNCT
dpc-4050	86	23	sd	sd	NOUN
dpc-4050	86	24	=	=	SYM
dpc-4050	86	25	6.4	6.4	NUM
dpc-4050	86	26	)	)	PUNCT
dpc-4050	86	27	,	,	PUNCT
dpc-4050	86	28	have	have	AUX
dpc-4050	86	29	been	be	AUX
dpc-4050	86	30	included	include	VERB
dpc-4050	86	31	in	in	ADP
dpc-4050	86	32	the	the	DET
dpc-4050	86	33	study	study	NOUN
dpc-4050	86	34	.	.	PUNCT
dpc-4050	87	1	the	the	DET
dpc-4050	87	2	diagnosis	diagnosis	NOUN
dpc-4050	87	3	was	be	AUX
dpc-4050	87	4	pso	pso	NOUN
dpc-4050	87	5	for	for	ADP
dpc-4050	87	6	24	24	NUM
dpc-4050	87	7	patients	patient	NOUN
dpc-4050	87	8	(	(	PUNCT
dpc-4050	87	9	32.9	32.9	NUM
dpc-4050	87	10	%	%	NOUN
dpc-4050	87	11	)	)	PUNCT
dpc-4050	87	12	,	,	PUNCT
dpc-4050	87	13	4	4	NUM
dpc-4050	87	14	original	original	ADJ
dpc-4050	87	15	article	article	NOUN
dpc-4050	87	16	|	|	ADV
dpc-4050	87	17	dermatol	dermatol	ADJ
dpc-4050	87	18	pract	pract	NOUN
dpc-4050	87	19	concept	concept	NOUN
dpc-4050	87	20	.	.	PUNCT
dpc-4050	88	1	2024;14(3):e2024166	2024;14(3):e2024166	NUM
dpc-4050	88	2	similarly	similarly	ADV
dpc-4050	88	3	,	,	PUNCT
dpc-4050	88	4	with	with	ADP
dpc-4050	88	5	what	what	PRON
dpc-4050	88	6	was	be	AUX
dpc-4050	88	7	seen	see	VERB
dpc-4050	88	8	for	for	ADP
dpc-4050	88	9	pasi	pasi	NOUN
dpc-4050	88	10	score	score	NOUN
dpc-4050	88	11	,	,	PUNCT
dpc-4050	88	12	the	the	DET
dpc-4050	88	13	one	one	NUM
dpc-4050	88	14	-	-	PUNCT
dpc-4050	88	15	way	way	NOUN
dpc-4050	88	16	anova	anova	PROPN
dpc-4050	88	17	model	model	PROPN
dpc-4050	88	18	presented	present	VERB
dpc-4050	88	19	a	a	DET
dpc-4050	88	20	significant	significant	ADJ
dpc-4050	88	21	effect	effect	NOUN
dpc-4050	88	22	of	of	ADP
dpc-4050	88	23	time	time	NOUN
dpc-4050	88	24	on	on	ADP
dpc-4050	88	25	vas	vas	X
dpc-4050	88	26	score	score	NOUN
dpc-4050	88	27	(	(	PUNCT
dpc-4050	88	28	p	p	X
dpc-4050	88	29	<	<	X
dpc-4050	88	30	0.0001	0.0001	NUM
dpc-4050	88	31	)	)	PUNCT
dpc-4050	88	32	and	and	CCONJ
dpc-4050	88	33	pairwise	pairwise	NOUN
dpc-4050	88	34	comparisons	comparison	NOUN
dpc-4050	88	35	showed	show	VERB
dpc-4050	88	36	a	a	DET
dpc-4050	88	37	significant	significant	ADJ
dpc-4050	88	38	difference	difference	NOUN
dpc-4050	88	39	between	between	ADP
dpc-4050	88	40	baseline	baseline	NOUN
dpc-4050	88	41	and	and	CCONJ
dpc-4050	88	42	all	all	DET
dpc-4050	88	43	the	the	DET
dpc-4050	88	44	other	other	ADJ
dpc-4050	88	45	time	time	NOUN
dpc-4050	88	46	points	point	NOUN
dpc-4050	88	47	(	(	PUNCT
dpc-4050	88	48	p	p	X
dpc-4050	88	49	<	<	X
dpc-4050	88	50	0.0001	0.0001	NUM
dpc-4050	88	51	)	)	PUNCT
dpc-4050	88	52	.	.	PUNCT
dpc-4050	89	1	see	see	VERB
dpc-4050	89	2	table	table	NOUN
dpc-4050	89	3	5	5	NUM
dpc-4050	89	4	for	for	ADP
dpc-4050	89	5	details	detail	NOUN
dpc-4050	89	6	.	.	PUNCT
dpc-4050	90	1	dlqi	dlqi	PROPN
dpc-4050	90	2	score	score	NOUN
dpc-4050	90	3	as	as	SCONJ
dpc-4050	90	4	presented	present	VERB
dpc-4050	90	5	in	in	ADP
dpc-4050	90	6	table	table	NOUN
dpc-4050	90	7	6	6	NUM
dpc-4050	90	8	,	,	PUNCT
dpc-4050	90	9	dlqi	dlqi	ADJ
dpc-4050	90	10	score	score	NOUN
dpc-4050	90	11	decreased	decrease	VERB
dpc-4050	90	12	significantly	significantly	ADV
dpc-4050	90	13	from	from	ADP
dpc-4050	90	14	baseline	baseline	NOUN
dpc-4050	90	15	to	to	ADP
dpc-4050	90	16	week	week	NOUN
dpc-4050	90	17	52	52	NUM
dpc-4050	90	18	.	.	PUNCT
dpc-4050	91	1	mean	mean	VERB
dpc-4050	91	2	and	and	CCONJ
dpc-4050	91	3	median	median	NOUN
dpc-4050	91	4	changed	change	VERB
dpc-4050	91	5	from	from	ADP
dpc-4050	91	6	15.9	15.9	NUM
dpc-4050	91	7	and	and	CCONJ
dpc-4050	91	8	16.0	16.0	NUM
dpc-4050	91	9	to	to	PART
dpc-4050	91	10	0.5	0.5	NUM
dpc-4050	91	11	and	and	CCONJ
dpc-4050	91	12	0	0	NUM
dpc-4050	91	13	,	,	PUNCT
dpc-4050	91	14	respectively	respectively	ADV
dpc-4050	91	15	.	.	PUNCT
dpc-4050	92	1	the	the	DET
dpc-4050	92	2	wilcoxon	wilcoxon	PROPN
dpc-4050	92	3	signed	sign	VERB
dpc-4050	92	4	rank	rank	NOUN
dpc-4050	92	5	test	test	NOUN
dpc-4050	92	6	highlighted	highlight	VERB
dpc-4050	92	7	a	a	DET
dpc-4050	92	8	significant	significant	ADJ
dpc-4050	92	9	difference	difference	NOUN
dpc-4050	92	10	between	between	ADP
dpc-4050	92	11	the	the	DET
dpc-4050	92	12	two	two	NUM
dpc-4050	92	13	considered	consider	VERB
dpc-4050	92	14	time	time	NOUN
dpc-4050	92	15	points	point	NOUN
dpc-4050	92	16	,	,	PUNCT
dpc-4050	92	17	p	p	X
dpc-4050	92	18	<	<	X
dpc-4050	92	19	0.0001	0.0001	NUM
dpc-4050	92	20	.	.	PUNCT
dpc-4050	93	1	see	see	VERB
dpc-4050	93	2	figure	figure	NOUN
dpc-4050	93	3	3	3	NUM
dpc-4050	93	4	for	for	ADP
dpc-4050	93	5	a	a	DET
dpc-4050	93	6	graphical	graphical	ADJ
dpc-4050	93	7	representation	representation	NOUN
dpc-4050	93	8	of	of	ADP
dpc-4050	93	9	mean	mean	PROPN
dpc-4050	93	10	vas	vas	NOUN
dpc-4050	93	11	and	and	CCONJ
dpc-4050	93	12	dlqi	dlqi	ADJ
dpc-4050	93	13	score	score	NOUN
dpc-4050	93	14	.	.	PUNCT
dpc-4050	94	1	subgroups	subgroup	NOUN
dpc-4050	94	2	analyses	analyse	VERB
dpc-4050	94	3	the	the	DET
dpc-4050	94	4	results	result	NOUN
dpc-4050	94	5	of	of	ADP
dpc-4050	94	6	a	a	DET
dpc-4050	94	7	preliminary	preliminary	ADJ
dpc-4050	94	8	,	,	PUNCT
dpc-4050	94	9	comparative	comparative	ADJ
dpc-4050	94	10	test	test	NOUN
dpc-4050	94	11	indicated	indicate	VERB
dpc-4050	94	12	that	that	SCONJ
dpc-4050	94	13	the	the	DET
dpc-4050	94	14	proposed	propose	VERB
dpc-4050	94	15	subgroups	subgroup	NOUN
dpc-4050	94	16	are	be	AUX
dpc-4050	94	17	not	not	PART
dpc-4050	94	18	significantly	significantly	ADV
dpc-4050	94	19	different	different	ADJ
dpc-4050	94	20	in	in	ADP
dpc-4050	94	21	term	term	NOUN
dpc-4050	94	22	of	of	ADP
dpc-4050	94	23	age	age	NOUN
dpc-4050	94	24	,	,	PUNCT
dpc-4050	94	25	pasi	pasi	NOUN
dpc-4050	94	26	,	,	PUNCT
dpc-4050	94	27	vas	vas	X
dpc-4050	94	28	and	and	CCONJ
dpc-4050	94	29	dlqi	dlqi	VERB
dpc-4050	94	30	score	score	NOUN
dpc-4050	94	31	at	at	ADP
dpc-4050	94	32	baseline	baseline	NOUN
dpc-4050	94	33	.	.	PUNCT
dpc-4050	95	1	there	there	PRON
dpc-4050	95	2	was	be	VERB
dpc-4050	95	3	only	only	ADV
dpc-4050	95	4	a	a	DET
dpc-4050	95	5	statistically	statistically	ADV
dpc-4050	95	6	significant	significant	ADJ
dpc-4050	95	7	difference	difference	NOUN
dpc-4050	95	8	between	between	ADP
dpc-4050	95	9	mean	mean	ADJ
dpc-4050	95	10	pasi	pasi	NOUN
dpc-4050	95	11	score	score	NOUN
dpc-4050	95	12	at	at	ADP
dpc-4050	95	13	baseline	baseline	NOUN
dpc-4050	95	14	for	for	ADP
dpc-4050	95	15	bmi	bmi	NOUN
dpc-4050	95	16	<	<	X
dpc-4050	95	17	25	25	NUM
dpc-4050	95	18	patients	patient	NOUN
dpc-4050	95	19	and	and	CCONJ
dpc-4050	95	20	bmi	bmi	VERB
dpc-4050	95	21	≥	≥	NUM
dpc-4050	95	22	25	25	NUM
dpc-4050	95	23	ones	one	NOUN
dpc-4050	95	24	;	;	PUNCT
dpc-4050	95	25	10.9	10.9	NUM
dpc-4050	95	26	(	(	PUNCT
dpc-4050	95	27	sd	sd	NOUN
dpc-4050	95	28	=	=	SYM
dpc-4050	95	29	6.7	6.7	NUM
dpc-4050	95	30	)	)	PUNCT
dpc-4050	95	31	and	and	CCONJ
dpc-4050	95	32	16.1	16.1	NUM
dpc-4050	95	33	(	(	PUNCT
dpc-4050	95	34	sd	sd	NOUN
dpc-4050	95	35	=	=	SYM
dpc-4050	95	36	9.1	9.1	NUM
dpc-4050	95	37	)	)	PUNCT
dpc-4050	95	38	respectively	respectively	ADV
dpc-4050	95	39	(	(	PUNCT
dpc-4050	95	40	table	table	NOUN
dpc-4050	95	41	7	7	NUM
dpc-4050	95	42	)	)	PUNCT
dpc-4050	95	43	.	.	PUNCT
dpc-4050	96	1	sex	sex	NOUN
dpc-4050	96	2	for	for	ADP
dpc-4050	96	3	pasi	pasi	NOUN
dpc-4050	96	4	score	score	NOUN
dpc-4050	96	5	,	,	PUNCT
dpc-4050	96	6	the	the	DET
dpc-4050	96	7	anova	anova	PROPN
dpc-4050	96	8	mixed	mixed	ADJ
dpc-4050	96	9	model	model	NOUN
dpc-4050	96	10	showed	show	VERB
dpc-4050	96	11	a	a	DET
dpc-4050	96	12	statistically	statistically	ADV
dpc-4050	96	13	significant	significant	ADJ
dpc-4050	96	14	difference	difference	NOUN
dpc-4050	96	15	between	between	ADP
dpc-4050	96	16	sex	sex	NOUN
dpc-4050	96	17	(	(	PUNCT
dpc-4050	96	18	p	p	X
dpc-4050	96	19	=	=	NOUN
dpc-4050	96	20	0.037	0.037	NUM
dpc-4050	96	21	)	)	PUNCT
dpc-4050	96	22	and	and	CCONJ
dpc-4050	96	23	,	,	PUNCT
dpc-4050	96	24	as	as	SCONJ
dpc-4050	96	25	already	already	ADV
dpc-4050	96	26	reported	report	VERB
dpc-4050	96	27	,	,	PUNCT
dpc-4050	96	28	between	between	ADP
dpc-4050	96	29	timepoints	timepoint	NOUN
dpc-4050	96	30	(	(	PUNCT
dpc-4050	96	31	p	p	X
dpc-4050	96	32	<	<	X
dpc-4050	96	33	0.0001	0.0001	NUM
dpc-4050	96	34	)	)	PUNCT
dpc-4050	96	35	.	.	PUNCT
dpc-4050	97	1	pairwise	pairwise	NOUN
dpc-4050	97	2	comparisons	comparison	NOUN
dpc-4050	97	3	showed	show	VERB
dpc-4050	97	4	that	that	SCONJ
dpc-4050	97	5	all	all	DET
dpc-4050	97	6	timepoints	timepoint	NOUN
dpc-4050	97	7	are	be	AUX
dpc-4050	97	8	significantly	significantly	ADV
dpc-4050	97	9	different	different	ADJ
dpc-4050	97	10	from	from	ADP
dpc-4050	97	11	the	the	DET
dpc-4050	97	12	baseline	baseline	NOUN
dpc-4050	97	13	(	(	PUNCT
dpc-4050	97	14	p	p	X
dpc-4050	97	15	<	<	X
dpc-4050	97	16	0.0001	0.0001	NUM
dpc-4050	97	17	)	)	PUNCT
dpc-4050	97	18	but	but	CCONJ
dpc-4050	97	19	there	there	PRON
dpc-4050	97	20	are	be	VERB
dpc-4050	97	21	no	no	DET
dpc-4050	97	22	significant	significant	ADJ
dpc-4050	97	23	differences	difference	NOUN
dpc-4050	97	24	between	between	ADP
dpc-4050	97	25	the	the	DET
dpc-4050	97	26	remaining	remain	VERB
dpc-4050	97	27	pairs	pair	NOUN
dpc-4050	97	28	of	of	ADP
dpc-4050	97	29	timepoints	timepoint	NOUN
dpc-4050	97	30	.	.	PUNCT
dpc-4050	98	1	see	see	VERB
dpc-4050	98	2	figure	figure	NOUN
dpc-4050	98	3	4	4	NUM
dpc-4050	98	4	for	for	ADP
dpc-4050	98	5	details	detail	NOUN
dpc-4050	98	6	.	.	PUNCT
dpc-4050	99	1	anova	anova	PROPN
dpc-4050	99	2	mixed	mixed	ADJ
dpc-4050	99	3	model	model	NOUN
dpc-4050	99	4	also	also	ADV
dpc-4050	99	5	revealed	reveal	VERB
dpc-4050	99	6	a	a	DET
dpc-4050	99	7	statistically	statistically	ADV
dpc-4050	99	8	significant	significant	ADJ
dpc-4050	99	9	difference	difference	NOUN
dpc-4050	99	10	in	in	ADP
dpc-4050	99	11	vas	vas	PROPN
dpc-4050	99	12	scores	score	NOUN
dpc-4050	99	13	between	between	ADP
dpc-4050	99	14	time	time	NOUN
dpc-4050	99	15	points	point	NOUN
dpc-4050	99	16	(	(	PUNCT
dpc-4050	99	17	p	p	X
dpc-4050	99	18	<	<	X
dpc-4050	99	19	0.0001	0.0001	NUM
dpc-4050	99	20	)	)	PUNCT
dpc-4050	99	21	but	but	CCONJ
dpc-4050	99	22	no	no	DET
dpc-4050	99	23	significant	significant	ADJ
dpc-4050	99	24	difference	difference	NOUN
dpc-4050	99	25	in	in	ADP
dpc-4050	99	26	vas	vas	X
dpc-4050	99	27	score	score	NOUN
dpc-4050	99	28	between	between	ADP
dpc-4050	99	29	males	male	NOUN
dpc-4050	99	30	and	and	CCONJ
dpc-4050	99	31	females	female	NOUN
dpc-4050	99	32	(	(	PUNCT
dpc-4050	99	33	p	p	X
dpc-4050	99	34	=	=	NOUN
dpc-4050	99	35	0.247	0.247	NUM
dpc-4050	99	36	)	)	PUNCT
dpc-4050	99	37	.	.	PUNCT
dpc-4050	100	1	concerning	concern	VERB
dpc-4050	100	2	dlqi	dlqi	PROPN
dpc-4050	100	3	index	index	NOUN
dpc-4050	100	4	,	,	PUNCT
dpc-4050	100	5	no	no	DET
dpc-4050	100	6	statistically	statistically	ADV
dpc-4050	100	7	significant	significant	ADJ
dpc-4050	100	8	differences	difference	NOUN
dpc-4050	100	9	have	have	AUX
dpc-4050	100	10	been	be	AUX
dpc-4050	100	11	highlighted	highlight	VERB
dpc-4050	100	12	between	between	ADP
dpc-4050	100	13	males	male	NOUN
dpc-4050	100	14	and	and	CCONJ
dpc-4050	100	15	females	female	NOUN
dpc-4050	100	16	,	,	PUNCT
dpc-4050	100	17	p	p	X
dpc-4050	100	18	=	=	PROPN
dpc-4050	100	19	0.829	0.829	NUM
dpc-4050	100	20	.	.	PUNCT
dpc-4050	101	1	pso	pso	NOUN
dpc-4050	101	2	versus	versus	ADP
dpc-4050	101	3	pso	pso	NOUN
dpc-4050	101	4	-	-	PUNCT
dpc-4050	101	5	psa	psa	NOUN
dpc-4050	101	6	for	for	ADP
dpc-4050	101	7	pasi	pasi	NOUN
dpc-4050	101	8	score	score	NOUN
dpc-4050	101	9	,	,	PUNCT
dpc-4050	101	10	the	the	DET
dpc-4050	101	11	anova	anova	PROPN
dpc-4050	101	12	mixed	mixed	ADJ
dpc-4050	101	13	model	model	NOUN
dpc-4050	101	14	highlighted	highlight	VERB
dpc-4050	101	15	a	a	DET
dpc-4050	101	16	statistically	statistically	ADV
dpc-4050	101	17	significant	significant	ADJ
dpc-4050	101	18	difference	difference	NOUN
dpc-4050	101	19	between	between	ADP
dpc-4050	101	20	time	time	NOUN
dpc-4050	101	21	points	point	NOUN
dpc-4050	101	22	(	(	PUNCT
dpc-4050	101	23	p	p	X
dpc-4050	101	24	<	<	X
dpc-4050	101	25	0.0001	0.0001	NUM
dpc-4050	101	26	)	)	PUNCT
dpc-4050	101	27	and	and	CCONJ
dpc-4050	101	28	no	no	DET
dpc-4050	101	29	significant	significant	ADJ
dpc-4050	101	30	difference	difference	NOUN
dpc-4050	101	31	between	between	ADP
dpc-4050	101	32	the	the	DET
dpc-4050	101	33	groups	group	NOUN
dpc-4050	101	34	(	(	PUNCT
dpc-4050	101	35	p	p	X
dpc-4050	101	36	=	=	NOUN
dpc-4050	101	37	0.647	0.647	NUM
dpc-4050	101	38	)	)	PUNCT
dpc-4050	101	39	.	.	PUNCT
dpc-4050	102	1	pairwise	pairwise	NOUN
dpc-4050	102	2	comparisons	comparison	NOUN
dpc-4050	102	3	showed	show	VERB
dpc-4050	102	4	that	that	SCONJ
dpc-4050	102	5	all	all	DET
dpc-4050	102	6	times	time	NOUN
dpc-4050	102	7	are	be	AUX
dpc-4050	102	8	significantly	significantly	ADV
dpc-4050	102	9	different	different	ADJ
dpc-4050	102	10	from	from	ADP
dpc-4050	102	11	the	the	DET
dpc-4050	102	12	baseline	baseline	NOUN
dpc-4050	102	13	(	(	PUNCT
dpc-4050	102	14	p	p	X
dpc-4050	102	15	<	<	X
dpc-4050	102	16	0.0001	0.0001	NUM
dpc-4050	102	17	)	)	PUNCT
dpc-4050	102	18	but	but	CCONJ
dpc-4050	102	19	there	there	PRON
dpc-4050	102	20	are	be	VERB
dpc-4050	102	21	no	no	DET
dpc-4050	102	22	significant	significant	ADJ
dpc-4050	102	23	differences	difference	NOUN
dpc-4050	102	24	between	between	ADP
dpc-4050	102	25	the	the	DET
dpc-4050	102	26	remaining	remain	VERB
dpc-4050	102	27	pairs	pair	NOUN
dpc-4050	102	28	of	of	ADP
dpc-4050	102	29	timepoints	timepoint	NOUN
dpc-4050	102	30	.	.	PUNCT
dpc-4050	103	1	for	for	ADP
dpc-4050	103	2	vas	vas	PROPN
dpc-4050	103	3	score	score	NOUN
dpc-4050	103	4	,	,	PUNCT
dpc-4050	103	5	the	the	DET
dpc-4050	103	6	anova	anova	PROPN
dpc-4050	103	7	mixed	mixed	ADJ
dpc-4050	103	8	model	model	NOUN
dpc-4050	103	9	showed	show	VERB
dpc-4050	103	10	a	a	DET
dpc-4050	103	11	statistically	statistically	ADV
dpc-4050	103	12	significant	significant	ADJ
dpc-4050	103	13	difference	difference	NOUN
dpc-4050	103	14	between	between	ADP
dpc-4050	103	15	time	time	NOUN
dpc-4050	103	16	points	point	NOUN
dpc-4050	103	17	(	(	PUNCT
dpc-4050	103	18	p	p	X
dpc-4050	103	19	=	=	NOUN
dpc-4050	103	20	0.011	0.011	NUM
dpc-4050	103	21	)	)	PUNCT
dpc-4050	103	22	and	and	CCONJ
dpc-4050	103	23	no	no	DET
dpc-4050	103	24	significant	significant	ADJ
dpc-4050	103	25	difference	difference	NOUN
dpc-4050	103	26	between	between	ADP
dpc-4050	103	27	the	the	DET
dpc-4050	103	28	groups	group	NOUN
dpc-4050	103	29	(	(	PUNCT
dpc-4050	103	30	p	p	X
dpc-4050	103	31	=	=	NOUN
dpc-4050	103	32	0.239	0.239	NUM
dpc-4050	103	33	)	)	PUNCT
dpc-4050	103	34	.	.	PUNCT
dpc-4050	104	1	for	for	ADP
dpc-4050	104	2	dlqi	dlqi	PROPN
dpc-4050	104	3	index	index	NOUN
dpc-4050	104	4	,	,	PUNCT
dpc-4050	104	5	the	the	DET
dpc-4050	104	6	anova	anova	PROPN
dpc-4050	104	7	mixed	mixed	ADJ
dpc-4050	104	8	model	model	NOUN
dpc-4050	104	9	revealed	reveal	VERB
dpc-4050	104	10	a	a	DET
dpc-4050	104	11	statistically	statistically	ADV
dpc-4050	104	12	significant	significant	ADJ
dpc-4050	104	13	difference	difference	NOUN
dpc-4050	104	14	between	between	ADP
dpc-4050	104	15	time	time	NOUN
dpc-4050	104	16	points	point	NOUN
dpc-4050	104	17	psa	psa	VERB
dpc-4050	104	18	for	for	ADP
dpc-4050	104	19	1	1	NUM
dpc-4050	104	20	patient	patient	NOUN
dpc-4050	104	21	(	(	PUNCT
dpc-4050	104	22	1.4	1.4	NUM
dpc-4050	104	23	%	%	NOUN
dpc-4050	104	24	)	)	PUNCT
dpc-4050	104	25	and	and	CCONJ
dpc-4050	104	26	both	both	PRON
dpc-4050	104	27	of	of	ADP
dpc-4050	104	28	them	they	PRON
dpc-4050	104	29	(	(	PUNCT
dpc-4050	104	30	pso	pso	NOUN
dpc-4050	104	31	-	-	PUNCT
dpc-4050	104	32	psa	psa	NOUN
dpc-4050	104	33	)	)	PUNCT
dpc-4050	104	34	for	for	ADP
dpc-4050	104	35	48	48	NUM
dpc-4050	104	36	patients	patient	NOUN
dpc-4050	104	37	(	(	PUNCT
dpc-4050	104	38	65.8	65.8	NUM
dpc-4050	104	39	%	%	NOUN
dpc-4050	104	40	)	)	PUNCT
dpc-4050	104	41	.	.	PUNCT
dpc-4050	105	1	the	the	DET
dpc-4050	105	2	mean	mean	ADJ
dpc-4050	105	3	disease	disease	NOUN
dpc-4050	105	4	duration	duration	NOUN
dpc-4050	105	5	was	be	AUX
dpc-4050	105	6	25.3	25.3	NUM
dpc-4050	105	7	years	year	NOUN
dpc-4050	105	8	(	(	PUNCT
dpc-4050	105	9	sd	sd	NOUN
dpc-4050	105	10	=	=	SYM
dpc-4050	105	11	16.0	16.0	NUM
dpc-4050	105	12	)	)	PUNCT
dpc-4050	105	13	,	,	PUNCT
dpc-4050	105	14	with	with	ADP
dpc-4050	105	15	a	a	DET
dpc-4050	105	16	minimum	minimum	NOUN
dpc-4050	105	17	of	of	ADP
dpc-4050	105	18	1	1	NUM
dpc-4050	105	19	year	year	NOUN
dpc-4050	105	20	and	and	CCONJ
dpc-4050	105	21	a	a	DET
dpc-4050	105	22	maximum	maximum	NOUN
dpc-4050	105	23	of	of	ADP
dpc-4050	105	24	63	63	NUM
dpc-4050	105	25	years	year	NOUN
dpc-4050	105	26	.	.	PUNCT
dpc-4050	106	1	most	most	ADJ
dpc-4050	106	2	patients	patient	NOUN
dpc-4050	106	3	(	(	PUNCT
dpc-4050	106	4	n	n	NOUN
dpc-4050	106	5	=	=	SYM
dpc-4050	106	6	62	62	NUM
dpc-4050	106	7	;	;	PUNCT
dpc-4050	106	8	84.9	84.9	NUM
dpc-4050	106	9	%	%	NOUN
dpc-4050	106	10	)	)	PUNCT
dpc-4050	106	11	had	have	AUX
dpc-4050	106	12	undergone	undergo	VERB
dpc-4050	106	13	a	a	DET
dpc-4050	106	14	traditional	traditional	ADJ
dpc-4050	106	15	systemic	systemic	ADJ
dpc-4050	106	16	therapy	therapy	NOUN
dpc-4050	106	17	and	and	CCONJ
dpc-4050	106	18	15	15	NUM
dpc-4050	106	19	patients	patient	NOUN
dpc-4050	106	20	(	(	PUNCT
dpc-4050	106	21	20.5	20.5	NUM
dpc-4050	106	22	%	%	NOUN
dpc-4050	106	23	)	)	PUNCT
dpc-4050	106	24	were	be	AUX
dpc-4050	106	25	bio	bio	ADV
dpc-4050	106	26	naive	naive	ADJ
dpc-4050	106	27	.	.	PUNCT
dpc-4050	107	1	the	the	DET
dpc-4050	107	2	most	most	ADV
dpc-4050	107	3	frequently	frequently	ADV
dpc-4050	107	4	prescribed	prescribe	VERB
dpc-4050	107	5	traditional	traditional	ADJ
dpc-4050	107	6	therapy	therapy	NOUN
dpc-4050	107	7	before	before	ADP
dpc-4050	107	8	treatment	treatment	NOUN
dpc-4050	107	9	with	with	ADP
dpc-4050	107	10	ixekizumab	ixekizumab	NOUN
dpc-4050	107	11	was	be	AUX
dpc-4050	107	12	methotrexate	methotrexate	NOUN
dpc-4050	107	13	(	(	PUNCT
dpc-4050	107	14	47	47	NUM
dpc-4050	107	15	patients	patient	NOUN
dpc-4050	107	16	)	)	PUNCT
dpc-4050	107	17	and	and	CCONJ
dpc-4050	107	18	the	the	DET
dpc-4050	107	19	most	most	ADV
dpc-4050	107	20	frequently	frequently	ADV
dpc-4050	107	21	prescribed	prescribe	VERB
dpc-4050	107	22	biologic	biologic	NOUN
dpc-4050	107	23	was	be	AUX
dpc-4050	107	24	an	an	DET
dpc-4050	107	25	anti	anti	ADJ
dpc-4050	107	26	tnf	tnf	PROPN
dpc-4050	107	27	-	-	PUNCT
dpc-4050	107	28	α	α	PROPN
dpc-4050	107	29	agent	agent	NOUN
dpc-4050	107	30	.	.	PUNCT
dpc-4050	108	1	most	most	ADJ
dpc-4050	108	2	patients	patient	NOUN
dpc-4050	108	3	(	(	PUNCT
dpc-4050	108	4	n	n	NOUN
dpc-4050	108	5	=	=	SYM
dpc-4050	108	6	60	60	NUM
dpc-4050	108	7	;	;	PUNCT
dpc-4050	108	8	82.2	82.2	NUM
dpc-4050	108	9	%	%	NOUN
dpc-4050	108	10	)	)	PUNCT
dpc-4050	108	11	had	have	VERB
dpc-4050	108	12	comorbidities	comorbiditie	NOUN
dpc-4050	108	13	and	and	CCONJ
dpc-4050	108	14	the	the	DET
dpc-4050	108	15	most	most	ADV
dpc-4050	108	16	frequent	frequent	ADJ
dpc-4050	108	17	were	be	AUX
dpc-4050	108	18	the	the	DET
dpc-4050	108	19	cardiovascular	cardiovascular	ADJ
dpc-4050	108	20	diseases	disease	NOUN
dpc-4050	108	21	.	.	PUNCT
dpc-4050	109	1	see	see	VERB
dpc-4050	109	2	table	table	NOUN
dpc-4050	109	3	1	1	NUM
dpc-4050	109	4	for	for	ADP
dpc-4050	109	5	clinical	clinical	ADJ
dpc-4050	109	6	and	and	CCONJ
dpc-4050	109	7	demographic	demographic	ADJ
dpc-4050	109	8	details	detail	NOUN
dpc-4050	109	9	about	about	ADP
dpc-4050	109	10	the	the	DET
dpc-4050	109	11	sample	sample	NOUN
dpc-4050	109	12	.	.	PUNCT
dpc-4050	110	1	concerning	concern	VERB
dpc-4050	110	2	the	the	DET
dpc-4050	110	3	safety	safety	NOUN
dpc-4050	110	4	of	of	ADP
dpc-4050	110	5	ixekizumab	ixekizumab	NOUN
dpc-4050	110	6	,	,	PUNCT
dpc-4050	110	7	during	during	ADP
dpc-4050	110	8	the	the	DET
dpc-4050	110	9	study	study	NOUN
dpc-4050	110	10	only	only	ADV
dpc-4050	110	11	2	2	NUM
dpc-4050	110	12	mild	mild	ADJ
dpc-4050	110	13	adverse	adverse	ADJ
dpc-4050	110	14	events	event	NOUN
dpc-4050	110	15	have	have	AUX
dpc-4050	110	16	been	be	AUX
dpc-4050	110	17	recorded	record	VERB
dpc-4050	110	18	(	(	PUNCT
dpc-4050	110	19	oral	oral	ADJ
dpc-4050	110	20	candidiasis	candidiasis	NOUN
dpc-4050	110	21	and	and	CCONJ
dpc-4050	110	22	pain	pain	NOUN
dpc-4050	110	23	at	at	ADP
dpc-4050	110	24	the	the	DET
dpc-4050	110	25	injection	injection	NOUN
dpc-4050	110	26	site	site	NOUN
dpc-4050	110	27	)	)	PUNCT
dpc-4050	110	28	.	.	PUNCT
dpc-4050	111	1	in	in	ADP
dpc-4050	111	2	order	order	NOUN
dpc-4050	111	3	to	to	PART
dpc-4050	111	4	evaluate	evaluate	VERB
dpc-4050	111	5	the	the	DET
dpc-4050	111	6	effectiveness	effectiveness	NOUN
dpc-4050	111	7	of	of	ADP
dpc-4050	111	8	the	the	DET
dpc-4050	111	9	ixekizumab	ixekizumab	NOUN
dpc-4050	111	10	,	,	PUNCT
dpc-4050	111	11	detailed	detailed	ADJ
dpc-4050	111	12	analyses	analysis	NOUN
dpc-4050	111	13	of	of	ADP
dpc-4050	111	14	the	the	DET
dpc-4050	111	15	score	score	NOUN
dpc-4050	111	16	trend	trend	NOUN
dpc-4050	111	17	for	for	ADP
dpc-4050	111	18	the	the	DET
dpc-4050	111	19	pasi	pasi	NOUN
dpc-4050	111	20	,	,	PUNCT
dpc-4050	111	21	vas	vas	PROPN
dpc-4050	111	22	and	and	CCONJ
dpc-4050	111	23	dlqi	dlqi	PROPN
dpc-4050	111	24	were	be	AUX
dpc-4050	111	25	performed	perform	VERB
dpc-4050	111	26	.	.	PUNCT
dpc-4050	112	1	pasi	pasi	NOUN
dpc-4050	112	2	score	score	NOUN
dpc-4050	112	3	at	at	ADP
dpc-4050	112	4	baseline	baseline	NOUN
dpc-4050	112	5	the	the	DET
dpc-4050	112	6	mean	mean	ADJ
dpc-4050	112	7	pasi	pasi	NOUN
dpc-4050	112	8	score	score	NOUN
dpc-4050	112	9	was	be	AUX
dpc-4050	112	10	14.6	14.6	NUM
dpc-4050	112	11	(	(	PUNCT
dpc-4050	112	12	sd=8.7	sd=8.7	NOUN
dpc-4050	112	13	)	)	PUNCT
dpc-4050	112	14	,	,	PUNCT
dpc-4050	112	15	with	with	ADP
dpc-4050	112	16	a	a	DET
dpc-4050	112	17	minimum	minimum	NOUN
dpc-4050	112	18	of	of	ADP
dpc-4050	112	19	1	1	NUM
dpc-4050	112	20	and	and	CCONJ
dpc-4050	112	21	a	a	DET
dpc-4050	112	22	maximum	maximum	NOUN
dpc-4050	112	23	of	of	ADP
dpc-4050	112	24	60	60	NUM
dpc-4050	112	25	points	point	NOUN
dpc-4050	112	26	.	.	PUNCT
dpc-4050	113	1	after	after	ADP
dpc-4050	113	2	only	only	ADV
dpc-4050	113	3	16	16	NUM
dpc-4050	113	4	weeks	week	NOUN
dpc-4050	113	5	of	of	ADP
dpc-4050	113	6	treatment	treatment	NOUN
dpc-4050	113	7	,	,	PUNCT
dpc-4050	113	8	pasi	pasi	NOUN
dpc-4050	113	9	scores	score	NOUN
dpc-4050	113	10	had	have	AUX
dpc-4050	113	11	improved	improve	VERB
dpc-4050	113	12	,	,	PUNCT
dpc-4050	113	13	reaching	reach	VERB
dpc-4050	113	14	a	a	DET
dpc-4050	113	15	mean	mean	ADJ
dpc-4050	113	16	value	value	NOUN
dpc-4050	113	17	of	of	ADP
dpc-4050	113	18	1.4	1.4	NUM
dpc-4050	113	19	(	(	PUNCT
dpc-4050	113	20	sd=2.4	sd=2.4	PROPN
dpc-4050	113	21	)	)	PUNCT
dpc-4050	113	22	,	,	PUNCT
dpc-4050	113	23	with	with	ADP
dpc-4050	113	24	a	a	DET
dpc-4050	113	25	minimum	minimum	NOUN
dpc-4050	113	26	of	of	ADP
dpc-4050	113	27	0	0	NUM
dpc-4050	113	28	and	and	CCONJ
dpc-4050	113	29	a	a	DET
dpc-4050	113	30	maximum	maximum	ADJ
dpc-4050	113	31	score	score	NOUN
dpc-4050	113	32	of	of	ADP
dpc-4050	113	33	10	10	NUM
dpc-4050	113	34	points	point	NOUN
dpc-4050	113	35	.	.	PUNCT
dpc-4050	114	1	this	this	DET
dpc-4050	114	2	trend	trend	NOUN
dpc-4050	114	3	remained	remain	VERB
dpc-4050	114	4	stable	stable	ADJ
dpc-4050	114	5	until	until	ADP
dpc-4050	114	6	the	the	DET
dpc-4050	114	7	end	end	NOUN
dpc-4050	114	8	of	of	ADP
dpc-4050	114	9	the	the	DET
dpc-4050	114	10	study	study	NOUN
dpc-4050	114	11	(	(	PUNCT
dpc-4050	114	12	table	table	NOUN
dpc-4050	114	13	2	2	NUM
dpc-4050	114	14	and	and	CCONJ
dpc-4050	114	15	figure	figure	NOUN
dpc-4050	114	16	1	1	NUM
dpc-4050	114	17	)	)	PUNCT
dpc-4050	114	18	.	.	PUNCT
dpc-4050	115	1	the	the	DET
dpc-4050	115	2	oneway	oneway	PROPN
dpc-4050	115	3	anova	anova	PROPN
dpc-4050	115	4	model	model	PROPN
dpc-4050	115	5	presented	present	VERB
dpc-4050	115	6	a	a	DET
dpc-4050	115	7	significant	significant	ADJ
dpc-4050	115	8	effect	effect	NOUN
dpc-4050	115	9	of	of	ADP
dpc-4050	115	10	time	time	NOUN
dpc-4050	115	11	on	on	ADP
dpc-4050	115	12	pasi	pasi	NOUN
dpc-4050	115	13	score	score	NOUN
dpc-4050	115	14	(	(	PUNCT
dpc-4050	115	15	p	p	X
dpc-4050	115	16	<	<	X
dpc-4050	115	17	0.0001	0.0001	NUM
dpc-4050	115	18	)	)	PUNCT
dpc-4050	115	19	;	;	PUNCT
dpc-4050	115	20	pairwise	pairwise	NOUN
dpc-4050	115	21	comparisons	comparison	NOUN
dpc-4050	115	22	highlighted	highlight	VERB
dpc-4050	115	23	a	a	DET
dpc-4050	115	24	significant	significant	ADJ
dpc-4050	115	25	difference	difference	NOUN
dpc-4050	115	26	only	only	ADV
dpc-4050	115	27	between	between	ADP
dpc-4050	115	28	baseline	baseline	NOUN
dpc-4050	115	29	and	and	CCONJ
dpc-4050	115	30	all	all	DET
dpc-4050	115	31	the	the	DET
dpc-4050	115	32	other	other	ADJ
dpc-4050	115	33	time	time	NOUN
dpc-4050	115	34	points	point	NOUN
dpc-4050	115	35	(	(	PUNCT
dpc-4050	115	36	p	p	X
dpc-4050	115	37	<	<	X
dpc-4050	115	38	0.0001	0.0001	NUM
dpc-4050	115	39	)	)	PUNCT
dpc-4050	115	40	.	.	PUNCT
dpc-4050	116	1	pasi90	pasi90	NOUN
dpc-4050	116	2	has	have	AUX
dpc-4050	116	3	been	be	AUX
dpc-4050	116	4	achieved	achieve	VERB
dpc-4050	116	5	by	by	ADP
dpc-4050	116	6	all	all	DET
dpc-4050	116	7	the	the	DET
dpc-4050	116	8	patients	patient	NOUN
dpc-4050	116	9	in	in	ADP
dpc-4050	116	10	week	week	NOUN
dpc-4050	116	11	16	16	NUM
dpc-4050	116	12	and	and	CCONJ
dpc-4050	116	13	remained	remain	VERB
dpc-4050	116	14	stable	stable	ADJ
dpc-4050	116	15	until	until	ADP
dpc-4050	116	16	the	the	DET
dpc-4050	116	17	end	end	NOUN
dpc-4050	116	18	of	of	ADP
dpc-4050	116	19	the	the	DET
dpc-4050	116	20	study	study	NOUN
dpc-4050	116	21	.	.	PUNCT
dpc-4050	117	1	pasi100	pasi100	PROPN
dpc-4050	117	2	has	have	AUX
dpc-4050	117	3	been	be	AUX
dpc-4050	117	4	achieved	achieve	VERB
dpc-4050	117	5	by	by	ADP
dpc-4050	117	6	55.1	55.1	NUM
dpc-4050	117	7	%	%	NOUN
dpc-4050	117	8	of	of	ADP
dpc-4050	117	9	patients	patient	NOUN
dpc-4050	117	10	on	on	ADP
dpc-4050	117	11	weeks	week	NOUN
dpc-4050	117	12	16	16	NUM
dpc-4050	117	13	and	and	CCONJ
dpc-4050	117	14	by	by	ADP
dpc-4050	117	15	81.3	81.3	NUM
dpc-4050	117	16	%	%	NOUN
dpc-4050	117	17	on	on	ADP
dpc-4050	117	18	week	week	NOUN
dpc-4050	117	19	104	104	NUM
dpc-4050	117	20	(	(	PUNCT
dpc-4050	117	21	table	table	NOUN
dpc-4050	117	22	3	3	NUM
dpc-4050	117	23	and	and	CCONJ
dpc-4050	117	24	figure	figure	NOUN
dpc-4050	117	25	2	2	NUM
dpc-4050	117	26	)	)	PUNCT
dpc-4050	117	27	.	.	PUNCT
dpc-4050	118	1	the	the	DET
dpc-4050	118	2	proportions	proportion	NOUN
dpc-4050	118	3	of	of	ADP
dpc-4050	118	4	patients	patient	NOUN
dpc-4050	118	5	achieving	achieve	VERB
dpc-4050	118	6	pasi	pasi	NOUN
dpc-4050	118	7	90	90	NUM
dpc-4050	118	8	and	and	CCONJ
dpc-4050	118	9	pasi	pasi	NOUN
dpc-4050	118	10	100	100	NUM
dpc-4050	118	11	,	,	PUNCT
dpc-4050	118	12	in	in	ADP
dpc-4050	118	13	the	the	DET
dpc-4050	118	14	bio	bio	ADJ
dpc-4050	118	15	-	-	ADJ
dpc-4050	118	16	naïve	naïve	ADJ
dpc-4050	118	17	group	group	NOUN
dpc-4050	118	18	and	and	CCONJ
dpc-4050	118	19	in	in	ADP
dpc-4050	118	20	the	the	DET
dpc-4050	118	21	bio	bio	ADJ
dpc-4050	118	22	-	-	PUNCT
dpc-4050	118	23	experienced	experienced	ADJ
dpc-4050	118	24	group	group	NOUN
dpc-4050	118	25	,	,	PUNCT
dpc-4050	118	26	are	be	AUX
dpc-4050	118	27	displayed	display	VERB
dpc-4050	118	28	in	in	ADP
dpc-4050	118	29	table	table	NOUN
dpc-4050	118	30	4	4	NUM
dpc-4050	118	31	.	.	PUNCT
dpc-4050	119	1	pasi	pasi	NOUN
dpc-4050	119	2	90	90	NUM
dpc-4050	119	3	was	be	AUX
dpc-4050	119	4	achieved	achieve	VERB
dpc-4050	119	5	by	by	ADP
dpc-4050	119	6	all	all	DET
dpc-4050	119	7	the	the	DET
dpc-4050	119	8	patients	patient	NOUN
dpc-4050	119	9	in	in	ADP
dpc-4050	119	10	both	both	CCONJ
dpc-4050	119	11	the	the	DET
dpc-4050	119	12	groups	group	NOUN
dpc-4050	119	13	in	in	ADP
dpc-4050	119	14	week	week	NOUN
dpc-4050	119	15	16	16	NUM
dpc-4050	119	16	and	and	CCONJ
dpc-4050	119	17	the	the	DET
dpc-4050	119	18	result	result	NOUN
dpc-4050	119	19	was	be	AUX
dpc-4050	119	20	maintained	maintain	VERB
dpc-4050	119	21	until	until	ADP
dpc-4050	119	22	week	week	NOUN
dpc-4050	119	23	156	156	NUM
dpc-4050	119	24	.	.	PUNCT
dpc-4050	120	1	pasi	pasi	PROPN
dpc-4050	120	2	100	100	NUM
dpc-4050	120	3	,	,	PUNCT
dpc-4050	120	4	for	for	ADP
dpc-4050	120	5	all	all	DET
dpc-4050	120	6	the	the	DET
dpc-4050	120	7	bio	bio	ADJ
dpc-4050	120	8	-	-	ADJ
dpc-4050	120	9	naïve	naïve	ADJ
dpc-4050	120	10	patients	patient	NOUN
dpc-4050	120	11	,	,	PUNCT
dpc-4050	120	12	is	be	AUX
dpc-4050	120	13	achieved	achieve	VERB
dpc-4050	120	14	in	in	ADP
dpc-4050	120	15	week	week	NOUN
dpc-4050	120	16	24	24	NUM
dpc-4050	120	17	and	and	CCONJ
dpc-4050	120	18	maintained	maintain	VERB
dpc-4050	120	19	in	in	ADP
dpc-4050	120	20	week	week	NOUN
dpc-4050	120	21	52	52	NUM
dpc-4050	120	22	and	and	CCONJ
dpc-4050	120	23	104	104	NUM
dpc-4050	120	24	.	.	PUNCT
dpc-4050	121	1	in	in	ADP
dpc-4050	121	2	week	week	NOUN
dpc-4050	121	3	156	156	NUM
dpc-4050	121	4	the	the	DET
dpc-4050	121	5	proportion	proportion	NOUN
dpc-4050	121	6	of	of	ADP
dpc-4050	121	7	patient	patient	ADJ
dpc-4050	121	8	achieving	achieve	VERB
dpc-4050	121	9	pasi	pasi	NOUN
dpc-4050	121	10	100	100	NUM
dpc-4050	121	11	decreased	decrease	VERB
dpc-4050	121	12	to	to	ADP
dpc-4050	121	13	83.3	83.3	NUM
dpc-4050	121	14	%	%	NOUN
dpc-4050	121	15	.	.	PUNCT
dpc-4050	122	1	for	for	ADP
dpc-4050	122	2	the	the	DET
dpc-4050	122	3	bio	bio	ADJ
dpc-4050	122	4	-	-	PUNCT
dpc-4050	122	5	experienced	experienced	ADJ
dpc-4050	122	6	group	group	NOUN
dpc-4050	122	7	,	,	PUNCT
dpc-4050	122	8	the	the	DET
dpc-4050	122	9	proportion	proportion	NOUN
dpc-4050	122	10	of	of	ADP
dpc-4050	122	11	patients	patient	NOUN
dpc-4050	122	12	achieving	achieve	VERB
dpc-4050	122	13	pasi	pasi	NOUN
dpc-4050	122	14	100	100	NUM
dpc-4050	122	15	is	be	AUX
dpc-4050	122	16	constantly	constantly	ADV
dpc-4050	122	17	increased	increase	VERB
dpc-4050	122	18	from	from	ADP
dpc-4050	122	19	52.7	52.7	NUM
dpc-4050	122	20	%	%	NOUN
dpc-4050	122	21	of	of	ADP
dpc-4050	122	22	week	week	NOUN
dpc-4050	122	23	16	16	NUM
dpc-4050	122	24	to	to	PART
dpc-4050	122	25	80.0	80.0	NUM
dpc-4050	122	26	%	%	NOUN
dpc-4050	122	27	of	of	ADP
dpc-4050	122	28	week	week	NOUN
dpc-4050	122	29	156	156	NUM
dpc-4050	122	30	.	.	PUNCT
dpc-4050	123	1	vas	vas	X
dpc-4050	123	2	score	score	NOUN
dpc-4050	123	3	at	at	ADP
dpc-4050	123	4	baseline	baseline	NOUN
dpc-4050	123	5	the	the	DET
dpc-4050	123	6	mean	mean	ADJ
dpc-4050	123	7	pain	pain	NOUN
dpc-4050	123	8	vas	vas	X
dpc-4050	123	9	score	score	NOUN
dpc-4050	123	10	was	be	AUX
dpc-4050	123	11	16.5	16.5	NUM
dpc-4050	123	12	points	point	NOUN
dpc-4050	123	13	(	(	PUNCT
dpc-4050	123	14	sd=23.3	sd=23.3	PROPN
dpc-4050	123	15	)	)	PUNCT
dpc-4050	123	16	,	,	PUNCT
dpc-4050	123	17	with	with	ADP
dpc-4050	123	18	a	a	DET
dpc-4050	123	19	minimum	minimum	NOUN
dpc-4050	123	20	of	of	ADP
dpc-4050	123	21	0	0	NUM
dpc-4050	123	22	and	and	CCONJ
dpc-4050	123	23	a	a	DET
dpc-4050	123	24	maximum	maximum	NOUN
dpc-4050	123	25	of	of	ADP
dpc-4050	123	26	80	80	NUM
dpc-4050	123	27	.	.	PUNCT
dpc-4050	124	1	mean	mean	PROPN
dpc-4050	124	2	vas	vas	X
dpc-4050	124	3	score	score	NOUN
dpc-4050	124	4	decreased	decrease	VERB
dpc-4050	124	5	with	with	ADP
dpc-4050	124	6	time	time	NOUN
dpc-4050	124	7	reaching	reach	VERB
dpc-4050	124	8	its	its	PRON
dpc-4050	124	9	minimum	minimum	NOUN
dpc-4050	124	10	of	of	ADP
dpc-4050	124	11	1.7	1.7	NUM
dpc-4050	124	12	points	point	NOUN
dpc-4050	124	13	at	at	ADP
dpc-4050	124	14	week	week	NOUN
dpc-4050	124	15	52	52	NUM
dpc-4050	124	16	and	and	CCONJ
dpc-4050	124	17	maintained	maintain	VERB
dpc-4050	124	18	at	at	ADP
dpc-4050	124	19	week	week	NOUN
dpc-4050	124	20	104	104	NUM
dpc-4050	124	21	.	.	PUNCT
dpc-4050	125	1	at	at	ADP
dpc-4050	125	2	week	week	NOUN
dpc-4050	125	3	156	156	NUM
dpc-4050	125	4	mean	mean	NOUN
dpc-4050	125	5	vas	vas	X
dpc-4050	125	6	score	score	NOUN
dpc-4050	125	7	presented	present	VERB
dpc-4050	125	8	a	a	DET
dpc-4050	125	9	light	light	ADJ
dpc-4050	125	10	increase	increase	NOUN
dpc-4050	125	11	(	(	PUNCT
dpc-4050	125	12	2.3	2.3	NUM
dpc-4050	125	13	)	)	PUNCT
dpc-4050	125	14	.	.	PUNCT
dpc-4050	126	1	original	original	ADJ
dpc-4050	126	2	article	article	NOUN
dpc-4050	126	3	|	|	ADV
dpc-4050	126	4	dermatol	dermatol	ADJ
dpc-4050	126	5	pract	pract	NOUN
dpc-4050	126	6	concept	concept	NOUN
dpc-4050	126	7	.	.	PUNCT
dpc-4050	127	1	2024;14(3):e2024166	2024;14(3):e2024166	NUM
dpc-4050	127	2	5	5	NUM
dpc-4050	127	3	table	table	NOUN
dpc-4050	127	4	1	1	NUM
dpc-4050	127	5	.	.	PUNCT
dpc-4050	128	1	clinical	clinical	ADJ
dpc-4050	128	2	and	and	CCONJ
dpc-4050	128	3	demographic	demographic	ADJ
dpc-4050	128	4	characteristics	characteristic	NOUN
dpc-4050	128	5	of	of	ADP
dpc-4050	128	6	the	the	DET
dpc-4050	128	7	sample	sample	NOUN
dpc-4050	128	8	(	(	PUNCT
dpc-4050	128	9	n	n	NOUN
dpc-4050	128	10	=	=	SYM
dpc-4050	128	11	73	73	NUM
dpc-4050	128	12	)	)	PUNCT
dpc-4050	128	13	characteristics	characteristic	NOUN
dpc-4050	128	14	sex	sex	NOUN
dpc-4050	128	15	(	(	PUNCT
dpc-4050	128	16	n;%	n;%	NOUN
dpc-4050	128	17	)	)	PUNCT
dpc-4050	128	18	male	male	NOUN
dpc-4050	128	19	41	41	NUM
dpc-4050	129	1	56.2	56.2	NUM
dpc-4050	129	2	female	female	ADJ
dpc-4050	129	3	32	32	NUM
dpc-4050	129	4	43.8	43.8	NUM
dpc-4050	129	5	diagnosis	diagnosis	NOUN
dpc-4050	129	6	(	(	PUNCT
dpc-4050	129	7	n;%	n;%	NOUN
dpc-4050	129	8	)	)	PUNCT
dpc-4050	129	9	pso	pso	NOUN
dpc-4050	129	10	-	-	PUNCT
dpc-4050	129	11	psa	psa	NOUN
dpc-4050	129	12	48	48	NUM
dpc-4050	129	13	65.8	65.8	NUM
dpc-4050	129	14	pso	pso	NOUN
dpc-4050	129	15	24	24	NUM
dpc-4050	129	16	32.9	32.9	NUM
dpc-4050	129	17	psa	psa	NOUN
dpc-4050	129	18	1	1	NUM
dpc-4050	129	19	1.4	1.4	NUM
dpc-4050	129	20	age	age	NOUN
dpc-4050	129	21	(	(	PUNCT
dpc-4050	129	22	mean	mean	VERB
dpc-4050	129	23	;	;	PUNCT
dpc-4050	129	24	sd	sd	X
dpc-4050	129	25	)	)	PUNCT
dpc-4050	129	26	71.5	71.5	NUM
dpc-4050	129	27	6.4	6.4	NUM
dpc-4050	129	28	bmi	bmi	NOUN
dpc-4050	129	29	(	(	PUNCT
dpc-4050	129	30	mean	mean	VERB
dpc-4050	129	31	;	;	PUNCT
dpc-4050	129	32	sd	sd	X
dpc-4050	129	33	)	)	PUNCT
dpc-4050	129	34	27.3	27.3	NUM
dpc-4050	129	35	4.1	4.1	NUM
dpc-4050	129	36	disease	disease	NOUN
dpc-4050	129	37	duration	duration	NOUN
dpc-4050	129	38	(	(	PUNCT
dpc-4050	129	39	mean	mean	VERB
dpc-4050	129	40	;	;	PUNCT
dpc-4050	129	41	sd	sd	X
dpc-4050	129	42	)	)	PUNCT
dpc-4050	129	43	25.3	25.3	NUM
dpc-4050	129	44	16.0	16.0	NUM
dpc-4050	129	45	pso	pso	NOUN
dpc-4050	129	46	locations	location	NOUN
dpc-4050	129	47	(	(	PUNCT
dpc-4050	129	48	n;%	n;%	NOUN
dpc-4050	129	49	)	)	PUNCT
dpc-4050	129	50	difficult	difficult	ADJ
dpc-4050	129	51	areas	area	NOUN
dpc-4050	129	52	30	30	NUM
dpc-4050	129	53	41.1	41.1	NUM
dpc-4050	129	54	widespread	widespread	ADJ
dpc-4050	129	55	23	23	NUM
dpc-4050	129	56	31.5	31.5	NUM
dpc-4050	129	57	missing	miss	VERB
dpc-4050	129	58	19	19	NUM
dpc-4050	129	59	26.4	26.4	NUM
dpc-4050	129	60	psa	psa	NOUN
dpc-4050	129	61	subtype	subtype	NOUN
dpc-4050	129	62	(	(	PUNCT
dpc-4050	129	63	n;%	n;%	NOUN
dpc-4050	129	64	)	)	PUNCT
dpc-4050	129	65	polyarticular	polyarticular	NOUN
dpc-4050	129	66	27	27	NUM
dpc-4050	129	67	37.0	37.0	NUM
dpc-4050	129	68	oligoarticular	oligoarticular	ADJ
dpc-4050	129	69	21	21	NUM
dpc-4050	129	70	28.8	28.8	NUM
dpc-4050	129	71	missing	miss	VERB
dpc-4050	129	72	1	1	NUM
dpc-4050	129	73	2.0	2.0	NUM
dpc-4050	129	74	traditional	traditional	ADJ
dpc-4050	129	75	therapy	therapy	NOUN
dpc-4050	129	76	(	(	PUNCT
dpc-4050	129	77	n;%	n;%	NOUN
dpc-4050	129	78	)	)	PUNCT
dpc-4050	130	1	yes	yes	INTJ
dpc-4050	130	2	62	62	NUM
dpc-4050	130	3	84.9	84.9	NUM
dpc-4050	130	4	no	no	DET
dpc-4050	130	5	11	11	NUM
dpc-4050	130	6	15.1	15.1	NUM
dpc-4050	130	7	traditional	traditional	ADJ
dpc-4050	130	8	therapy	therapy	NOUN
dpc-4050	130	9	drug	drug	NOUN
dpc-4050	130	10	details	detail	NOUN
dpc-4050	130	11	(	(	PUNCT
dpc-4050	130	12	frequency	frequency	NOUN
dpc-4050	130	13	of	of	ADP
dpc-4050	130	14	patients	patient	NOUN
dpc-4050	130	15	that	that	PRON
dpc-4050	130	16	underwent	undergo	VERB
dpc-4050	130	17	a	a	DET
dpc-4050	130	18	certain	certain	ADJ
dpc-4050	130	19	traditional	traditional	ADJ
dpc-4050	130	20	therapy	therapy	NOUN
dpc-4050	130	21	.	.	PUNCT
dpc-4050	131	1	the	the	DET
dpc-4050	131	2	same	same	ADJ
dpc-4050	131	3	patient	patient	NOUN
dpc-4050	131	4	could	could	AUX
dpc-4050	131	5	have	have	AUX
dpc-4050	131	6	undergone	undergo	VERB
dpc-4050	131	7	more	more	ADJ
dpc-4050	131	8	than	than	ADP
dpc-4050	131	9	one	one	NUM
dpc-4050	131	10	type	type	NOUN
dpc-4050	131	11	of	of	ADP
dpc-4050	131	12	traditional	traditional	ADJ
dpc-4050	131	13	medicine	medicine	NOUN
dpc-4050	131	14	)	)	PUNCT
dpc-4050	131	15	acitretin	acitretin	VERB
dpc-4050	131	16	10	10	NUM
dpc-4050	131	17	cyclosporine	cyclosporine	NOUN
dpc-4050	131	18	25	25	NUM
dpc-4050	131	19	oral	oral	ADJ
dpc-4050	131	20	steroids	steroid	NOUN
dpc-4050	131	21	5	5	NUM
dpc-4050	131	22	phototherapy	phototherapy	NOUN
dpc-4050	131	23	7	7	NUM
dpc-4050	131	24	methotrexate	methotrexate	NOUN
dpc-4050	131	25	47	47	NUM
dpc-4050	131	26	salazopyrine	salazopyrine	NOUN
dpc-4050	131	27	3	3	NUM
dpc-4050	131	28	bio	bio	ADJ
dpc-4050	131	29	-	-	ADJ
dpc-4050	131	30	naive	naive	ADJ
dpc-4050	131	31	(	(	PUNCT
dpc-4050	131	32	n;%	n;%	NOUN
dpc-4050	131	33	)	)	PUNCT
dpc-4050	132	1	no	no	DET
dpc-4050	132	2	58	58	NUM
dpc-4050	132	3	79.5	79.5	NUM
dpc-4050	132	4	yes	yes	NUM
dpc-4050	132	5	15	15	NUM
dpc-4050	132	6	20.5	20.5	NUM
dpc-4050	132	7	bio	bio	ADV
dpc-4050	132	8	-	-	ADJ
dpc-4050	132	9	experienced	experienced	ADJ
dpc-4050	132	10	(	(	PUNCT
dpc-4050	132	11	n	n	CCONJ
dpc-4050	132	12	%	%	NOUN
dpc-4050	132	13	)	)	PUNCT
dpc-4050	132	14	anti	anti	PROPN
dpc-4050	132	15	tnf	tnf	PROPN
dpc-4050	132	16	-	-	PUNCT
dpc-4050	132	17	alpha	alpha	NOUN
dpc-4050	132	18	43	43	NUM
dpc-4050	132	19	58.9	58.9	NUM
dpc-4050	132	20	anti	anti	X
dpc-4050	132	21	tnf	tnf	PROPN
dpc-4050	132	22	-	-	PUNCT
dpc-4050	132	23	alpha	alpha	NOUN
dpc-4050	132	24	,	,	PUNCT
dpc-4050	132	25	anti	anti	X
dpc-4050	132	26	il-17	il-17	ADP
dpc-4050	132	27	4	4	NUM
dpc-4050	132	28	5.5	5.5	NUM
dpc-4050	132	29	anti	anti	X
dpc-4050	132	30	tnf	tnf	PROPN
dpc-4050	132	31	-	-	PUNCT
dpc-4050	132	32	alpha	alpha	NOUN
dpc-4050	132	33	,	,	PUNCT
dpc-4050	132	34	anti	anti	X
dpc-4050	132	35	il-17	il-17	ADV
dpc-4050	132	36	,	,	PUNCT
dpc-4050	132	37	anti	anti	ADJ
dpc-4050	132	38	il-23	il-23	NOUN
dpc-4050	132	39	3	3	NUM
dpc-4050	132	40	4.1	4.1	NUM
dpc-4050	132	41	anti	anti	X
dpc-4050	132	42	tnf	tnf	PROPN
dpc-4050	132	43	-	-	PUNCT
dpc-4050	132	44	alpha	alpha	NOUN
dpc-4050	132	45	,	,	PUNCT
dpc-4050	132	46	anti	anti	ADJ
dpc-4050	132	47	il-23	il-23	NOUN
dpc-4050	132	48	3	3	NUM
dpc-4050	132	49	4.1	4.1	NUM
dpc-4050	132	50	anti	anti	NOUN
dpc-4050	132	51	il-23	il-23	NOUN
dpc-4050	132	52	2	2	NUM
dpc-4050	132	53	2.7	2.7	NUM
dpc-4050	132	54	apremilast	apremilast	NOUN
dpc-4050	132	55	2	2	NUM
dpc-4050	132	56	2.7	2.7	NUM
dpc-4050	132	57	anti	anti	X
dpc-4050	132	58	il-17	il-17	ADP
dpc-4050	132	59	1	1	NUM
dpc-4050	132	60	1.4	1.4	NUM
dpc-4050	132	61	comorbidities	comorbiditie	NOUN
dpc-4050	132	62	(	(	PUNCT
dpc-4050	132	63	n;%	n;%	NOUN
dpc-4050	132	64	)	)	PUNCT
dpc-4050	132	65	yes	yes	INTJ
dpc-4050	132	66	(	(	PUNCT
dpc-4050	132	67	60	60	NUM
dpc-4050	132	68	82.2	82.2	NUM
dpc-4050	132	69	no	no	DET
dpc-4050	132	70	13	13	NUM
dpc-4050	132	71	17.8	17.8	NUM
dpc-4050	132	72	comorbidities	comorbiditie	NOUN
dpc-4050	132	73	details	detail	NOUN
dpc-4050	132	74	(	(	PUNCT
dpc-4050	132	75	frequency	frequency	NOUN
dpc-4050	132	76	of	of	ADP
dpc-4050	132	77	patients	patient	NOUN
dpc-4050	132	78	that	that	PRON
dpc-4050	132	79	presents	present	VERB
dpc-4050	132	80	the	the	DET
dpc-4050	132	81	same	same	ADJ
dpc-4050	132	82	comorbidity	comorbidity	NOUN
dpc-4050	132	83	.	.	PUNCT
dpc-4050	133	1	the	the	DET
dpc-4050	133	2	same	same	ADJ
dpc-4050	133	3	patient	patient	NOUN
dpc-4050	133	4	could	could	AUX
dpc-4050	133	5	have	have	VERB
dpc-4050	133	6	more	more	ADJ
dpc-4050	133	7	than	than	ADP
dpc-4050	133	8	one	one	NUM
dpc-4050	133	9	comorbidity	comorbidity	NOUN
dpc-4050	133	10	)	)	PUNCT
dpc-4050	133	11	cardiovascular	cardiovascular	NOUN
dpc-4050	133	12	42	42	NUM
dpc-4050	133	13	other	other	ADJ
dpc-4050	133	14	18	18	NUM
dpc-4050	133	15	diabetes	diabetes	NOUN
dpc-4050	133	16	11	11	NUM
dpc-4050	133	17	dyslipidemia	dyslipidemia	NOUN
dpc-4050	133	18	10	10	NUM
dpc-4050	133	19	thyroid	thyroid	NOUN
dpc-4050	133	20	gland	gland	NOUN
dpc-4050	133	21	disorders	disorder	NOUN
dpc-4050	133	22	7	7	NUM
dpc-4050	133	23	depression	depression	NOUN
dpc-4050	133	24	3	3	NUM
dpc-4050	133	25	obesity	obesity	NOUN
dpc-4050	133	26	3	3	NUM
dpc-4050	133	27	fibromyalgia	fibromyalgia	NOUN
dpc-4050	133	28	2	2	NUM
dpc-4050	133	29	bipolar	bipolar	ADJ
dpc-4050	133	30	disorder	disorder	NOUN
dpc-4050	133	31	1	1	NUM
dpc-4050	133	32	tuberculosis	tuberculosis	NOUN
dpc-4050	133	33	1	1	NUM
dpc-4050	133	34	bmi	bmi	NOUN
dpc-4050	133	35	=	=	SYM
dpc-4050	133	36	body	body	NOUN
dpc-4050	133	37	mass	mass	PROPN
dpc-4050	133	38	index	index	NOUN
dpc-4050	133	39	;	;	PUNCT
dpc-4050	133	40	psa	psa	VERB
dpc-4050	133	41	=	=	SYM
dpc-4050	133	42	psoriatic	psoriatic	ADJ
dpc-4050	133	43	arthritis	arthritis	NOUN
dpc-4050	133	44	;	;	PUNCT
dpc-4050	133	45	pso	pso	NOUN
dpc-4050	133	46	=	=	NOUN
dpc-4050	133	47	psoriasis	psoriasis	NOUN
dpc-4050	133	48	;	;	PUNCT
dpc-4050	133	49	sd	sd	ADP
dpc-4050	133	50	standard	standard	ADJ
dpc-4050	133	51	deviation	deviation	NOUN
dpc-4050	133	52	.	.	PUNCT
dpc-4050	134	1	6	6	NUM
dpc-4050	134	2	original	original	ADJ
dpc-4050	134	3	article	article	NOUN
dpc-4050	134	4	|	|	ADV
dpc-4050	134	5	dermatol	dermatol	ADJ
dpc-4050	134	6	pract	pract	NOUN
dpc-4050	134	7	concept	concept	NOUN
dpc-4050	134	8	.	.	PUNCT
dpc-4050	135	1	2024;14(3):e2024166	2024;14(3):e2024166	NUM
dpc-4050	135	2	table	table	NOUN
dpc-4050	135	3	2	2	NUM
dpc-4050	135	4	.	.	PUNCT
dpc-4050	135	5	descriptive	descriptive	ADJ
dpc-4050	135	6	statistics	statistic	NOUN
dpc-4050	135	7	for	for	ADP
dpc-4050	135	8	pasi	pasi	NOUN
dpc-4050	135	9	score	score	NOUN
dpc-4050	135	10	at	at	ADP
dpc-4050	135	11	each	each	DET
dpc-4050	135	12	timepoints	timepoint	NOUN
dpc-4050	135	13	and	and	CCONJ
dpc-4050	135	14	pairwise	pairwise	NOUN
dpc-4050	135	15	comparisons	comparison	NOUN
dpc-4050	135	16	p	p	NOUN
dpc-4050	135	17	-	-	PUNCT
dpc-4050	135	18	value	value	NOUN
dpc-4050	135	19	.	.	PUNCT
dpc-4050	136	1	baseline	baseline	PROPN
dpc-4050	136	2	week	week	NOUN
dpc-4050	136	3	16	16	NUM
dpc-4050	136	4	week	week	NOUN
dpc-4050	136	5	24	24	NUM
dpc-4050	136	6	week	week	NOUN
dpc-4050	136	7	52	52	NUM
dpc-4050	136	8	week	week	NOUN
dpc-4050	136	9	104	104	NUM
dpc-4050	136	10	week	week	NOUN
dpc-4050	136	11	156	156	NUM
dpc-4050	136	12	n	n	NUM
dpc-4050	136	13	72	72	NUM
dpc-4050	136	14	69	69	NUM
dpc-4050	136	15	68	68	NUM
dpc-4050	136	16	64	64	NUM
dpc-4050	136	17	48	48	NUM
dpc-4050	136	18	40	40	NUM
dpc-4050	136	19	mean	mean	NOUN
dpc-4050	136	20	14.58	14.58	NUM
dpc-4050	136	21	1.43	1.43	NUM
dpc-4050	136	22	0.55	0.55	NUM
dpc-4050	136	23	0.59	0.59	NUM
dpc-4050	136	24	0.47	0.47	NUM
dpc-4050	136	25	0.81	0.81	NUM
dpc-4050	136	26	std	std	NOUN
dpc-4050	136	27	.	.	PUNCT
dpc-4050	137	1	dev	dev	PROPN
dpc-4050	137	2	.	.	PUNCT
dpc-4050	138	1	8.71	8.71	NUM
dpc-4050	138	2	2.39	2.39	NUM
dpc-4050	138	3	1.23	1.23	NUM
dpc-4050	138	4	1.54	1.54	NUM
dpc-4050	138	5	1.15	1.15	NUM
dpc-4050	138	6	1.82	1.82	NUM
dpc-4050	138	7	median	median	NOUN
dpc-4050	138	8	15	15	NUM
dpc-4050	138	9	0	0	NUM
dpc-4050	138	10	0	0	NUM
dpc-4050	138	11	0	0	NUM
dpc-4050	138	12	0	0	NUM
dpc-4050	138	13	0	0	NUM
dpc-4050	138	14	min	min	NOUN
dpc-4050	138	15	1	1	NUM
dpc-4050	138	16	0	0	NUM
dpc-4050	138	17	0	0	NUM
dpc-4050	138	18	0	0	NUM
dpc-4050	138	19	0	0	NUM
dpc-4050	138	20	0	0	NUM
dpc-4050	138	21	max	max	NOUN
dpc-4050	138	22	60	60	NUM
dpc-4050	138	23	10	10	NUM
dpc-4050	138	24	6	6	NUM
dpc-4050	138	25	8	8	NUM
dpc-4050	138	26	5	5	NUM
dpc-4050	138	27	7	7	NUM
dpc-4050	138	28	pairwise	pairwise	NOUN
dpc-4050	138	29	comparisons	comparison	NOUN
dpc-4050	138	30	(	(	PUNCT
dpc-4050	138	31	timepoints	timepoint	NOUN
dpc-4050	138	32	)	)	PUNCT
dpc-4050	138	33	baseline	baseline	NOUN
dpc-4050	138	34	versus	versus	ADP
dpc-4050	138	35	other	other	ADJ
dpc-4050	138	36	timepoints	timepoint	NOUN
dpc-4050	138	37	(	(	PUNCT
dpc-4050	138	38	p	p	NOUN
dpc-4050	138	39	-	-	PUNCT
dpc-4050	138	40	value	value	NOUN
dpc-4050	138	41	)	)	PUNCT
dpc-4050	138	42	<	<	X
dpc-4050	138	43	0.0001	0.0001	NUM
dpc-4050	138	44	<	<	X
dpc-4050	138	45	0.0001	0.0001	NUM
dpc-4050	138	46	<	<	X
dpc-4050	138	47	0.0001	0.0001	NUM
dpc-4050	138	48	<	<	X
dpc-4050	138	49	0.0001	0.0001	NUM
dpc-4050	138	50	<	<	NOUN
dpc-4050	138	51	0.0001	0.0001	NUM
dpc-4050	138	52	figure	figure	NOUN
dpc-4050	138	53	1	1	NUM
dpc-4050	138	54	.	.	NOUN
dpc-4050	138	55	trend	trend	NOUN
dpc-4050	138	56	in	in	ADP
dpc-4050	138	57	mean	mean	NOUN
dpc-4050	138	58	psoriasis	psoriasis	NOUN
dpc-4050	138	59	area	area	NOUN
dpc-4050	138	60	and	and	CCONJ
dpc-4050	138	61	severity	severity	NOUN
dpc-4050	138	62	index	index	NOUN
dpc-4050	138	63	(	(	PUNCT
dpc-4050	138	64	pasi	pasi	NOUN
dpc-4050	138	65	)	)	PUNCT
dpc-4050	138	66	score	score	NOUN
dpc-4050	138	67	at	at	ADP
dpc-4050	138	68	each	each	DET
dpc-4050	138	69	time	time	NOUN
dpc-4050	138	70	point	point	NOUN
dpc-4050	138	71	.	.	PUNCT
dpc-4050	139	1	table	table	NOUN
dpc-4050	139	2	3	3	NUM
dpc-4050	139	3	.	.	X
dpc-4050	139	4	proportion	proportion	NOUN
dpc-4050	139	5	of	of	ADP
dpc-4050	139	6	patients	patient	NOUN
dpc-4050	139	7	achieving	achieve	VERB
dpc-4050	139	8	psoriasis	psoriasis	NOUN
dpc-4050	139	9	area	area	NOUN
dpc-4050	139	10	and	and	CCONJ
dpc-4050	139	11	severity	severity	NOUN
dpc-4050	139	12	index	index	NOUN
dpc-4050	139	13	(	(	PUNCT
dpc-4050	139	14	pasi	pasi	NOUN
dpc-4050	139	15	)	)	PUNCT
dpc-4050	139	16	90	90	NUM
dpc-4050	139	17	and	and	CCONJ
dpc-4050	139	18	pasi	pasi	NOUN
dpc-4050	139	19	100	100	NUM
dpc-4050	139	20	at	at	ADP
dpc-4050	139	21	each	each	DET
dpc-4050	139	22	time	time	NOUN
dpc-4050	139	23	point	point	NOUN
dpc-4050	139	24	week	week	NOUN
dpc-4050	139	25	16	16	NUM
dpc-4050	139	26	week	week	NOUN
dpc-4050	139	27	24	24	NUM
dpc-4050	139	28	week	week	NOUN
dpc-4050	139	29	52	52	NUM
dpc-4050	139	30	week	week	NOUN
dpc-4050	139	31	104	104	NUM
dpc-4050	139	32	week	week	NOUN
dpc-4050	139	33	156	156	NUM
dpc-4050	139	34	patients	patient	NOUN
dpc-4050	139	35	achieving	achieve	VERB
dpc-4050	139	36	pasi	pasi	NOUN
dpc-4050	139	37	90	90	NUM
dpc-4050	139	38	69/69	69/69	NUM
dpc-4050	139	39	68/68	68/68	NUM
dpc-4050	139	40	64/64	64/64	NUM
dpc-4050	139	41	48/48	48/48	NUM
dpc-4050	139	42	40/40	40/40	NUM
dpc-4050	139	43	pasi	pasi	NOUN
dpc-4050	139	44	90	90	NUM
dpc-4050	139	45	100	100	NUM
dpc-4050	139	46	%	%	NOUN
dpc-4050	139	47	100	100	NUM
dpc-4050	139	48	%	%	NOUN
dpc-4050	139	49	100	100	NUM
dpc-4050	139	50	%	%	NOUN
dpc-4050	139	51	100	100	NUM
dpc-4050	139	52	%	%	NOUN
dpc-4050	139	53	100	100	NUM
dpc-4050	139	54	%	%	NOUN
dpc-4050	139	55	patients	patient	NOUN
dpc-4050	139	56	achieving	achieve	VERB
dpc-4050	139	57	pasi	pasi	NOUN
dpc-4050	139	58	100	100	NUM
dpc-4050	139	59	38/69	38/69	NUM
dpc-4050	139	60	51/68	51/68	NUM
dpc-4050	139	61	50/64	50/64	NUM
dpc-4050	139	62	39/48	39/48	NUM
dpc-4050	139	63	33/41	33/41	NUM
dpc-4050	139	64	pasi	pasi	NOUN
dpc-4050	139	65	100	100	NUM
dpc-4050	139	66	55.1	55.1	NUM
dpc-4050	139	67	%	%	NOUN
dpc-4050	139	68	75.0	75.0	NUM
dpc-4050	139	69	%	%	NOUN
dpc-4050	139	70	78.1	78.1	NUM
dpc-4050	139	71	%	%	NOUN
dpc-4050	139	72	81.3	81.3	NUM
dpc-4050	139	73	%	%	NOUN
dpc-4050	139	74	80.5	80.5	NUM
dpc-4050	139	75	%	%	NOUN
dpc-4050	139	76	figure	figure	NOUN
dpc-4050	139	77	2	2	NUM
dpc-4050	139	78	.	.	NOUN
dpc-4050	139	79	proportion	proportion	NOUN
dpc-4050	139	80	of	of	ADP
dpc-4050	139	81	patients	patient	NOUN
dpc-4050	139	82	achieving	achieve	VERB
dpc-4050	139	83	psoriasis	psoriasis	NOUN
dpc-4050	139	84	area	area	NOUN
dpc-4050	139	85	and	and	CCONJ
dpc-4050	139	86	severity	severity	NOUN
dpc-4050	139	87	index	index	NOUN
dpc-4050	139	88	(	(	PUNCT
dpc-4050	139	89	pasi	pasi	NOUN
dpc-4050	139	90	)	)	PUNCT
dpc-4050	139	91	90	90	NUM
dpc-4050	139	92	and	and	CCONJ
dpc-4050	139	93	pasi	pasi	VERB
dpc-4050	139	94	100	100	NUM
dpc-4050	139	95	at	at	ADP
dpc-4050	139	96	each	each	DET
dpc-4050	139	97	time	time	NOUN
dpc-4050	139	98	point	point	NOUN
dpc-4050	139	99	.	.	PUNCT
dpc-4050	140	1	table	table	NOUN
dpc-4050	140	2	4	4	NUM
dpc-4050	140	3	.	.	PUNCT
dpc-4050	141	1	proportions	proportion	NOUN
dpc-4050	141	2	of	of	ADP
dpc-4050	141	3	patients	patient	NOUN
dpc-4050	141	4	achieving	achieve	VERB
dpc-4050	141	5	psoriasis	psoriasis	NOUN
dpc-4050	141	6	area	area	NOUN
dpc-4050	141	7	and	and	CCONJ
dpc-4050	141	8	severity	severity	NOUN
dpc-4050	141	9	index	index	NOUN
dpc-4050	141	10	(	(	PUNCT
dpc-4050	141	11	pasi	pasi	NOUN
dpc-4050	141	12	)	)	PUNCT
dpc-4050	141	13	90	90	NUM
dpc-4050	141	14	and	and	CCONJ
dpc-4050	141	15	pasi	pasi	NOUN
dpc-4050	141	16	100	100	NUM
dpc-4050	141	17	at	at	ADP
dpc-4050	141	18	each	each	DET
dpc-4050	141	19	time	time	NOUN
dpc-4050	141	20	point	point	NOUN
dpc-4050	141	21	.	.	PUNCT
dpc-4050	142	1	bio	bio	ADJ
dpc-4050	142	2	-	-	ADJ
dpc-4050	142	3	naive	naive	ADJ
dpc-4050	142	4	vs	vs	ADP
dpc-4050	142	5	not	not	PART
dpc-4050	142	6	bio	bio	ADJ
dpc-4050	142	7	-	-	ADJ
dpc-4050	142	8	naive	naive	ADJ
dpc-4050	142	9	week	week	NOUN
dpc-4050	142	10	16	16	NUM
dpc-4050	142	11	week	week	NOUN
dpc-4050	142	12	24	24	NUM
dpc-4050	142	13	week	week	NOUN
dpc-4050	142	14	52	52	NUM
dpc-4050	142	15	week	week	NOUN
dpc-4050	142	16	104	104	NUM
dpc-4050	142	17	week	week	NOUN
dpc-4050	142	18	156	156	NUM
dpc-4050	142	19	bio	bio	ADJ
dpc-4050	142	20	-	-	ADJ
dpc-4050	142	21	naïve	naïve	ADJ
dpc-4050	142	22	patients	patient	NOUN
dpc-4050	142	23	achieving	achieve	VERB
dpc-4050	142	24	pasi	pasi	NOUN
dpc-4050	143	1	90	90	NUM
dpc-4050	143	2	14/14	14/14	NUM
dpc-4050	143	3	13/13	13/13	NUM
dpc-4050	143	4	12/12	12/12	NUM
dpc-4050	143	5	7/7	7/7	NUM
dpc-4050	143	6	5/5	5/5	NUM
dpc-4050	143	7	pasi	pasi	NOUN
dpc-4050	143	8	90	90	NUM
dpc-4050	143	9	(	(	PUNCT
dpc-4050	143	10	bio	bio	NOUN
dpc-4050	143	11	-	-	ADJ
dpc-4050	143	12	naïve	naïve	ADJ
dpc-4050	143	13	)	)	PUNCT
dpc-4050	143	14	100.0	100.0	NUM
dpc-4050	143	15	%	%	NOUN
dpc-4050	143	16	100.0	100.0	NUM
dpc-4050	143	17	%	%	NOUN
dpc-4050	143	18	100.0	100.0	NUM
dpc-4050	143	19	%	%	NOUN
dpc-4050	143	20	100.0	100.0	NUM
dpc-4050	143	21	%	%	NOUN
dpc-4050	143	22	100.0	100.0	NUM
dpc-4050	143	23	%	%	NOUN
dpc-4050	143	24	bio	bio	ADJ
dpc-4050	143	25	-	-	ADJ
dpc-4050	143	26	naïve	naïve	ADJ
dpc-4050	143	27	patients	patient	NOUN
dpc-4050	143	28	achieving	achieve	VERB
dpc-4050	143	29	pasi	pasi	NOUN
dpc-4050	143	30	100	100	NUM
dpc-4050	143	31	9/14	9/14	NUM
dpc-4050	143	32	13/13	13/13	NUM
dpc-4050	143	33	12/12	12/12	NUM
dpc-4050	143	34	7/7	7/7	NUM
dpc-4050	143	35	5/6	5/6	NUM
dpc-4050	143	36	pasi	pasi	NOUN
dpc-4050	143	37	100	100	NUM
dpc-4050	143	38	(	(	PUNCT
dpc-4050	143	39	bio	bio	NOUN
dpc-4050	143	40	-	-	ADJ
dpc-4050	143	41	naïve	naïve	ADJ
dpc-4050	143	42	)	)	PUNCT
dpc-4050	143	43	64.3	64.3	NUM
dpc-4050	143	44	%	%	NOUN
dpc-4050	143	45	100.0	100.0	NUM
dpc-4050	143	46	%	%	NOUN
dpc-4050	143	47	100.0	100.0	NUM
dpc-4050	143	48	%	%	NOUN
dpc-4050	143	49	100.0	100.0	NUM
dpc-4050	143	50	%	%	NOUN
dpc-4050	143	51	83.3	83.3	NUM
dpc-4050	143	52	%	%	NOUN
dpc-4050	143	53	bio	bio	ADJ
dpc-4050	143	54	-	-	ADJ
dpc-4050	143	55	experienced	experienced	ADJ
dpc-4050	143	56	patients	patient	NOUN
dpc-4050	143	57	achieving	achieve	VERB
dpc-4050	143	58	pasi	pasi	NOUN
dpc-4050	143	59	90	90	NUM
dpc-4050	143	60	55/55	55/55	NUM
dpc-4050	143	61	55/55	55/55	NUM
dpc-4050	143	62	52/52	52/52	NUM
dpc-4050	143	63	41/41	41/41	NUM
dpc-4050	143	64	35/35	35/35	NUM
dpc-4050	143	65	pasi	pasi	NOUN
dpc-4050	143	66	90	90	NUM
dpc-4050	143	67	(	(	PUNCT
dpc-4050	143	68	bio	bio	ADV
dpc-4050	143	69	-	-	ADJ
dpc-4050	143	70	experienced	experienced	ADJ
dpc-4050	143	71	)	)	PUNCT
dpc-4050	143	72	100.0	100.0	NUM
dpc-4050	143	73	%	%	NOUN
dpc-4050	143	74	100.0	100.0	NUM
dpc-4050	143	75	%	%	NOUN
dpc-4050	143	76	100.0	100.0	NUM
dpc-4050	143	77	%	%	NOUN
dpc-4050	143	78	100.0	100.0	NUM
dpc-4050	143	79	%	%	NOUN
dpc-4050	143	80	100.0	100.0	NUM
dpc-4050	143	81	%	%	NOUN
dpc-4050	143	82	bio	bio	ADJ
dpc-4050	143	83	-	-	ADJ
dpc-4050	143	84	experienced	experienced	ADJ
dpc-4050	143	85	patients	patient	NOUN
dpc-4050	143	86	achieving	achieve	VERB
dpc-4050	143	87	pasi	pasi	NOUN
dpc-4050	143	88	100	100	NUM
dpc-4050	143	89	29/55	29/55	NUM
dpc-4050	143	90	38/55	38/55	NUM
dpc-4050	143	91	38/52	38/52	NUM
dpc-4050	143	92	32/41	32/41	NUM
dpc-4050	143	93	28/35	28/35	NUM
dpc-4050	143	94	pasi	pasi	NOUN
dpc-4050	143	95	100	100	NUM
dpc-4050	143	96	(	(	PUNCT
dpc-4050	143	97	bio	bio	ADV
dpc-4050	143	98	-	-	ADJ
dpc-4050	143	99	experienced	experienced	ADJ
dpc-4050	143	100	)	)	PUNCT
dpc-4050	143	101	52.7	52.7	NUM
dpc-4050	143	102	%	%	NOUN
dpc-4050	143	103	69.1	69.1	NUM
dpc-4050	143	104	%	%	NOUN
dpc-4050	143	105	73.1	73.1	NUM
dpc-4050	143	106	%	%	NOUN
dpc-4050	143	107	78.0	78.0	NUM
dpc-4050	143	108	%	%	NOUN
dpc-4050	143	109	80.0	80.0	NUM
dpc-4050	143	110	%	%	NOUN
dpc-4050	143	111	original	original	ADJ
dpc-4050	143	112	article	article	NOUN
dpc-4050	143	113	|	|	ADV
dpc-4050	143	114	dermatol	dermatol	ADJ
dpc-4050	143	115	pract	pract	NOUN
dpc-4050	143	116	concept	concept	NOUN
dpc-4050	143	117	.	.	PUNCT
dpc-4050	144	1	2024;14(3):e2024166	2024;14(3):e2024166	NUM
dpc-4050	144	2	7	7	NUM
dpc-4050	144	3	table	table	NOUN
dpc-4050	144	4	5	5	NUM
dpc-4050	144	5	.	.	PUNCT
dpc-4050	144	6	descriptive	descriptive	ADJ
dpc-4050	144	7	statistics	statistic	NOUN
dpc-4050	144	8	for	for	ADP
dpc-4050	144	9	visual	visual	ADJ
dpc-4050	144	10	analogue	analogue	NOUN
dpc-4050	144	11	scale	scale	NOUN
dpc-4050	144	12	score	score	NOUN
dpc-4050	144	13	at	at	ADP
dpc-4050	144	14	each	each	DET
dpc-4050	144	15	timepoints	timepoint	NOUN
dpc-4050	144	16	and	and	CCONJ
dpc-4050	144	17	pairwise	pairwise	NOUN
dpc-4050	144	18	comparisons	comparison	NOUN
dpc-4050	144	19	p	p	NOUN
dpc-4050	144	20	-	-	PUNCT
dpc-4050	144	21	value	value	NOUN
dpc-4050	144	22	baseline	baseline	NOUN
dpc-4050	144	23	week	week	NOUN
dpc-4050	144	24	16	16	NUM
dpc-4050	144	25	week	week	NOUN
dpc-4050	144	26	24	24	NUM
dpc-4050	144	27	week	week	NOUN
dpc-4050	144	28	52	52	NUM
dpc-4050	144	29	week	week	NOUN
dpc-4050	144	30	104	104	NUM
dpc-4050	144	31	week	week	NOUN
dpc-4050	144	32	156	156	NUM
dpc-4050	144	33	n	n	PRON
dpc-4050	144	34	56	56	NUM
dpc-4050	144	35	53	53	NUM
dpc-4050	144	36	53	53	NUM
dpc-4050	144	37	50	50	NUM
dpc-4050	144	38	43	43	NUM
dpc-4050	144	39	38	38	NUM
dpc-4050	144	40	mean	mean	NOUN
dpc-4050	144	41	16.5	16.5	NUM
dpc-4050	144	42	4.8	4.8	NUM
dpc-4050	144	43	2.9	2.9	NUM
dpc-4050	144	44	1.7	1.7	NUM
dpc-4050	144	45	1.7	1.7	NUM
dpc-4050	144	46	2.3	2.3	NUM
dpc-4050	144	47	standard	standard	ADJ
dpc-4050	144	48	deviation	deviation	NOUN
dpc-4050	144	49	23.3	23.3	NUM
dpc-4050	144	50	9.8	9.8	NUM
dpc-4050	144	51	6.2	6.2	NUM
dpc-4050	144	52	4.4	4.4	NUM
dpc-4050	144	53	5.0	5.0	NUM
dpc-4050	144	54	4.4	4.4	NUM
dpc-4050	144	55	median	median	NOUN
dpc-4050	144	56	7.5	7.5	NUM
dpc-4050	144	57	0.0	0.0	NUM
dpc-4050	144	58	0.0	0.0	NUM
dpc-4050	144	59	0.0	0.0	NUM
dpc-4050	144	60	0.0	0.0	NUM
dpc-4050	144	61	0.0	0.0	NUM
dpc-4050	144	62	min	min	NOUN
dpc-4050	144	63	0	0	NUM
dpc-4050	144	64	0	0	NUM
dpc-4050	144	65	0	0	NUM
dpc-4050	144	66	0	0	NUM
dpc-4050	144	67	0	0	NUM
dpc-4050	144	68	0	0	NUM
dpc-4050	144	69	max	max	PROPN
dpc-4050	144	70	80	80	NUM
dpc-4050	144	71	50	50	NUM
dpc-4050	144	72	30	30	NUM
dpc-4050	144	73	20	20	NUM
dpc-4050	144	74	30	30	NUM
dpc-4050	144	75	20	20	NUM
dpc-4050	144	76	pairwise	pairwise	NOUN
dpc-4050	144	77	comparisons	comparison	NOUN
dpc-4050	144	78	(	(	PUNCT
dpc-4050	144	79	timepoints	timepoint	NOUN
dpc-4050	144	80	)	)	PUNCT
dpc-4050	144	81	baseline	baseline	NOUN
dpc-4050	144	82	versus	versus	ADP
dpc-4050	144	83	other	other	ADJ
dpc-4050	144	84	timepoints	timepoint	NOUN
dpc-4050	144	85	(	(	PUNCT
dpc-4050	144	86	p	p	NOUN
dpc-4050	144	87	-	-	PUNCT
dpc-4050	144	88	value	value	NOUN
dpc-4050	144	89	)	)	PUNCT
dpc-4050	144	90	<	<	X
dpc-4050	144	91	0.0001	0.0001	NUM
dpc-4050	144	92	<	<	X
dpc-4050	144	93	0.0001	0.0001	NUM
dpc-4050	144	94	<	<	X
dpc-4050	144	95	0.0001	0.0001	NUM
dpc-4050	144	96	<	<	X
dpc-4050	144	97	0.0001	0.0001	NUM
dpc-4050	144	98	<	<	NOUN
dpc-4050	144	99	0.0001	0.0001	NUM
dpc-4050	144	100	table	table	NOUN
dpc-4050	144	101	6	6	NUM
dpc-4050	144	102	.	.	PUNCT
dpc-4050	144	103	descriptive	descriptive	ADJ
dpc-4050	144	104	statistics	statistic	NOUN
dpc-4050	144	105	for	for	ADP
dpc-4050	144	106	dermatology	dermatology	NOUN
dpc-4050	144	107	life	life	NOUN
dpc-4050	144	108	quality	quality	NOUN
dpc-4050	144	109	index	index	NOUN
dpc-4050	144	110	(	(	PUNCT
dpc-4050	144	111	dlqi	dlqi	ADJ
dpc-4050	144	112	)	)	PUNCT
dpc-4050	144	113	at	at	ADP
dpc-4050	144	114	each	each	DET
dpc-4050	144	115	time	time	NOUN
dpc-4050	144	116	point	point	NOUN
dpc-4050	145	1	dlqi	dlqi	VERB
dpc-4050	145	2	_	_	PUNCT
dpc-4050	146	1	basale	basale	PROPN
dpc-4050	146	2	dlqi	dlqi	PROPN
dpc-4050	146	3	_	_	PROPN
dpc-4050	146	4	week52	week52	VERB
dpc-4050	146	5	p	p	NOUN
dpc-4050	146	6	-	-	PUNCT
dpc-4050	146	7	value	value	NOUN
dpc-4050	146	8	n	n	NOUN
dpc-4050	146	9	73	73	NUM
dpc-4050	146	10	65	65	NUM
dpc-4050	146	11	mean	mean	NOUN
dpc-4050	146	12	15.9	15.9	NUM
dpc-4050	146	13	0.5	0.5	NUM
dpc-4050	146	14	<	<	NOUN
dpc-4050	146	15	0.0001	0.0001	NUM
dpc-4050	146	16	sd	sd	ADP
dpc-4050	146	17	6.2	6.2	NUM
dpc-4050	146	18	1.6	1.6	NUM
dpc-4050	146	19	median	median	NOUN
dpc-4050	146	20	16.0	16.0	NUM
dpc-4050	146	21	0.0	0.0	NUM
dpc-4050	146	22	min	min	NOUN
dpc-4050	146	23	1	1	NUM
dpc-4050	146	24	0	0	NUM
dpc-4050	146	25	max	max	PROPN
dpc-4050	146	26	29	29	NUM
dpc-4050	146	27	10	10	NUM
dpc-4050	146	28	sd	sd	NOUN
dpc-4050	146	29	=	=	PUNCT
dpc-4050	146	30	standard	standard	ADJ
dpc-4050	146	31	deviation	deviation	NOUN
dpc-4050	146	32	.	.	PUNCT
dpc-4050	147	1	figure	figure	NOUN
dpc-4050	147	2	3	3	NUM
dpc-4050	147	3	.	.	PUNCT
dpc-4050	148	1	mean	mean	PROPN
dpc-4050	148	2	visual	visual	ADJ
dpc-4050	148	3	analogue	analogue	NOUN
dpc-4050	148	4	scale	scale	NOUN
dpc-4050	148	5	(	(	PUNCT
dpc-4050	148	6	vas	vas	NOUN
dpc-4050	148	7	)	)	PUNCT
dpc-4050	148	8	and	and	CCONJ
dpc-4050	148	9	dermatology	dermatology	NOUN
dpc-4050	148	10	life	life	NOUN
dpc-4050	148	11	quality	quality	NOUN
dpc-4050	148	12	index	index	NOUN
dpc-4050	148	13	(	(	PUNCT
dpc-4050	148	14	dlqi	dlqi	ADJ
dpc-4050	148	15	)	)	PUNCT
dpc-4050	148	16	score	score	NOUN
dpc-4050	148	17	at	at	ADP
dpc-4050	148	18	each	each	DET
dpc-4050	148	19	timepoints	timepoint	NOUN
dpc-4050	148	20	.	.	PUNCT
dpc-4050	149	1	(	(	PUNCT
dpc-4050	149	2	p	p	X
dpc-4050	149	3	<	<	X
dpc-4050	149	4	0.0001	0.0001	NUM
dpc-4050	149	5	)	)	PUNCT
dpc-4050	149	6	and	and	CCONJ
dpc-4050	149	7	no	no	DET
dpc-4050	149	8	significant	significant	ADJ
dpc-4050	149	9	difference	difference	NOUN
dpc-4050	149	10	between	between	ADP
dpc-4050	149	11	the	the	DET
dpc-4050	149	12	groups	group	NOUN
dpc-4050	149	13	(	(	PUNCT
dpc-4050	149	14	p	p	X
dpc-4050	149	15	=	=	NOUN
dpc-4050	149	16	0.291	0.291	NUM
dpc-4050	149	17	)	)	PUNCT
dpc-4050	149	18	.	.	PUNCT
dpc-4050	150	1	bio	bio	ADJ
dpc-4050	150	2	-	-	ADJ
dpc-4050	150	3	naive	naive	ADJ
dpc-4050	150	4	versus	versus	ADP
dpc-4050	150	5	bio	bio	NOUN
dpc-4050	150	6	-	-	ADJ
dpc-4050	150	7	experienced	experienced	ADJ
dpc-4050	150	8	for	for	ADP
dpc-4050	150	9	pasi	pasi	NOUN
dpc-4050	150	10	score	score	NOUN
dpc-4050	150	11	,	,	PUNCT
dpc-4050	150	12	the	the	DET
dpc-4050	150	13	anova	anova	PROPN
dpc-4050	150	14	mixed	mixed	ADJ
dpc-4050	150	15	model	model	NOUN
dpc-4050	150	16	highlighted	highlight	VERB
dpc-4050	150	17	a	a	DET
dpc-4050	150	18	statistically	statistically	ADV
dpc-4050	150	19	significant	significant	ADJ
dpc-4050	150	20	difference	difference	NOUN
dpc-4050	150	21	between	between	ADP
dpc-4050	150	22	time	time	NOUN
dpc-4050	150	23	points	point	NOUN
dpc-4050	150	24	(	(	PUNCT
dpc-4050	150	25	p	p	X
dpc-4050	150	26	<	<	X
dpc-4050	150	27	0.0001	0.0001	NUM
dpc-4050	150	28	)	)	PUNCT
dpc-4050	150	29	and	and	CCONJ
dpc-4050	150	30	no	no	DET
dpc-4050	150	31	significant	significant	ADJ
dpc-4050	150	32	difference	difference	NOUN
dpc-4050	150	33	between	between	ADP
dpc-4050	150	34	the	the	DET
dpc-4050	150	35	groups	group	NOUN
dpc-4050	150	36	(	(	PUNCT
dpc-4050	150	37	p	p	X
dpc-4050	150	38	=	=	NOUN
dpc-4050	150	39	0.99	0.99	NUM
dpc-4050	150	40	)	)	PUNCT
dpc-4050	150	41	.	.	PUNCT
dpc-4050	151	1	pairwise	pairwise	NOUN
dpc-4050	151	2	comparisons	comparison	NOUN
dpc-4050	151	3	showed	show	VERB
dpc-4050	151	4	that	that	SCONJ
dpc-4050	151	5	all	all	DET
dpc-4050	151	6	times	time	NOUN
dpc-4050	151	7	are	be	AUX
dpc-4050	151	8	significantly	significantly	ADV
dpc-4050	151	9	different	different	ADJ
dpc-4050	151	10	from	from	ADP
dpc-4050	151	11	the	the	DET
dpc-4050	151	12	baseline	baseline	NOUN
dpc-4050	151	13	(	(	PUNCT
dpc-4050	151	14	p	p	X
dpc-4050	151	15	<	<	X
dpc-4050	151	16	0.0001	0.0001	NUM
dpc-4050	151	17	)	)	PUNCT
dpc-4050	151	18	but	but	CCONJ
dpc-4050	151	19	there	there	PRON
dpc-4050	151	20	are	be	VERB
dpc-4050	151	21	no	no	DET
dpc-4050	151	22	significant	significant	ADJ
dpc-4050	151	23	differences	difference	NOUN
dpc-4050	151	24	between	between	ADP
dpc-4050	151	25	the	the	DET
dpc-4050	151	26	remaining	remain	VERB
dpc-4050	151	27	pairs	pair	NOUN
dpc-4050	151	28	of	of	ADP
dpc-4050	151	29	times	time	NOUN
dpc-4050	151	30	.	.	PUNCT
dpc-4050	152	1	for	for	ADP
dpc-4050	152	2	vas	vas	PROPN
dpc-4050	152	3	score	score	NOUN
dpc-4050	152	4	,	,	PUNCT
dpc-4050	152	5	the	the	DET
dpc-4050	152	6	anova	anova	PROPN
dpc-4050	152	7	mixed	mixed	ADJ
dpc-4050	152	8	model	model	NOUN
dpc-4050	152	9	showed	show	VERB
dpc-4050	152	10	a	a	DET
dpc-4050	152	11	statistically	statistically	ADV
dpc-4050	152	12	significant	significant	ADJ
dpc-4050	152	13	difference	difference	NOUN
dpc-4050	152	14	between	between	ADP
dpc-4050	152	15	time	time	NOUN
dpc-4050	152	16	points	point	NOUN
dpc-4050	152	17	(	(	PUNCT
dpc-4050	152	18	p	p	X
dpc-4050	152	19	<	<	X
dpc-4050	152	20	0.0001	0.0001	NUM
dpc-4050	152	21	)	)	PUNCT
dpc-4050	152	22	and	and	CCONJ
dpc-4050	152	23	no	no	DET
dpc-4050	152	24	significant	significant	ADJ
dpc-4050	152	25	difference	difference	NOUN
dpc-4050	152	26	between	between	ADP
dpc-4050	152	27	the	the	DET
dpc-4050	152	28	groups	group	NOUN
dpc-4050	152	29	(	(	PUNCT
dpc-4050	152	30	p	p	X
dpc-4050	152	31	=	=	NOUN
dpc-4050	152	32	0.259	0.259	NUM
dpc-4050	152	33	)	)	PUNCT
dpc-4050	152	34	.	.	PUNCT
dpc-4050	153	1	pairwise	pairwise	NOUN
dpc-4050	153	2	comparisons	comparison	NOUN
dpc-4050	153	3	showed	show	VERB
dpc-4050	153	4	that	that	SCONJ
dpc-4050	153	5	all	all	DET
dpc-4050	153	6	times	time	NOUN
dpc-4050	153	7	are	be	AUX
dpc-4050	153	8	significantly	significantly	ADV
dpc-4050	153	9	different	different	ADJ
dpc-4050	153	10	from	from	ADP
dpc-4050	153	11	the	the	DET
dpc-4050	153	12	baseline	baseline	NOUN
dpc-4050	153	13	but	but	CCONJ
dpc-4050	153	14	there	there	PRON
dpc-4050	153	15	are	be	VERB
dpc-4050	153	16	no	no	DET
dpc-4050	153	17	significant	significant	ADJ
dpc-4050	153	18	differences	difference	NOUN
dpc-4050	153	19	between	between	ADP
dpc-4050	153	20	the	the	DET
dpc-4050	153	21	remaining	remain	VERB
dpc-4050	153	22	pairs	pair	NOUN
dpc-4050	153	23	of	of	ADP
dpc-4050	153	24	times	time	NOUN
dpc-4050	153	25	.	.	PUNCT
dpc-4050	154	1	for	for	ADP
dpc-4050	154	2	dlqi	dlqi	PROPN
dpc-4050	154	3	index	index	NOUN
dpc-4050	154	4	,	,	PUNCT
dpc-4050	154	5	the	the	DET
dpc-4050	154	6	anova	anova	PROPN
dpc-4050	154	7	mixed	mixed	ADJ
dpc-4050	154	8	model	model	NOUN
dpc-4050	154	9	revealed	reveal	VERB
dpc-4050	154	10	a	a	DET
dpc-4050	154	11	statistically	statistically	ADV
dpc-4050	154	12	significant	significant	ADJ
dpc-4050	154	13	difference	difference	NOUN
dpc-4050	154	14	between	between	ADP
dpc-4050	154	15	time	time	NOUN
dpc-4050	154	16	points	point	NOUN
dpc-4050	154	17	(	(	PUNCT
dpc-4050	154	18	p	p	X
dpc-4050	154	19	<	<	X
dpc-4050	154	20	0.0001	0.0001	NUM
dpc-4050	154	21	)	)	PUNCT
dpc-4050	154	22	and	and	CCONJ
dpc-4050	154	23	no	no	DET
dpc-4050	154	24	significant	significant	ADJ
dpc-4050	154	25	difference	difference	NOUN
dpc-4050	154	26	between	between	ADP
dpc-4050	154	27	the	the	DET
dpc-4050	154	28	groups	group	NOUN
dpc-4050	154	29	(	(	PUNCT
dpc-4050	154	30	p	p	X
dpc-4050	154	31	=	=	NOUN
dpc-4050	154	32	0.265	0.265	NUM
dpc-4050	154	33	)	)	PUNCT
dpc-4050	154	34	.	.	PUNCT
dpc-4050	155	1	bmi	bmi	PROPN
dpc-4050	155	2	<	<	X
dpc-4050	155	3	25	25	NUM
dpc-4050	155	4	versus	versus	ADP
dpc-4050	155	5	bmi	bmi	X
dpc-4050	155	6	≥	≥	NUM
dpc-4050	155	7	25	25	NUM
dpc-4050	155	8	as	as	SCONJ
dpc-4050	155	9	seen	see	VERB
dpc-4050	155	10	in	in	ADP
dpc-4050	155	11	table	table	NOUN
dpc-4050	155	12	5	5	NUM
dpc-4050	155	13	,	,	PUNCT
dpc-4050	155	14	there	there	PRON
dpc-4050	155	15	was	be	VERB
dpc-4050	155	16	a	a	DET
dpc-4050	155	17	statistically	statistically	ADV
dpc-4050	155	18	significant	significant	ADJ
dpc-4050	155	19	difference	difference	NOUN
dpc-4050	155	20	between	between	ADP
dpc-4050	155	21	mean	mean	ADJ
dpc-4050	155	22	pasi	pasi	NOUN
dpc-4050	155	23	score	score	NOUN
dpc-4050	155	24	at	at	ADP
dpc-4050	155	25	baseline	baseline	NOUN
dpc-4050	155	26	for	for	ADP
dpc-4050	155	27	bmi	bmi	NOUN
dpc-4050	155	28	<	<	X
dpc-4050	155	29	25	25	NUM
dpc-4050	155	30	patients	patient	NOUN
dpc-4050	155	31	and	and	CCONJ
dpc-4050	155	32	bmi	bmi	VERB
dpc-4050	155	33	≥	≥	NUM
dpc-4050	155	34	25	25	NUM
dpc-4050	155	35	ones	one	NOUN
dpc-4050	155	36	;	;	PUNCT
dpc-4050	155	37	10.9	10.9	NUM
dpc-4050	155	38	(	(	PUNCT
dpc-4050	155	39	sd=6.7	sd=6.7	VERB
dpc-4050	155	40	)	)	PUNCT
dpc-4050	155	41	and	and	CCONJ
dpc-4050	155	42	16.1	16.1	NUM
dpc-4050	155	43	(	(	PUNCT
dpc-4050	155	44	sd=9.1	sd=9.1	NOUN
dpc-4050	155	45	)	)	PUNCT
dpc-4050	155	46	respectively	respectively	ADV
dpc-4050	155	47	.	.	PUNCT
dpc-4050	156	1	for	for	ADP
dpc-4050	156	2	pasi	pasi	NOUN
dpc-4050	156	3	score	score	NOUN
dpc-4050	156	4	,	,	PUNCT
dpc-4050	156	5	the	the	DET
dpc-4050	156	6	anova	anova	PROPN
dpc-4050	156	7	mixed	mixed	ADJ
dpc-4050	156	8	model	model	NOUN
dpc-4050	156	9	highlighted	highlight	VERB
dpc-4050	156	10	a	a	DET
dpc-4050	156	11	statistically	statistically	ADV
dpc-4050	156	12	significant	significant	ADJ
dpc-4050	156	13	difference	difference	NOUN
dpc-4050	156	14	between	between	ADP
dpc-4050	156	15	time	time	NOUN
dpc-4050	156	16	points	point	NOUN
dpc-4050	156	17	(	(	PUNCT
dpc-4050	156	18	p	p	X
dpc-4050	156	19	<	<	X
dpc-4050	156	20	0.0001	0.0001	NUM
dpc-4050	156	21	)	)	PUNCT
dpc-4050	156	22	and	and	CCONJ
dpc-4050	156	23	no	no	DET
dpc-4050	156	24	significant	significant	ADJ
dpc-4050	156	25	difference	difference	NOUN
dpc-4050	156	26	between	between	ADP
dpc-4050	156	27	the	the	DET
dpc-4050	156	28	groups	group	NOUN
dpc-4050	156	29	(	(	PUNCT
dpc-4050	156	30	p	p	X
dpc-4050	156	31	=	=	NOUN
dpc-4050	156	32	0.374	0.374	NUM
dpc-4050	156	33	)	)	PUNCT
dpc-4050	156	34	.	.	PUNCT
dpc-4050	157	1	pairwise	pairwise	NOUN
dpc-4050	157	2	comparisons	comparison	NOUN
dpc-4050	157	3	showed	show	VERB
dpc-4050	157	4	that	that	SCONJ
dpc-4050	157	5	all	all	DET
dpc-4050	157	6	times	time	NOUN
dpc-4050	157	7	are	be	AUX
dpc-4050	157	8	significantly	significantly	ADV
dpc-4050	157	9	different	different	ADJ
dpc-4050	157	10	from	from	ADP
dpc-4050	157	11	the	the	DET
dpc-4050	157	12	baseline	baseline	NOUN
dpc-4050	157	13	(	(	PUNCT
dpc-4050	157	14	p	p	X
dpc-4050	157	15	<	<	X
dpc-4050	157	16	0.0001	0.0001	NUM
dpc-4050	157	17	)	)	PUNCT
dpc-4050	157	18	but	but	CCONJ
dpc-4050	157	19	there	there	PRON
dpc-4050	157	20	are	be	VERB
dpc-4050	157	21	no	no	DET
dpc-4050	157	22	significant	significant	ADJ
dpc-4050	157	23	differences	difference	NOUN
dpc-4050	157	24	between	between	ADP
dpc-4050	157	25	the	the	DET
dpc-4050	157	26	remaining	remain	VERB
dpc-4050	157	27	pairs	pair	NOUN
dpc-4050	157	28	of	of	ADP
dpc-4050	157	29	times	time	NOUN
dpc-4050	157	30	.	.	PUNCT
dpc-4050	158	1	for	for	ADP
dpc-4050	158	2	vas	vas	PROPN
dpc-4050	158	3	score	score	NOUN
dpc-4050	158	4	,	,	PUNCT
dpc-4050	158	5	the	the	DET
dpc-4050	158	6	anova	anova	PROPN
dpc-4050	158	7	mixed	mixed	ADJ
dpc-4050	158	8	model	model	NOUN
dpc-4050	158	9	showed	show	VERB
dpc-4050	158	10	a	a	DET
dpc-4050	158	11	statistically	statistically	ADV
dpc-4050	158	12	significant	significant	ADJ
dpc-4050	158	13	difference	difference	NOUN
dpc-4050	158	14	between	between	ADP
dpc-4050	158	15	time	time	NOUN
dpc-4050	158	16	points	point	NOUN
dpc-4050	158	17	(	(	PUNCT
dpc-4050	158	18	p	p	X
dpc-4050	158	19	<	<	X
dpc-4050	158	20	0.0001	0.0001	NUM
dpc-4050	158	21	)	)	PUNCT
dpc-4050	158	22	.	.	PUNCT
dpc-4050	159	1	no	no	DET
dpc-4050	159	2	significant	significant	ADJ
dpc-4050	159	3	difference	difference	NOUN
dpc-4050	159	4	between	between	ADP
dpc-4050	159	5	the	the	DET
dpc-4050	159	6	groups	group	NOUN
dpc-4050	159	7	(	(	PUNCT
dpc-4050	159	8	p	p	X
dpc-4050	159	9	=	=	NOUN
dpc-4050	159	10	0.970	0.970	NUM
dpc-4050	159	11	)	)	PUNCT
dpc-4050	159	12	was	be	AUX
dpc-4050	159	13	observed	observe	VERB
dpc-4050	159	14	.	.	PUNCT
dpc-4050	160	1	pairwise	pairwise	NOUN
dpc-4050	160	2	comparisons	comparison	NOUN
dpc-4050	160	3	showed	show	VERB
dpc-4050	160	4	that	that	SCONJ
dpc-4050	160	5	all	all	DET
dpc-4050	160	6	times	time	NOUN
dpc-4050	160	7	are	be	AUX
dpc-4050	160	8	significantly	significantly	ADV
dpc-4050	160	9	different	different	ADJ
dpc-4050	160	10	from	from	ADP
dpc-4050	160	11	the	the	DET
dpc-4050	160	12	baseline	baseline	NOUN
dpc-4050	160	13	but	but	CCONJ
dpc-4050	160	14	there	there	PRON
dpc-4050	160	15	are	be	VERB
dpc-4050	160	16	no	no	DET
dpc-4050	160	17	significant	significant	ADJ
dpc-4050	160	18	differences	difference	NOUN
dpc-4050	160	19	between	between	ADP
dpc-4050	160	20	the	the	DET
dpc-4050	160	21	remaining	remain	VERB
dpc-4050	160	22	pairs	pair	NOUN
dpc-4050	160	23	of	of	ADP
dpc-4050	160	24	times	time	NOUN
dpc-4050	160	25	.	.	PUNCT
dpc-4050	161	1	for	for	ADP
dpc-4050	161	2	dlqi	dlqi	PROPN
dpc-4050	161	3	index	index	NOUN
dpc-4050	161	4	,	,	PUNCT
dpc-4050	161	5	the	the	DET
dpc-4050	161	6	anova	anova	PROPN
dpc-4050	161	7	mixed	mixed	ADJ
dpc-4050	161	8	model	model	NOUN
dpc-4050	161	9	highlighted	highlight	VERB
dpc-4050	161	10	a	a	DET
dpc-4050	161	11	statistically	statistically	ADV
dpc-4050	161	12	significant	significant	ADJ
dpc-4050	161	13	difference	difference	NOUN
dpc-4050	161	14	between	between	ADP
dpc-4050	161	15	time	time	NOUN
dpc-4050	161	16	points	point	NOUN
dpc-4050	161	17	(	(	PUNCT
dpc-4050	161	18	p	p	X
dpc-4050	161	19	<	<	X
dpc-4050	161	20	0.0001	0.0001	NUM
dpc-4050	161	21	)	)	PUNCT
dpc-4050	161	22	and	and	CCONJ
dpc-4050	161	23	no	no	DET
dpc-4050	161	24	significant	significant	ADJ
dpc-4050	161	25	difference	difference	NOUN
dpc-4050	161	26	between	between	ADP
dpc-4050	161	27	the	the	DET
dpc-4050	161	28	groups	group	NOUN
dpc-4050	161	29	(	(	PUNCT
dpc-4050	161	30	p	p	X
dpc-4050	161	31	=	=	NOUN
dpc-4050	161	32	0.668	0.668	NUM
dpc-4050	161	33	)	)	PUNCT
dpc-4050	161	34	.	.	PUNCT
dpc-4050	162	1	for	for	ADP
dpc-4050	162	2	a	a	DET
dpc-4050	162	3	fully	fully	ADV
dpc-4050	162	4	detailed	detailed	ADJ
dpc-4050	162	5	description	description	NOUN
dpc-4050	162	6	of	of	ADP
dpc-4050	162	7	subgroups	subgroup	NOUN
dpc-4050	162	8	comparison	comparison	NOUN
dpc-4050	162	9	see	see	VERB
dpc-4050	162	10	table	table	NOUN
dpc-4050	162	11	8	8	NUM
dpc-4050	162	12	.	.	SYM
dpc-4050	162	13	8	8	NUM
dpc-4050	162	14	original	original	ADJ
dpc-4050	162	15	article	article	NOUN
dpc-4050	162	16	|	|	ADV
dpc-4050	162	17	dermatol	dermatol	ADJ
dpc-4050	162	18	pract	pract	NOUN
dpc-4050	162	19	concept	concept	NOUN
dpc-4050	162	20	.	.	PUNCT
dpc-4050	163	1	2024;14(3):e2024166	2024;14(3):e2024166	NUM
dpc-4050	163	2	conclusions	conclusion	NOUN
dpc-4050	163	3	as	as	SCONJ
dpc-4050	163	4	we	we	PRON
dpc-4050	163	5	know	know	VERB
dpc-4050	163	6	,	,	PUNCT
dpc-4050	163	7	psoriasis	psoriasis	NOUN
dpc-4050	163	8	is	be	AUX
dpc-4050	163	9	a	a	DET
dpc-4050	163	10	chronic	chronic	ADJ
dpc-4050	163	11	and	and	CCONJ
dpc-4050	163	12	relapsing	relapse	VERB
dpc-4050	163	13	dermatosis	dermatosis	NOUN
dpc-4050	163	14	.	.	PUNCT
dpc-4050	164	1	approximately	approximately	ADV
dpc-4050	164	2	15	15	NUM
dpc-4050	164	3	-	-	SYM
dpc-4050	164	4	20	20	NUM
dpc-4050	164	5	%	%	NOUN
dpc-4050	164	6	of	of	ADP
dpc-4050	164	7	affected	affected	ADJ
dpc-4050	164	8	patients	patient	NOUN
dpc-4050	164	9	are	be	AUX
dpc-4050	164	10	over	over	ADP
dpc-4050	164	11	65	65	NUM
dpc-4050	164	12	years	year	NOUN
dpc-4050	164	13	of	of	ADP
dpc-4050	164	14	age	age	NOUN
dpc-4050	164	15	and	and	CCONJ
dpc-4050	164	16	are	be	AUX
dpc-4050	164	17	affected	affect	VERB
dpc-4050	164	18	by	by	ADP
dpc-4050	164	19	many	many	ADJ
dpc-4050	164	20	comorbidities	comorbiditie	NOUN
dpc-4050	164	21	(	(	PUNCT
dpc-4050	164	22	cardiovascular	cardiovascular	ADJ
dpc-4050	164	23	,	,	PUNCT
dpc-4050	164	24	metabolic	metabolic	NOUN
dpc-4050	164	25	,	,	PUNCT
dpc-4050	164	26	renal	renal	ADJ
dpc-4050	164	27	,	,	PUNCT
dpc-4050	164	28	intestinal	intestinal	ADJ
dpc-4050	164	29	,	,	PUNCT
dpc-4050	164	30	etc	etc	X
dpc-4050	164	31	)	)	PUNCT
dpc-4050	165	1	[	[	X
dpc-4050	165	2	11	11	NUM
dpc-4050	165	3	-	-	SYM
dpc-4050	165	4	12	12	NUM
dpc-4050	165	5	]	]	PUNCT
dpc-4050	165	6	.	.	PUNCT
dpc-4050	166	1	therefore	therefore	ADV
dpc-4050	166	2	,	,	PUNCT
dpc-4050	166	3	in	in	ADP
dpc-4050	166	4	this	this	DET
dpc-4050	166	5	category	category	NOUN
dpc-4050	166	6	of	of	ADP
dpc-4050	166	7	patients	patient	NOUN
dpc-4050	166	8	,	,	PUNCT
dpc-4050	166	9	when	when	SCONJ
dpc-4050	166	10	considering	consider	VERB
dpc-4050	166	11	treatment	treatment	NOUN
dpc-4050	166	12	of	of	ADP
dpc-4050	166	13	psoriasis	psoriasis	NOUN
dpc-4050	166	14	,	,	PUNCT
dpc-4050	166	15	it	it	PRON
dpc-4050	166	16	is	be	AUX
dpc-4050	166	17	very	very	ADV
dpc-4050	166	18	important	important	ADJ
dpc-4050	166	19	to	to	PART
dpc-4050	166	20	take	take	VERB
dpc-4050	166	21	into	into	ADP
dpc-4050	166	22	account	account	NOUN
dpc-4050	166	23	not	not	PART
dpc-4050	166	24	only	only	ADV
dpc-4050	166	25	the	the	DET
dpc-4050	166	26	clinical	clinical	ADJ
dpc-4050	166	27	presentation	presentation	NOUN
dpc-4050	166	28	and	and	CCONJ
dpc-4050	166	29	severity	severity	NOUN
dpc-4050	166	30	of	of	ADP
dpc-4050	166	31	skin	skin	NOUN
dpc-4050	166	32	disease	disease	NOUN
dpc-4050	166	33	but	but	CCONJ
dpc-4050	166	34	also	also	ADV
dpc-4050	166	35	all	all	DET
dpc-4050	166	36	the	the	DET
dpc-4050	166	37	associated	associated	ADJ
dpc-4050	166	38	pathologies	pathology	NOUN
dpc-4050	166	39	.	.	PUNCT
dpc-4050	167	1	data	datum	NOUN
dpc-4050	167	2	on	on	ADP
dpc-4050	167	3	the	the	DET
dpc-4050	167	4	efficacy	efficacy	NOUN
dpc-4050	167	5	and	and	CCONJ
dpc-4050	167	6	safety	safety	NOUN
dpc-4050	167	7	of	of	ADP
dpc-4050	167	8	other	other	ADJ
dpc-4050	167	9	biological	biological	ADJ
dpc-4050	167	10	drugs	drug	NOUN
dpc-4050	167	11	in	in	ADP
dpc-4050	167	12	the	the	DET
dpc-4050	167	13	treatment	treatment	NOUN
dpc-4050	167	14	of	of	ADP
dpc-4050	167	15	patients	patient	NOUN
dpc-4050	167	16	with	with	ADP
dpc-4050	167	17	psoriasis	psoriasis	NOUN
dpc-4050	167	18	treated	treat	VERB
dpc-4050	167	19	with	with	ADP
dpc-4050	167	20	biological	biological	ADJ
dpc-4050	167	21	drugs	drug	NOUN
dpc-4050	167	22	have	have	AUX
dpc-4050	167	23	been	be	AUX
dpc-4050	167	24	presented	present	VERB
dpc-4050	167	25	in	in	ADP
dpc-4050	167	26	the	the	DET
dpc-4050	167	27	literature	literature	NOUN
dpc-4050	167	28	.	.	PUNCT
dpc-4050	168	1	in	in	ADP
dpc-4050	168	2	particular	particular	ADJ
dpc-4050	168	3	,	,	PUNCT
dpc-4050	168	4	for	for	ADP
dpc-4050	168	5	example	example	NOUN
dpc-4050	168	6	,	,	PUNCT
dpc-4050	168	7	in	in	ADP
dpc-4050	168	8	the	the	DET
dpc-4050	168	9	work	work	NOUN
dpc-4050	168	10	presented	present	VERB
dpc-4050	168	11	by	by	ADP
dpc-4050	168	12	ruggiero	ruggiero	PROPN
dpc-4050	168	13	and	and	CCONJ
dpc-4050	168	14	collaborators	collaborator	NOUN
dpc-4050	168	15	,	,	PUNCT
dpc-4050	168	16	the	the	DET
dpc-4050	168	17	authors	author	NOUN
dpc-4050	168	18	focus	focus	VERB
dpc-4050	168	19	their	their	PRON
dpc-4050	168	20	attention	attention	NOUN
dpc-4050	168	21	on	on	ADP
dpc-4050	168	22	the	the	DET
dpc-4050	168	23	elderly	elderly	ADJ
dpc-4050	168	24	patient	patient	NOUN
dpc-4050	168	25	being	be	AUX
dpc-4050	168	26	treated	treat	VERB
dpc-4050	168	27	with	with	ADP
dpc-4050	168	28	guselkumab	guselkumab	NOUN
dpc-4050	168	29	,	,	PUNCT
dpc-4050	168	30	risankizumab	risankizumab	NOUN
dpc-4050	168	31	and	and	CCONJ
dpc-4050	168	32	tildrakizumab	tildrakizumab	NOUN
dpc-4050	168	33	over	over	ADP
dpc-4050	168	34	the	the	DET
dpc-4050	168	35	age	age	NOUN
dpc-4050	168	36	of	of	ADP
dpc-4050	168	37	65	65	NUM
dpc-4050	168	38	,	,	PUNCT
dpc-4050	168	39	but	but	CCONJ
dpc-4050	168	40	there	there	PRON
dpc-4050	168	41	are	be	VERB
dpc-4050	168	42	no	no	DET
dpc-4050	168	43	data	datum	NOUN
dpc-4050	168	44	in	in	ADP
dpc-4050	168	45	clinical	clinical	ADJ
dpc-4050	168	46	practice	practice	NOUN
dpc-4050	168	47	on	on	ADP
dpc-4050	168	48	the	the	DET
dpc-4050	168	49	efficacy	efficacy	NOUN
dpc-4050	168	50	of	of	ADP
dpc-4050	168	51	ixekizumab	ixekizumab	NOUN
dpc-4050	168	52	in	in	ADP
dpc-4050	168	53	the	the	DET
dpc-4050	168	54	elderly	elderly	ADJ
dpc-4050	168	55	patients	patient	NOUN
dpc-4050	168	56	[	[	X
dpc-4050	168	57	13	13	NUM
dpc-4050	168	58	]	]	PUNCT
dpc-4050	168	59	.	.	PUNCT
dpc-4050	169	1	however	however	ADV
dpc-4050	169	2	,	,	PUNCT
dpc-4050	169	3	most	most	ADJ
dpc-4050	169	4	of	of	ADP
dpc-4050	169	5	the	the	DET
dpc-4050	169	6	reported	report	VERB
dpc-4050	169	7	relevant	relevant	ADJ
dpc-4050	169	8	clinical	clinical	ADJ
dpc-4050	169	9	studies	study	NOUN
dpc-4050	169	10	on	on	ADP
dpc-4050	169	11	biologics	biologic	NOUN
dpc-4050	169	12	in	in	ADP
dpc-4050	169	13	elderly	elderly	ADJ
dpc-4050	169	14	patients	patient	NOUN
dpc-4050	169	15	have	have	AUX
dpc-4050	169	16	focused	focus	VERB
dpc-4050	169	17	on	on	ADP
dpc-4050	169	18	the	the	DET
dpc-4050	169	19	efficacy	efficacy	NOUN
dpc-4050	169	20	and	and	CCONJ
dpc-4050	169	21	safety	safety	NOUN
dpc-4050	169	22	of	of	ADP
dpc-4050	169	23	anti	anti	ADJ
dpc-4050	169	24	-	-	ADJ
dpc-4050	169	25	tnfα	tnfα	ADJ
dpc-4050	169	26	drugs	drug	NOUN
dpc-4050	169	27	,	,	PUNCT
dpc-4050	169	28	owing	owe	VERB
dpc-4050	169	29	to	to	ADP
dpc-4050	169	30	their	their	PRON
dpc-4050	169	31	longer	long	ADJ
dpc-4050	169	32	market	market	NOUN
dpc-4050	169	33	availability	availability	NOUN
dpc-4050	169	34	[	[	X
dpc-4050	169	35	11,12	11,12	NUM
dpc-4050	169	36	-	-	SYM
dpc-4050	169	37	14	14	NUM
dpc-4050	169	38	]	]	PUNCT
dpc-4050	169	39	.	.	PUNCT
dpc-4050	170	1	regarding	regard	VERB
dpc-4050	170	2	anti	anti	ADJ
dpc-4050	170	3	-	-	ADJ
dpc-4050	170	4	il-17	il-17	ADJ
dpc-4050	170	5	inhibitors	inhibitor	NOUN
dpc-4050	170	6	,	,	PUNCT
dpc-4050	170	7	a	a	DET
dpc-4050	170	8	recent	recent	ADJ
dpc-4050	170	9	study	study	NOUN
dpc-4050	170	10	including	include	VERB
dpc-4050	170	11	114	114	NUM
dpc-4050	170	12	elderly	elderly	ADJ
dpc-4050	170	13	patients	patient	NOUN
dpc-4050	170	14	showed	show	VERB
dpc-4050	170	15	that	that	SCONJ
dpc-4050	170	16	these	these	DET
dpc-4050	170	17	drugs	drug	NOUN
dpc-4050	170	18	were	be	AUX
dpc-4050	170	19	an	an	DET
dpc-4050	170	20	effective	effective	ADJ
dpc-4050	170	21	and	and	CCONJ
dpc-4050	170	22	safe	safe	ADJ
dpc-4050	170	23	therapeutic	therapeutic	ADJ
dpc-4050	170	24	option	option	NOUN
dpc-4050	170	25	for	for	ADP
dpc-4050	170	26	patients	patient	NOUN
dpc-4050	170	27	with	with	ADP
dpc-4050	170	28	psoriasis	psoriasis	NOUN
dpc-4050	170	29	aged	age	VERB
dpc-4050	170	30	≥	≥	NOUN
dpc-4050	170	31	65	65	NUM
dpc-4050	170	32	years	year	NOUN
dpc-4050	170	33	,	,	PUNCT
dpc-4050	170	34	with	with	ADP
dpc-4050	170	35	low	low	ADJ
dpc-4050	170	36	rates	rate	NOUN
dpc-4050	170	37	of	of	ADP
dpc-4050	170	38	only	only	ADV
dpc-4050	170	39	mild	mild	ADJ
dpc-4050	170	40	adverse	adverse	ADJ
dpc-4050	170	41	events	event	NOUN
dpc-4050	170	42	;	;	PUNCT
dpc-4050	170	43	however	however	ADV
dpc-4050	170	44	,	,	PUNCT
dpc-4050	170	45	the	the	DET
dpc-4050	170	46	discontinuation	discontinuation	NOUN
dpc-4050	170	47	rate	rate	NOUN
dpc-4050	170	48	was	be	AUX
dpc-4050	170	49	28.9	28.9	NUM
dpc-4050	170	50	%	%	NOUN
dpc-4050	170	51	,	,	PUNCT
dpc-4050	170	52	mostly	mostly	ADV
dpc-4050	170	53	related	relate	VERB
dpc-4050	170	54	to	to	ADP
dpc-4050	170	55	psoriasis	psoriasis	NOUN
dpc-4050	170	56	relapses	relapse	NOUN
dpc-4050	170	57	.	.	PUNCT
dpc-4050	171	1	a	a	DET
dpc-4050	171	2	post	post	X
dpc-4050	171	3	hoc	hoc	X
dpc-4050	171	4	analysis	analysis	NOUN
dpc-4050	171	5	of	of	ADP
dpc-4050	171	6	three	three	NUM
dpc-4050	171	7	phase	phase	NOUN
dpc-4050	171	8	iii	iii	NUM
dpc-4050	171	9	secukinumab	secukinumab	NOUN
dpc-4050	171	10	trials	trial	NOUN
dpc-4050	171	11	(	(	PUNCT
dpc-4050	171	12	erasure	erasure	NOUN
dpc-4050	171	13	,	,	PUNCT
dpc-4050	171	14	fixture	fixture	NOUN
dpc-4050	171	15	and	and	CCONJ
dpc-4050	171	16	clear	clear	ADJ
dpc-4050	171	17	)	)	PUNCT
dpc-4050	171	18	showed	show	VERB
dpc-4050	171	19	comparable	comparable	ADJ
dpc-4050	171	20	efficacy	efficacy	NOUN
dpc-4050	171	21	profiles	profile	NOUN
dpc-4050	171	22	between	between	ADP
dpc-4050	171	23	elderly	elderly	ADJ
dpc-4050	171	24	and	and	CCONJ
dpc-4050	171	25	younger	young	ADJ
dpc-4050	171	26	patients	patient	NOUN
dpc-4050	171	27	;	;	PUNCT
dpc-4050	171	28	however	however	ADV
dpc-4050	171	29	,	,	PUNCT
dpc-4050	171	30	the	the	DET
dpc-4050	171	31	rates	rate	NOUN
dpc-4050	171	32	of	of	ADP
dpc-4050	171	33	serious	serious	ADJ
dpc-4050	171	34	aes	aes	NOUN
dpc-4050	171	35	and	and	CCONJ
dpc-4050	171	36	discontinuation	discontinuation	NOUN
dpc-4050	171	37	were	be	AUX
dpc-4050	171	38	higher	high	ADJ
dpc-4050	171	39	in	in	ADP
dpc-4050	171	40	older	old	ADJ
dpc-4050	171	41	participants	participant	NOUN
dpc-4050	171	42	[	[	X
dpc-4050	171	43	15,16	15,16	NUM
dpc-4050	171	44	]	]	PUNCT
dpc-4050	171	45	.	.	PUNCT
dpc-4050	172	1	for	for	ADP
dpc-4050	172	2	ixekizumab	ixekizumab	NOUN
dpc-4050	172	3	,	,	PUNCT
dpc-4050	172	4	a	a	DET
dpc-4050	172	5	retrospective	retrospective	ADJ
dpc-4050	172	6	observational	observational	ADJ
dpc-4050	172	7	study	study	NOUN
dpc-4050	172	8	showed	show	VERB
dpc-4050	172	9	optimal	optimal	ADJ
dpc-4050	172	10	efficacy	efficacy	NOUN
dpc-4050	172	11	and	and	CCONJ
dpc-4050	172	12	safety	safety	NOUN
dpc-4050	172	13	in	in	ADP
dpc-4050	172	14	elderly	elderly	ADJ
dpc-4050	172	15	patients	patient	NOUN
dpc-4050	172	16	throughout	throughout	ADP
dpc-4050	172	17	a	a	DET
dpc-4050	172	18	1	1	NUM
dpc-4050	172	19	-	-	PUNCT
dpc-4050	172	20	year	year	NOUN
dpc-4050	172	21	treatment	treatment	NOUN
dpc-4050	172	22	period	period	NOUN
dpc-4050	172	23	,	,	PUNCT
dpc-4050	172	24	confirming	confirm	VERB
dpc-4050	172	25	the	the	DET
dpc-4050	172	26	results	result	NOUN
dpc-4050	172	27	highlighted	highlight	VERB
dpc-4050	172	28	in	in	ADP
dpc-4050	172	29	the	the	DET
dpc-4050	172	30	drug	drug	NOUN
dpc-4050	172	31	product	product	NOUN
dpc-4050	172	32	information	information	NOUN
dpc-4050	172	33	,	,	PUNCT
dpc-4050	172	34	reporting	report	VERB
dpc-4050	172	35	that	that	SCONJ
dpc-4050	172	36	the	the	DET
dpc-4050	172	37	response	response	NOUN
dpc-4050	172	38	in	in	ADP
dpc-4050	172	39	elderly	elderly	ADJ
dpc-4050	172	40	patients	patient	NOUN
dpc-4050	172	41	seems	seem	VERB
dpc-4050	172	42	to	to	PART
dpc-4050	172	43	be	be	AUX
dpc-4050	172	44	higher	high	ADJ
dpc-4050	172	45	than	than	ADP
dpc-4050	172	46	that	that	PRON
dpc-4050	172	47	in	in	ADP
dpc-4050	172	48	younger	young	ADJ
dpc-4050	172	49	patients	patient	NOUN
dpc-4050	172	50	[	[	X
dpc-4050	172	51	17	17	NUM
dpc-4050	172	52	]	]	PUNCT
dpc-4050	172	53	.	.	PUNCT
dpc-4050	173	1	we	we	PRON
dpc-4050	173	2	performed	perform	VERB
dpc-4050	173	3	a	a	DET
dpc-4050	173	4	multicenter	multicenter	NOUN
dpc-4050	173	5	,	,	PUNCT
dpc-4050	173	6	retrospective	retrospective	ADJ
dpc-4050	173	7	,	,	PUNCT
dpc-4050	173	8	observational	observational	ADJ
dpc-4050	173	9	analysis	analysis	NOUN
dpc-4050	173	10	in	in	ADP
dpc-4050	173	11	real	real	ADJ
dpc-4050	173	12	life	life	NOUN
dpc-4050	173	13	in	in	ADP
dpc-4050	173	14	patients	patient	NOUN
dpc-4050	173	15	with	with	ADP
dpc-4050	173	16	chronic	chronic	ADJ
dpc-4050	173	17	plaque	plaque	NOUN
dpc-4050	173	18	psoriasis	psoriasis	NOUN
dpc-4050	173	19	and	and	CCONJ
dpc-4050	173	20	psoriatic	psoriatic	ADJ
dpc-4050	173	21	arthritis	arthritis	NOUN
dpc-4050	173	22	of	of	ADP
dpc-4050	173	23	elderly	elderly	ADJ
dpc-4050	173	24	patients	patient	NOUN
dpc-4050	173	25	(	(	PUNCT
dpc-4050	173	26	>	>	SYM
dpc-4050	173	27	65	65	NUM
dpc-4050	173	28	years	year	NOUN
dpc-4050	173	29	)	)	PUNCT
dpc-4050	173	30	treated	treat	VERB
dpc-4050	173	31	with	with	ADP
dpc-4050	173	32	ixekizumab	ixekizumab	NOUN
dpc-4050	173	33	.	.	PUNCT
dpc-4050	174	1	we	we	PRON
dpc-4050	174	2	included	include	VERB
dpc-4050	174	3	male	male	ADJ
dpc-4050	174	4	and	and	CCONJ
dpc-4050	174	5	female	female	ADJ
dpc-4050	174	6	patients	patient	NOUN
dpc-4050	174	7	attending	attend	VERB
dpc-4050	174	8	the	the	DET
dpc-4050	174	9	outpatient	outpatient	NOUN
dpc-4050	174	10	clinics	clinic	NOUN
dpc-4050	174	11	of	of	ADP
dpc-4050	174	12	seven	seven	NUM
dpc-4050	174	13	italian	italian	ADJ
dpc-4050	174	14	referral	referral	ADJ
dpc-4050	174	15	center	center	NOUN
dpc-4050	174	16	for	for	ADP
dpc-4050	174	17	psoriasis	psoriasis	NOUN
dpc-4050	174	18	in	in	ADP
dpc-4050	174	19	lazio	lazio	PROPN
dpc-4050	174	20	region	region	NOUN
dpc-4050	174	21	:	:	PUNCT
dpc-4050	174	22	policlinico	policlinico	NOUN
dpc-4050	174	23	umberto	umberto	NOUN
dpc-4050	174	24	i	i	PRON
dpc-4050	174	25	università	università	PROPN
dpc-4050	174	26	roma	roma	PROPN
dpc-4050	174	27	la	la	PROPN
dpc-4050	174	28	sapienza	sapienza	PROPN
dpc-4050	174	29	,	,	PUNCT
dpc-4050	174	30	sant’andrea	sant’andrea	PROPN
dpc-4050	174	31	università	università	PROPN
dpc-4050	174	32	di	di	PROPN
dpc-4050	174	33	roma	roma	PROPN
dpc-4050	174	34	la	la	PROPN
dpc-4050	174	35	sapienza	sapienza	PROPN
dpc-4050	174	36	,	,	PUNCT
dpc-4050	174	37	polo	polo	NOUN
dpc-4050	174	38	pontino	pontino	PROPN
dpc-4050	174	39	università	università	PROPN
dpc-4050	174	40	roma	roma	PROPN
dpc-4050	174	41	la	la	PROPN
dpc-4050	174	42	sapienza	sapienza	PROPN
dpc-4050	174	43	,	,	PUNCT
dpc-4050	174	44	fondazione	fondazione	PROPN
dpc-4050	174	45	policlinico	policlinico	PROPN
dpc-4050	174	46	universitario	universitario	PROPN
dpc-4050	174	47	a.	a.	PROPN
dpc-4050	174	48	gemelli	gemelli	PROPN
dpc-4050	174	49	,	,	PUNCT
dpc-4050	174	50	università	università	PROPN
dpc-4050	174	51	campus	campus	NOUN
dpc-4050	174	52	biomedico	biomedico	PROPN
dpc-4050	174	53	roma	roma	PROPN
dpc-4050	174	54	;	;	PUNCT
dpc-4050	174	55	istituto	istituto	X
dpc-4050	174	56	dermopatico	dermopatico	NOUN
dpc-4050	174	57	dell’immacolata	dell’immacolata	NOUN
dpc-4050	174	58	–	–	PUNCT
dpc-4050	174	59	idi	idi	NOUN
dpc-4050	174	60	;	;	PUNCT
dpc-4050	174	61	policlinico	policlinico	NOUN
dpc-4050	174	62	tor	tor	NOUN
dpc-4050	174	63	vergata	vergata	NOUN
dpc-4050	174	64	.	.	PUNCT
dpc-4050	175	1	our	our	PRON
dpc-4050	175	2	results	result	NOUN
dpc-4050	175	3	show	show	VERB
dpc-4050	175	4	that	that	SCONJ
dpc-4050	175	5	ixekizumab	ixekizumab	NOUN
dpc-4050	175	6	was	be	AUX
dpc-4050	175	7	found	find	VERB
dpc-4050	175	8	to	to	PART
dpc-4050	175	9	be	be	AUX
dpc-4050	175	10	effective	effective	ADJ
dpc-4050	175	11	and	and	CCONJ
dpc-4050	175	12	safe	safe	ADJ
dpc-4050	175	13	in	in	ADP
dpc-4050	175	14	the	the	DET
dpc-4050	175	15	whole	whole	ADJ
dpc-4050	175	16	sample	sample	NOUN
dpc-4050	175	17	of	of	ADP
dpc-4050	175	18	enrolled	enrol	VERB
dpc-4050	175	19	patients	patient	NOUN
dpc-4050	175	20	,	,	PUNCT
dpc-4050	175	21	every	every	DET
dpc-4050	175	22	parameter	parameter	NOUN
dpc-4050	175	23	taken	take	VERB
dpc-4050	175	24	into	into	ADP
dpc-4050	175	25	consideration	consideration	NOUN
dpc-4050	175	26	has	have	AUX
dpc-4050	175	27	already	already	ADV
dpc-4050	175	28	significantly	significantly	ADV
dpc-4050	175	29	improved	improve	VERB
dpc-4050	175	30	at	at	ADP
dpc-4050	175	31	week	week	NOUN
dpc-4050	175	32	16	16	NUM
dpc-4050	175	33	,	,	PUNCT
dpc-4050	175	34	maintaining	maintain	VERB
dpc-4050	175	35	the	the	DET
dpc-4050	175	36	results	result	NOUN
dpc-4050	175	37	.	.	PUNCT
dpc-4050	176	1	subgroup	subgroup	PROPN
dpc-4050	176	2	analyzes	analyze	NOUN
dpc-4050	176	3	confirmed	confirm	VERB
dpc-4050	176	4	that	that	SCONJ
dpc-4050	176	5	time	time	NOUN
dpc-4050	176	6	is	be	AUX
dpc-4050	176	7	significant	significant	ADJ
dpc-4050	176	8	figure	figure	NOUN
dpc-4050	176	9	4	4	NUM
dpc-4050	176	10	.	.	NOUN
dpc-4050	176	11	trend	trend	NOUN
dpc-4050	176	12	in	in	ADP
dpc-4050	176	13	mean	mean	NOUN
dpc-4050	176	14	psoriasis	psoriasis	NOUN
dpc-4050	176	15	area	area	NOUN
dpc-4050	176	16	and	and	CCONJ
dpc-4050	176	17	severity	severity	NOUN
dpc-4050	176	18	index	index	NOUN
dpc-4050	176	19	(	(	PUNCT
dpc-4050	176	20	pasi	pasi	NOUN
dpc-4050	176	21	)	)	PUNCT
dpc-4050	176	22	score	score	NOUN
dpc-4050	176	23	by	by	ADP
dpc-4050	176	24	sex	sex	NOUN
dpc-4050	176	25	at	at	ADP
dpc-4050	176	26	each	each	DET
dpc-4050	176	27	time	time	NOUN
dpc-4050	176	28	point	point	NOUN
dpc-4050	176	29	.	.	PUNCT
dpc-4050	177	1	table	table	NOUN
dpc-4050	177	2	7	7	NUM
dpc-4050	177	3	.	.	PUNCT
dpc-4050	178	1	subgroups	subgroup	NOUN
dpc-4050	178	2	comparison	comparison	VERB
dpc-4050	178	3	on	on	ADP
dpc-4050	178	4	a	a	DET
dpc-4050	178	5	selected	select	VERB
dpc-4050	178	6	list	list	NOUN
dpc-4050	178	7	of	of	ADP
dpc-4050	178	8	variables	variables	ADJ
dpc-4050	178	9	female	female	ADJ
dpc-4050	178	10	male	male	ADJ
dpc-4050	178	11	pmean	pmean	NOUN
dpc-4050	178	12	sd	sd	AUX
dpc-4050	178	13	mean	mean	VERB
dpc-4050	178	14	sd	sd	ADP
dpc-4050	178	15	pasi	pasi	NOUN
dpc-4050	178	16	(	(	PUNCT
dpc-4050	178	17	baseline	baseline	PROPN
dpc-4050	178	18	)	)	PUNCT
dpc-4050	178	19	12.2	12.2	NUM
dpc-4050	178	20	6.5	6.5	NUM
dpc-4050	178	21	16.5	16.5	NUM
dpc-4050	178	22	9.8	9.8	NUM
dpc-4050	178	23	0.07	0.07	NUM
dpc-4050	178	24	vas	vas	X
dpc-4050	178	25	(	(	PUNCT
dpc-4050	178	26	baseline	baseline	PROPN
dpc-4050	178	27	)	)	PUNCT
dpc-4050	178	28	17.0	17.0	NUM
dpc-4050	178	29	25.2	25.2	NUM
dpc-4050	178	30	16.2	16.2	NUM
dpc-4050	178	31	22.3	22.3	NUM
dpc-4050	178	32	0.54	0.54	NUM
dpc-4050	178	33	dlqi	dlqi	NOUN
dpc-4050	178	34	(	(	PUNCT
dpc-4050	178	35	baseline	baseline	PROPN
dpc-4050	178	36	)	)	PUNCT
dpc-4050	178	37	15.7	15.7	NUM
dpc-4050	178	38	6.8	6.8	NUM
dpc-4050	178	39	16.1	16.1	NUM
dpc-4050	178	40	5.9	5.9	NUM
dpc-4050	178	41	0.79	0.79	NUM
dpc-4050	178	42	age	age	NOUN
dpc-4050	178	43	72.0	72.0	NUM
dpc-4050	178	44	5.9	5.9	NUM
dpc-4050	178	45	71.2	71.2	NUM
dpc-4050	178	46	6.7	6.7	NUM
dpc-4050	178	47	0.45	0.45	NUM
dpc-4050	178	48	pso	pso	NOUN
dpc-4050	178	49	pso	pso	NOUN
dpc-4050	178	50	-	-	PUNCT
dpc-4050	178	51	psa	psa	NOUN
dpc-4050	178	52	pmean	pmean	NOUN
dpc-4050	178	53	sd	sd	AUX
dpc-4050	178	54	mean	mean	VERB
dpc-4050	178	55	sd	sd	ADP
dpc-4050	178	56	pasi	pasi	NOUN
dpc-4050	178	57	(	(	PUNCT
dpc-4050	178	58	baseline	baseline	PROPN
dpc-4050	178	59	)	)	PUNCT
dpc-4050	178	60	15.4	15.4	NUM
dpc-4050	178	61	6.5	6.5	NUM
dpc-4050	178	62	14.2	14.2	NUM
dpc-4050	178	63	9.7	9.7	NUM
dpc-4050	178	64	0.47	0.47	NUM
dpc-4050	178	65	vas	vas	X
dpc-4050	178	66	(	(	PUNCT
dpc-4050	178	67	baseline	baseline	PROPN
dpc-4050	178	68	)	)	PUNCT
dpc-4050	178	69	6.0	6.0	NUM
dpc-4050	178	70	1.4	1.4	NUM
dpc-4050	178	71	16.8	16.8	NUM
dpc-4050	178	72	23.1	23.1	NUM
dpc-4050	178	73	0.07	0.07	NUM
dpc-4050	178	74	dlqi	dlqi	NOUN
dpc-4050	178	75	(	(	PUNCT
dpc-4050	178	76	baseline	baseline	PROPN
dpc-4050	178	77	)	)	PUNCT
dpc-4050	178	78	18.3	18.3	NUM
dpc-4050	178	79	3.8	3.8	NUM
dpc-4050	178	80	14.6	14.6	NUM
dpc-4050	178	81	6.9	6.9	NUM
dpc-4050	178	82	0.07	0.07	NUM
dpc-4050	178	83	age	age	NOUN
dpc-4050	178	84	71.0	71.0	NUM
dpc-4050	178	85	6.4	6.4	NUM
dpc-4050	178	86	71.4	71.4	NUM
dpc-4050	178	87	6.0	6.0	NUM
dpc-4050	178	88	0.21	0.21	NUM
dpc-4050	178	89	bio	bio	ADJ
dpc-4050	178	90	-	-	ADJ
dpc-4050	178	91	naive	naive	ADJ
dpc-4050	178	92	not	not	PART
dpc-4050	178	93	bio	bio	ADJ
dpc-4050	178	94	-	-	ADJ
dpc-4050	178	95	naive	naive	ADJ
dpc-4050	178	96	pmean	pmean	NOUN
dpc-4050	178	97	sd	sd	PART
dpc-4050	178	98	mean	mean	VERB
dpc-4050	178	99	sd	sd	ADP
dpc-4050	178	100	pasi	pasi	NOUN
dpc-4050	178	101	(	(	PUNCT
dpc-4050	178	102	baseline	baseline	PROPN
dpc-4050	178	103	)	)	PUNCT
dpc-4050	178	104	14.2	14.2	NUM
dpc-4050	178	105	8.9	8.9	NUM
dpc-4050	178	106	16.0	16.0	NUM
dpc-4050	178	107	8.1	8.1	NUM
dpc-4050	178	108	0.55	0.55	NUM
dpc-4050	178	109	vas	vas	X
dpc-4050	178	110	(	(	PUNCT
dpc-4050	178	111	baseline	baseline	PROPN
dpc-4050	178	112	)	)	PUNCT
dpc-4050	178	113	16.3	16.3	NUM
dpc-4050	178	114	23.5	23.5	NUM
dpc-4050	178	115	18.6	18.6	NUM
dpc-4050	178	116	23.2	23.2	NUM
dpc-4050	178	117	0.19	0.19	NUM
dpc-4050	178	118	dlqi	dlqi	NOUN
dpc-4050	178	119	(	(	PUNCT
dpc-4050	178	120	baseline	baseline	PROPN
dpc-4050	178	121	)	)	PUNCT
dpc-4050	178	122	15.3	15.3	NUM
dpc-4050	178	123	6.6	6.6	NUM
dpc-4050	178	124	18.0	18.0	NUM
dpc-4050	178	125	4.1	4.1	NUM
dpc-4050	178	126	0.23	0.23	NUM
dpc-4050	178	127	age	age	NOUN
dpc-4050	178	128	71.2	71.2	NUM
dpc-4050	178	129	6.1	6.1	NUM
dpc-4050	178	130	72.9	72.9	NUM
dpc-4050	178	131	7.2	7.2	NUM
dpc-4050	178	132	0.51	0.51	NUM
dpc-4050	178	133	bmi	bmi	NOUN
dpc-4050	178	134	<	<	X
dpc-4050	178	135	25	25	NUM
dpc-4050	178	136	bmi≥25	bmi≥25	PROPN
dpc-4050	178	137	pmean	pmean	NOUN
dpc-4050	178	138	sd	sd	AUX
dpc-4050	178	139	mean	mean	VERB
dpc-4050	178	140	sd	sd	ADP
dpc-4050	178	141	pasi	pasi	NOUN
dpc-4050	178	142	(	(	PUNCT
dpc-4050	178	143	baseline	baseline	PROPN
dpc-4050	178	144	)	)	PUNCT
dpc-4050	178	145	10.9	10.9	NUM
dpc-4050	178	146	6.7	6.7	NUM
dpc-4050	178	147	16.1	16.1	NUM
dpc-4050	178	148	9.1	9.1	NUM
dpc-4050	178	149	0.02	0.02	NUM
dpc-4050	178	150	vas	vas	X
dpc-4050	178	151	(	(	PUNCT
dpc-4050	178	152	baseline	baseline	PROPN
dpc-4050	178	153	)	)	PUNCT
dpc-4050	178	154	21.1	21.1	NUM
dpc-4050	178	155	28.3	28.3	NUM
dpc-4050	178	156	14.6	14.6	NUM
dpc-4050	178	157	20.8	20.8	NUM
dpc-4050	178	158	0.65	0.65	NUM
dpc-4050	178	159	dlqi	dlqi	NOUN
dpc-4050	178	160	(	(	PUNCT
dpc-4050	178	161	baseline	baseline	PROPN
dpc-4050	178	162	)	)	PUNCT
dpc-4050	178	163	15.1	15.1	NUM
dpc-4050	178	164	6.7	6.7	NUM
dpc-4050	178	165	16.2	16.2	NUM
dpc-4050	178	166	6.1	6.1	NUM
dpc-4050	178	167	0.41	0.41	NUM
dpc-4050	178	168	age	age	NOUN
dpc-4050	178	169	,	,	PUNCT
dpc-4050	178	170	years	year	NOUN
dpc-4050	178	171	71.8	71.8	NUM
dpc-4050	178	172	7.4	7.4	NUM
dpc-4050	178	173	71.4	71.4	NUM
dpc-4050	178	174	5.9	5.9	NUM
dpc-4050	178	175	0.89	0.89	NUM
dpc-4050	178	176	bmi	bmi	NOUN
dpc-4050	178	177	=	=	PUNCT
dpc-4050	178	178	body	body	NOUN
dpc-4050	178	179	mass	mass	PROPN
dpc-4050	178	180	index	index	NOUN
dpc-4050	178	181	;	;	PUNCT
dpc-4050	178	182	dlqi	dlqi	ADJ
dpc-4050	178	183	=	=	SYM
dpc-4050	178	184	dermatology	dermatology	NOUN
dpc-4050	178	185	life	life	NOUN
dpc-4050	178	186	quality	quality	NOUN
dpc-4050	178	187	index	index	NOUN
dpc-4050	178	188	psa	psa	NOUN
dpc-4050	178	189	=	=	SYM
dpc-4050	178	190	psoriatic	psoriatic	ADJ
dpc-4050	178	191	arthritis	arthritis	NOUN
dpc-4050	178	192	;	;	PUNCT
dpc-4050	178	193	pso	pso	NOUN
dpc-4050	178	194	=	=	NOUN
dpc-4050	178	195	psoriasis	psoriasis	NOUN
dpc-4050	178	196	;	;	PUNCT
dpc-4050	178	197	sd	sd	ADP
dpc-4050	178	198	standard	standard	ADJ
dpc-4050	178	199	deviation	deviation	NOUN
dpc-4050	178	200	.	.	PUNCT
dpc-4050	179	1	pasi	pasi	NOUN
dpc-4050	179	2	=	=	SYM
dpc-4050	179	3	psoriasis	psoriasis	NOUN
dpc-4050	179	4	area	area	NOUN
dpc-4050	179	5	and	and	CCONJ
dpc-4050	179	6	severity	severity	NOUN
dpc-4050	179	7	index	index	NOUN
dpc-4050	179	8	;	;	PUNCT
dpc-4050	179	9	sd	sd	NOUN
dpc-4050	179	10	=	=	SYM
dpc-4050	179	11	standard	standard	ADJ
dpc-4050	179	12	deviation	deviation	NOUN
dpc-4050	179	13	;	;	PUNCT
dpc-4050	179	14	vas	vas	X
dpc-4050	179	15	=	=	SYM
dpc-4050	179	16	visual	visual	ADJ
dpc-4050	179	17	analogue	analogue	NOUN
dpc-4050	179	18	scale	scale	NOUN
dpc-4050	179	19	.	.	PUNCT
dpc-4050	180	1	original	original	ADJ
dpc-4050	180	2	article	article	NOUN
dpc-4050	180	3	|	|	ADV
dpc-4050	180	4	dermatol	dermatol	ADJ
dpc-4050	180	5	pract	pract	NOUN
dpc-4050	180	6	concept	concept	NOUN
dpc-4050	180	7	.	.	PUNCT
dpc-4050	181	1	2024;14(3):e2024166	2024;14(3):e2024166	NUM
dpc-4050	181	2	9	9	NUM
dpc-4050	181	3	table	table	NOUN
dpc-4050	181	4	8	8	NUM
dpc-4050	181	5	.	.	PUNCT
dpc-4050	182	1	subgroups	subgroup	NOUN
dpc-4050	182	2	comparisons	comparison	NOUN
dpc-4050	182	3	sex	sex	NOUN
dpc-4050	182	4	pasi	pasi	NOUN
dpc-4050	182	5	score	score	NOUN
dpc-4050	182	6	p	p	NOUN
dpc-4050	182	7	-	-	PUNCT
dpc-4050	182	8	value	value	NOUN
dpc-4050	182	9	pasi	pasi	NOUN
dpc-4050	182	10	score	score	NOUN
dpc-4050	182	11	p	p	NOUN
dpc-4050	182	12	-	-	PUNCT
dpc-4050	182	13	value	value	NOUN
dpc-4050	182	14	m	m	NOUN
dpc-4050	182	15	vs	vs	ADP
dpc-4050	182	16	f	f	PROPN
dpc-4050	182	17	0.037	0.037	NUM
dpc-4050	182	18	naive	naive	ADJ
dpc-4050	182	19	,	,	PUNCT
dpc-4050	182	20	bio	bio	ADJ
dpc-4050	182	21	-	-	ADJ
dpc-4050	182	22	experienced	experienced	ADJ
dpc-4050	182	23	naive	naive	ADJ
dpc-4050	182	24	vs	vs	ADP
dpc-4050	182	25	bio	bio	ADJ
dpc-4050	182	26	-	-	ADJ
dpc-4050	182	27	experienced	experienced	ADJ
dpc-4050	182	28	0.99	0.99	NUM
dpc-4050	182	29	bl	bl	NOUN
dpc-4050	182	30	vs	vs	ADP
dpc-4050	182	31	week	week	NOUN
dpc-4050	182	32	16	16	NUM
dpc-4050	182	33	<	<	X
dpc-4050	182	34	0.0001	0.0001	NUM
dpc-4050	182	35	bl	bl	NOUN
dpc-4050	182	36	vs	vs	ADP
dpc-4050	182	37	week	week	NOUN
dpc-4050	182	38	16	16	NUM
dpc-4050	182	39	<	<	X
dpc-4050	182	40	0.0001	0.0001	NUM
dpc-4050	182	41	bl	bl	NOUN
dpc-4050	182	42	vs	vs	ADP
dpc-4050	182	43	week	week	NOUN
dpc-4050	182	44	24	24	NUM
dpc-4050	182	45	<	<	SYM
dpc-4050	182	46	0.0001	0.0001	NUM
dpc-4050	182	47	bl	bl	NOUN
dpc-4050	182	48	vs	vs	ADP
dpc-4050	182	49	week	week	NOUN
dpc-4050	182	50	24	24	NUM
dpc-4050	182	51	<	<	SYM
dpc-4050	182	52	0.0001	0.0001	NUM
dpc-4050	182	53	bl	bl	NOUN
dpc-4050	182	54	vs	vs	ADP
dpc-4050	182	55	week	week	NOUN
dpc-4050	182	56	52	52	NUM
dpc-4050	182	57	<	<	X
dpc-4050	182	58	.,0001	.,0001	X
dpc-4050	182	59	bl	bl	INTJ
dpc-4050	182	60	vs	vs	ADP
dpc-4050	182	61	week	week	NOUN
dpc-4050	182	62	52	52	NUM
dpc-4050	182	63	<	<	NOUN
dpc-4050	182	64	0.0001	0.0001	NUM
dpc-4050	182	65	bl	bl	NOUN
dpc-4050	182	66	vs	vs	ADP
dpc-4050	182	67	week	week	NOUN
dpc-4050	182	68	104	104	NUM
dpc-4050	182	69	<	<	X
dpc-4050	182	70	0.0001	0.0001	NUM
dpc-4050	182	71	bl	bl	NOUN
dpc-4050	182	72	vs	vs	ADP
dpc-4050	182	73	week	week	NOUN
dpc-4050	182	74	104	104	NUM
dpc-4050	182	75	<	<	X
dpc-4050	182	76	0.0001	0.0001	NUM
dpc-4050	182	77	bl	bl	NOUN
dpc-4050	182	78	vs	vs	ADP
dpc-4050	182	79	week	week	NOUN
dpc-4050	182	80	156	156	NUM
dpc-4050	182	81	<	<	X
dpc-4050	182	82	0.0001	0.0001	NUM
dpc-4050	182	83	bl	bl	NOUN
dpc-4050	182	84	vs	vs	ADP
dpc-4050	182	85	week	week	NOUN
dpc-4050	182	86	156	156	NUM
dpc-4050	182	87	<	<	X
dpc-4050	182	88	0.0001	0.0001	NUM
dpc-4050	182	89	vas	vas	NOUN
dpc-4050	182	90	score	score	NOUN
dpc-4050	182	91	p	p	NOUN
dpc-4050	182	92	-	-	PUNCT
dpc-4050	182	93	value	value	NOUN
dpc-4050	182	94	vas	vas	X
dpc-4050	182	95	score	score	NOUN
dpc-4050	182	96	p	p	NOUN
dpc-4050	182	97	-	-	PUNCT
dpc-4050	182	98	value	value	NOUN
dpc-4050	182	99	m	m	NOUN
dpc-4050	182	100	vs	vs	ADP
dpc-4050	182	101	f	f	PROPN
dpc-4050	182	102	0.247	0.247	NUM
dpc-4050	182	103	naive	naive	ADJ
dpc-4050	182	104	vs	vs	ADP
dpc-4050	182	105	bio	bio	ADJ
dpc-4050	182	106	-	-	ADJ
dpc-4050	182	107	experienced	experienced	ADJ
dpc-4050	182	108	0.259	0.259	NUM
dpc-4050	182	109	bl	bl	NOUN
dpc-4050	182	110	vs	vs	ADP
dpc-4050	182	111	week	week	NOUN
dpc-4050	182	112	16	16	NUM
dpc-4050	182	113	0.004	0.004	NUM
dpc-4050	182	114	bl	bl	NOUN
dpc-4050	182	115	vs	vs	ADP
dpc-4050	182	116	week	week	NOUN
dpc-4050	182	117	16	16	NUM
dpc-4050	182	118	<	<	X
dpc-4050	182	119	0.0001	0.0001	NUM
dpc-4050	182	120	bl	bl	NOUN
dpc-4050	182	121	vs	vs	ADP
dpc-4050	182	122	week	week	NOUN
dpc-4050	182	123	24	24	NUM
dpc-4050	182	124	0.005	0.005	NUM
dpc-4050	182	125	bl	bl	INTJ
dpc-4050	182	126	vs	vs	ADP
dpc-4050	182	127	week	week	NOUN
dpc-4050	182	128	24	24	NUM
dpc-4050	182	129	<	<	SYM
dpc-4050	182	130	0.0001	0.0001	NUM
dpc-4050	182	131	bl	bl	NOUN
dpc-4050	182	132	vs	vs	ADP
dpc-4050	182	133	week	week	NOUN
dpc-4050	182	134	52	52	NUM
dpc-4050	182	135	0.006	0.006	NUM
dpc-4050	182	136	bl	bl	NOUN
dpc-4050	182	137	vs	vs	ADP
dpc-4050	182	138	week	week	NOUN
dpc-4050	182	139	52	52	NUM
dpc-4050	182	140	<	<	NOUN
dpc-4050	182	141	0.0001	0.0001	NUM
dpc-4050	182	142	bl	bl	NOUN
dpc-4050	182	143	vs	vs	ADP
dpc-4050	182	144	week	week	NOUN
dpc-4050	182	145	104	104	NUM
dpc-4050	182	146	0	0	NUM
dpc-4050	182	147	bl	bl	INTJ
dpc-4050	182	148	vs	vs	ADP
dpc-4050	182	149	week	week	NOUN
dpc-4050	182	150	104	104	NUM
dpc-4050	182	151	<	<	X
dpc-4050	182	152	0.0001	0.0001	NUM
dpc-4050	182	153	bl	bl	NOUN
dpc-4050	182	154	vs	vs	ADP
dpc-4050	182	155	week	week	NOUN
dpc-4050	182	156	156	156	NUM
dpc-4050	182	157	0.015	0.015	NUM
dpc-4050	182	158	bl	bl	NOUN
dpc-4050	182	159	vs	vs	ADP
dpc-4050	182	160	week	week	NOUN
dpc-4050	182	161	156	156	NUM
dpc-4050	182	162	<	<	X
dpc-4050	182	163	0.0001	0.0001	NUM
dpc-4050	182	164	dlqi	dlqi	ADJ
dpc-4050	182	165	score	score	NOUN
dpc-4050	182	166	p	p	NOUN
dpc-4050	182	167	-	-	PUNCT
dpc-4050	182	168	value	value	NOUN
dpc-4050	182	169	dlqi	dlqi	NOUN
dpc-4050	182	170	score	score	NOUN
dpc-4050	182	171	p	p	NOUN
dpc-4050	182	172	-	-	PUNCT
dpc-4050	182	173	value	value	NOUN
dpc-4050	182	174	m	m	NOUN
dpc-4050	182	175	vs	vs	ADP
dpc-4050	182	176	f	f	PROPN
dpc-4050	182	177	0.829	0.829	NUM
dpc-4050	182	178	naive	naive	ADJ
dpc-4050	182	179	vs	vs	ADP
dpc-4050	182	180	bio	bio	NOUN
dpc-4050	182	181	-	-	ADJ
dpc-4050	182	182	experienced	experienced	ADJ
dpc-4050	182	183	0.265	0.265	NUM
dpc-4050	182	184	bl	bl	NOUN
dpc-4050	182	185	vs	vs	ADP
dpc-4050	182	186	week	week	NOUN
dpc-4050	182	187	52	52	NUM
dpc-4050	182	188	<	<	NOUN
dpc-4050	182	189	0.0001	0.0001	NUM
dpc-4050	182	190	bl	bl	NOUN
dpc-4050	182	191	vs	vs	ADP
dpc-4050	182	192	week	week	NOUN
dpc-4050	182	193	52	52	NUM
dpc-4050	182	194	<	<	SYM
dpc-4050	182	195	0.0001	0.0001	NUM
dpc-4050	182	196	bmi<25	bmi<25	PROPN
dpc-4050	182	197	,	,	PUNCT
dpc-4050	182	198	bmi≥25	bmi≥25	NOUN
dpc-4050	182	199	pasi	pasi	NOUN
dpc-4050	182	200	score	score	NOUN
dpc-4050	182	201	p	p	NOUN
dpc-4050	182	202	-	-	PUNCT
dpc-4050	182	203	value	value	NOUN
dpc-4050	182	204	pso	pso	NOUN
dpc-4050	182	205	,	,	PUNCT
dpc-4050	182	206	pso	pso	NOUN
dpc-4050	182	207	-	-	PUNCT
dpc-4050	182	208	psa	psa	NOUN
dpc-4050	182	209	pasi	pasi	NOUN
dpc-4050	182	210	score	score	VERB
dpc-4050	182	211	p	p	NOUN
dpc-4050	182	212	-	-	PUNCT
dpc-4050	182	213	value	value	NOUN
dpc-4050	182	214	bmi<25	bmi<25	NOUN
dpc-4050	182	215	vs	vs	ADP
dpc-4050	182	216	bmi≥25	bmi≥25	NOUN
dpc-4050	182	217	0.374	0.374	NUM
dpc-4050	182	218	pso	pso	NOUN
dpc-4050	182	219	vs	vs	ADP
dpc-4050	182	220	pso	pso	NOUN
dpc-4050	182	221	-	-	PUNCT
dpc-4050	182	222	psa	psa	NOUN
dpc-4050	182	223	0.647	0.647	NUM
dpc-4050	182	224	bl	bl	NOUN
dpc-4050	182	225	vs	vs	ADP
dpc-4050	182	226	week	week	NOUN
dpc-4050	182	227	16	16	NUM
dpc-4050	182	228	<	<	X
dpc-4050	182	229	0,0001	0,0001	X
dpc-4050	182	230	bl	bl	PROPN
dpc-4050	182	231	vs	vs	ADP
dpc-4050	182	232	week	week	NOUN
dpc-4050	182	233	16	16	NUM
dpc-4050	182	234	<	<	X
dpc-4050	182	235	0.0001	0.0001	NUM
dpc-4050	182	236	bl	bl	NOUN
dpc-4050	182	237	vs	vs	ADP
dpc-4050	182	238	week	week	NOUN
dpc-4050	182	239	24	24	NUM
dpc-4050	182	240	<	<	SYM
dpc-4050	182	241	0.0001	0.0001	NUM
dpc-4050	182	242	bl	bl	NOUN
dpc-4050	182	243	vs	vs	ADP
dpc-4050	182	244	week	week	NOUN
dpc-4050	182	245	24	24	NUM
dpc-4050	182	246	<	<	SYM
dpc-4050	182	247	0.0001	0.0001	NUM
dpc-4050	182	248	bl	bl	NOUN
dpc-4050	182	249	vs	vs	ADP
dpc-4050	182	250	week	week	NOUN
dpc-4050	182	251	52	52	NUM
dpc-4050	182	252	<	<	NOUN
dpc-4050	182	253	0.0001	0.0001	NUM
dpc-4050	182	254	bl	bl	NOUN
dpc-4050	182	255	vs	vs	ADP
dpc-4050	182	256	week	week	NOUN
dpc-4050	182	257	52	52	NUM
dpc-4050	182	258	<	<	NOUN
dpc-4050	182	259	0.0001	0.0001	NUM
dpc-4050	182	260	bl	bl	NOUN
dpc-4050	182	261	vs	vs	ADP
dpc-4050	182	262	week	week	NOUN
dpc-4050	182	263	104	104	NUM
dpc-4050	182	264	<	<	X
dpc-4050	182	265	0.0001	0.0001	NUM
dpc-4050	182	266	bl	bl	NOUN
dpc-4050	182	267	vs	vs	ADP
dpc-4050	182	268	week	week	NOUN
dpc-4050	182	269	104	104	NUM
dpc-4050	182	270	<	<	X
dpc-4050	182	271	0.0001	0.0001	NUM
dpc-4050	182	272	bl	bl	NOUN
dpc-4050	182	273	vs	vs	ADP
dpc-4050	182	274	week	week	NOUN
dpc-4050	182	275	156	156	NUM
dpc-4050	182	276	<	<	X
dpc-4050	182	277	0.0001	0.0001	NUM
dpc-4050	182	278	bl	bl	NOUN
dpc-4050	182	279	vs	vs	ADP
dpc-4050	182	280	week	week	NOUN
dpc-4050	182	281	156	156	NUM
dpc-4050	182	282	<	<	X
dpc-4050	182	283	0.0001	0.0001	NUM
dpc-4050	182	284	vas	vas	NOUN
dpc-4050	182	285	score	score	NOUN
dpc-4050	182	286	p	p	NOUN
dpc-4050	182	287	-	-	PUNCT
dpc-4050	182	288	value	value	NOUN
dpc-4050	182	289	vas	vas	X
dpc-4050	182	290	score	score	NOUN
dpc-4050	182	291	p	p	NOUN
dpc-4050	182	292	-	-	PUNCT
dpc-4050	182	293	value	value	NOUN
dpc-4050	182	294	bmi<25	bmi<25	NOUN
dpc-4050	182	295	vs	vs	ADP
dpc-4050	182	296	bmi≥25	bmi≥25	NOUN
dpc-4050	182	297	0.97	0.97	NUM
dpc-4050	182	298	pso	pso	NOUN
dpc-4050	182	299	vs	vs	ADP
dpc-4050	182	300	pso	pso	NOUN
dpc-4050	182	301	-	-	PUNCT
dpc-4050	182	302	psa	psa	NOUN
dpc-4050	182	303	0.239	0.239	NUM
dpc-4050	182	304	bl	bl	NOUN
dpc-4050	182	305	vs	vs	ADP
dpc-4050	182	306	week	week	NOUN
dpc-4050	182	307	16	16	NUM
dpc-4050	182	308	<	<	X
dpc-4050	182	309	0.0001	0.0001	NUM
dpc-4050	182	310	bl	bl	NOUN
dpc-4050	182	311	vs	vs	ADP
dpc-4050	182	312	week	week	NOUN
dpc-4050	182	313	16	16	NUM
dpc-4050	182	314	<	<	X
dpc-4050	182	315	0.0001	0.0001	NUM
dpc-4050	182	316	bl	bl	NOUN
dpc-4050	182	317	vs	vs	ADP
dpc-4050	182	318	week	week	NOUN
dpc-4050	182	319	24	24	NUM
dpc-4050	182	320	<	<	SYM
dpc-4050	182	321	0.0001	0.0001	NUM
dpc-4050	182	322	dlqi	dlqi	ADJ
dpc-4050	182	323	score	score	NOUN
dpc-4050	182	324	p	p	NOUN
dpc-4050	182	325	-	-	PUNCT
dpc-4050	182	326	value	value	NOUN
dpc-4050	182	327	bl	bl	NOUN
dpc-4050	182	328	vs	vs	ADP
dpc-4050	182	329	week	week	NOUN
dpc-4050	182	330	52	52	NUM
dpc-4050	182	331	<	<	SYM
dpc-4050	182	332	0.0001	0.0001	NUM
dpc-4050	182	333	pso	pso	NOUN
dpc-4050	182	334	vs	vs	ADP
dpc-4050	182	335	pso	pso	NOUN
dpc-4050	182	336	-	-	PUNCT
dpc-4050	182	337	psa	psa	NOUN
dpc-4050	182	338	0.291	0.291	NUM
dpc-4050	182	339	bl	bl	NOUN
dpc-4050	182	340	vs	vs	ADP
dpc-4050	182	341	week	week	NOUN
dpc-4050	182	342	104	104	NUM
dpc-4050	182	343	<	<	X
dpc-4050	182	344	0.0001	0.0001	NUM
dpc-4050	182	345	bl	bl	NOUN
dpc-4050	182	346	vs	vs	ADP
dpc-4050	182	347	week	week	NOUN
dpc-4050	182	348	52	52	NUM
dpc-4050	182	349	<	<	NOUN
dpc-4050	182	350	0.0001	0.0001	NUM
dpc-4050	182	351	bl	bl	NOUN
dpc-4050	182	352	vs	vs	ADP
dpc-4050	182	353	week	week	NOUN
dpc-4050	182	354	156	156	NUM
dpc-4050	182	355	<	<	X
dpc-4050	182	356	0.0001	0.0001	NUM
dpc-4050	182	357	dlqi	dlqi	ADJ
dpc-4050	182	358	score	score	NOUN
dpc-4050	182	359	p	p	NOUN
dpc-4050	182	360	-	-	PUNCT
dpc-4050	182	361	value	value	NOUN
dpc-4050	182	362	bmi<25	bmi<25	NOUN
dpc-4050	182	363	vs	vs	ADP
dpc-4050	182	364	bmi≥25	bmi≥25	NOUN
dpc-4050	182	365	0.668	0.668	NUM
dpc-4050	182	366	bl	bl	NOUN
dpc-4050	182	367	vs	vs	ADP
dpc-4050	182	368	week	week	NOUN
dpc-4050	182	369	52	52	NUM
dpc-4050	182	370	<	<	NOUN
dpc-4050	182	371	0.0001	0.0001	NUM
dpc-4050	182	372	bl	bl	NOUN
dpc-4050	182	373	=	=	NOUN
dpc-4050	182	374	baseline	baseline	PROPN
dpc-4050	182	375	;	;	PUNCT
dpc-4050	182	376	bmi	bmi	NOUN
dpc-4050	182	377	=	=	SYM
dpc-4050	182	378	body	body	PROPN
dpc-4050	182	379	mass	mass	PROPN
dpc-4050	182	380	index	index	NOUN
dpc-4050	182	381	;	;	PUNCT
dpc-4050	182	382	dlqi	dlqi	ADJ
dpc-4050	182	383	=	=	SYM
dpc-4050	182	384	dermatology	dermatology	NOUN
dpc-4050	182	385	life	life	NOUN
dpc-4050	182	386	quality	quality	NOUN
dpc-4050	182	387	index	index	NOUN
dpc-4050	182	388	;	;	PUNCT
dpc-4050	182	389	pso	pso	NOUN
dpc-4050	182	390	=	=	SYM
dpc-4050	182	391	psoriasis	psoriasis	NOUN
dpc-4050	182	392	psa	psa	NOUN
dpc-4050	182	393	=	=	SYM
dpc-4050	182	394	psoriatic	psoriatic	ADJ
dpc-4050	182	395	arthritis	arthritis	NOUN
dpc-4050	182	396	;	;	PUNCT
dpc-4050	182	397	pasi	pasi	VERB
dpc-4050	182	398	psoriasis	psoriasis	NOUN
dpc-4050	182	399	area	area	NOUN
dpc-4050	182	400	and	and	CCONJ
dpc-4050	182	401	severity	severity	NOUN
dpc-4050	182	402	index	index	NOUN
dpc-4050	182	403	;	;	PUNCT
dpc-4050	182	404	vas	vas	X
dpc-4050	182	405	=	=	SYM
dpc-4050	182	406	visual	visual	ADJ
dpc-4050	182	407	analogue	analogue	NOUN
dpc-4050	182	408	scale	scale	NOUN
dpc-4050	182	409	;	;	PUNCT
dpc-4050	182	410	vs	vs	ADP
dpc-4050	182	411	=	=	PUNCT
dpc-4050	182	412	versus	versus	X
dpc-4050	182	413	.	.	PUNCT
dpc-4050	183	1	but	but	CCONJ
dpc-4050	183	2	that	that	PRON
dpc-4050	183	3	,	,	PUNCT
dpc-4050	183	4	among	among	ADP
dpc-4050	183	5	subgroups	subgroup	NOUN
dpc-4050	183	6	,	,	PUNCT
dpc-4050	183	7	only	only	ADV
dpc-4050	183	8	gender	gender	NOUN
dpc-4050	183	9	for	for	ADP
dpc-4050	183	10	pasi	pasi	NOUN
dpc-4050	183	11	is	be	AUX
dpc-4050	183	12	significant	significant	ADJ
dpc-4050	183	13	.	.	PUNCT
dpc-4050	184	1	in	in	ADP
dpc-4050	184	2	detail	detail	NOUN
dpc-4050	184	3	,	,	PUNCT
dpc-4050	184	4	females	female	NOUN
dpc-4050	184	5	report	report	VERB
dpc-4050	184	6	lower	low	ADJ
dpc-4050	184	7	pasi	pasi	NOUN
dpc-4050	184	8	than	than	ADP
dpc-4050	184	9	males	male	NOUN
dpc-4050	184	10	.	.	PUNCT
dpc-4050	185	1	the	the	DET
dpc-4050	185	2	limitations	limitation	NOUN
dpc-4050	185	3	of	of	ADP
dpc-4050	185	4	our	our	PRON
dpc-4050	185	5	study	study	NOUN
dpc-4050	185	6	included	include	VERB
dpc-4050	185	7	its	its	PRON
dpc-4050	185	8	retrospective	retrospective	ADJ
dpc-4050	185	9	nature	nature	NOUN
dpc-4050	185	10	,	,	PUNCT
dpc-4050	185	11	relatively	relatively	ADV
dpc-4050	185	12	small	small	ADJ
dpc-4050	185	13	sample	sample	NOUN
dpc-4050	185	14	size	size	NOUN
dpc-4050	185	15	.	.	PUNCT
dpc-4050	186	1	we	we	PRON
dpc-4050	186	2	found	find	VERB
dpc-4050	186	3	that	that	SCONJ
dpc-4050	186	4	ixekizumab	ixekizumab	NOUN
dpc-4050	186	5	was	be	AUX
dpc-4050	186	6	a	a	DET
dpc-4050	186	7	good	good	ADJ
dpc-4050	186	8	option	option	NOUN
dpc-4050	186	9	in	in	ADP
dpc-4050	186	10	elderly	elderly	ADJ
dpc-4050	186	11	patients	patient	NOUN
dpc-4050	186	12	.	.	PUNCT
dpc-4050	187	1	however	however	ADV
dpc-4050	187	2	,	,	PUNCT
dpc-4050	187	3	more	more	ADJ
dpc-4050	187	4	data	datum	NOUN
dpc-4050	187	5	,	,	PUNCT
dpc-4050	187	6	both	both	CCONJ
dpc-4050	187	7	from	from	ADP
dpc-4050	187	8	dedicated	dedicated	ADJ
dpc-4050	187	9	trials	trial	NOUN
dpc-4050	187	10	and	and	CCONJ
dpc-4050	187	11	real	real	ADJ
dpc-4050	187	12	-	-	PUNCT
dpc-4050	187	13	life	life	NOUN
dpc-4050	187	14	reports	report	NOUN
dpc-4050	187	15	,	,	PUNCT
dpc-4050	187	16	are	be	AUX
dpc-4050	187	17	needed	need	VERB
dpc-4050	187	18	to	to	PART
dpc-4050	187	19	confirm	confirm	VERB
dpc-4050	187	20	our	our	PRON
dpc-4050	187	21	results	result	NOUN
dpc-4050	187	22	,	,	PUNCT
dpc-4050	187	23	our	our	PRON
dpc-4050	187	24	limitations	limitation	NOUN
dpc-4050	187	25	is	be	AUX
dpc-4050	187	26	that	that	SCONJ
dpc-4050	187	27	the	the	DET
dpc-4050	187	28	population	population	NOUN
dpc-4050	187	29	comes	come	VERB
dpc-4050	187	30	from	from	ADP
dpc-4050	187	31	lazio	lazio	PROPN
dpc-4050	187	32	region	region	NOUN
dpc-4050	187	33	and	and	CCONJ
dpc-4050	187	34	it	it	PRON
dpc-4050	187	35	is	be	AUX
dpc-4050	187	36	not	not	PART
dpc-4050	187	37	representative	representative	NOUN
dpc-4050	187	38	of	of	ADP
dpc-4050	187	39	the	the	DET
dpc-4050	187	40	italian	italian	ADJ
dpc-4050	187	41	population	population	NOUN
dpc-4050	187	42	.	.	PUNCT
dpc-4050	188	1	we	we	PRON
dpc-4050	188	2	consider	consider	VERB
dpc-4050	188	3	this	this	DET
dpc-4050	188	4	data	datum	NOUN
dpc-4050	188	5	a	a	DET
dpc-4050	188	6	useful	useful	ADJ
dpc-4050	188	7	tool	tool	NOUN
dpc-4050	188	8	for	for	ADP
dpc-4050	188	9	the	the	DET
dpc-4050	188	10	physician	physician	NOUN
dpc-4050	188	11	in	in	ADP
dpc-4050	188	12	clinical	clinical	ADJ
dpc-4050	188	13	practice	practice	NOUN
dpc-4050	188	14	because	because	SCONJ
dpc-4050	188	15	no	no	DET
dpc-4050	188	16	data	datum	NOUN
dpc-4050	188	17	from	from	ADP
dpc-4050	188	18	real	real	ADJ
dpc-4050	188	19	life	life	NOUN
dpc-4050	188	20	have	have	AUX
dpc-4050	188	21	been	be	AUX
dpc-4050	188	22	published	publish	VERB
dpc-4050	188	23	regarding	regard	VERB
dpc-4050	188	24	elderly	elderly	ADJ
dpc-4050	188	25	patients	patient	NOUN
dpc-4050	188	26	and	and	CCONJ
dpc-4050	188	27	ixekizumab	ixekizumab	NOUN
dpc-4050	188	28	treatment	treatment	NOUN
dpc-4050	188	29	.	.	PUNCT
dpc-4050	189	1	references	reference	NOUN
dpc-4050	189	2	1	1	NUM
dpc-4050	189	3	.	.	PUNCT
dpc-4050	189	4	chiricozzi	chiricozzi	PROPN
dpc-4050	189	5	a	a	PROPN
dpc-4050	189	6	,	,	PUNCT
dpc-4050	189	7	zhang	zhang	PROPN
dpc-4050	189	8	s	s	PROPN
dpc-4050	189	9	,	,	PUNCT
dpc-4050	189	10	dattola	dattola	PROPN
dpc-4050	189	11	a	a	PRON
dpc-4050	189	12	,	,	PUNCT
dpc-4050	189	13	et	et	PROPN
dpc-4050	189	14	al	al	PROPN
dpc-4050	189	15	.	.	PUNCT
dpc-4050	190	1	new	new	ADJ
dpc-4050	190	2	insights	insight	NOUN
dpc-4050	190	3	into	into	ADP
dpc-4050	190	4	the	the	DET
dpc-4050	190	5	pathogenesis	pathogenesis	NOUN
dpc-4050	190	6	of	of	ADP
dpc-4050	190	7	cutaneous	cutaneous	ADJ
dpc-4050	190	8	autoimmune	autoimmune	ADJ
dpc-4050	190	9	disorders	disorder	NOUN
dpc-4050	190	10	.	.	PUNCT
dpc-4050	191	1	j	j	PROPN
dpc-4050	191	2	biol	biol	PROPN
dpc-4050	191	3	regul	regul	PROPN
dpc-4050	191	4	homeost	homeost	ADJ
dpc-4050	191	5	agents	agent	NOUN
dpc-4050	191	6	.	.	PUNCT
dpc-4050	192	1	2012;26(2):165	2012;26(2):165	NUM
dpc-4050	192	2	-	-	SYM
dpc-4050	192	3	170	170	NUM
dpc-4050	192	4	.	.	PUNCT
dpc-4050	193	1	pmid	pmid	NOUN
dpc-4050	193	2	:	:	PUNCT
dpc-4050	193	3	22824743	22824743	NUM
dpc-4050	193	4	.	.	PUNCT
dpc-4050	194	1	2	2	X
dpc-4050	194	2	.	.	X
dpc-4050	194	3	vena	vena	PROPN
dpc-4050	194	4	ga	ga	PROPN
dpc-4050	194	5	,	,	PUNCT
dpc-4050	194	6	altomare	altomare	VERB
dpc-4050	194	7	g	g	PROPN
dpc-4050	194	8	,	,	PUNCT
dpc-4050	194	9	ayala	ayala	PROPN
dpc-4050	194	10	f	f	PROPN
dpc-4050	194	11	,	,	PUNCT
dpc-4050	194	12	et	et	PROPN
dpc-4050	194	13	al	al	PROPN
dpc-4050	194	14	.	.	PROPN
dpc-4050	195	1	incidence	incidence	NOUN
dpc-4050	195	2	of	of	ADP
dpc-4050	195	3	psoriasis	psoriasis	NOUN
dpc-4050	195	4	and	and	CCONJ
dpc-4050	195	5	association	association	NOUN
dpc-4050	195	6	with	with	ADP
dpc-4050	195	7	comorbidities	comorbiditie	NOUN
dpc-4050	195	8	in	in	ADP
dpc-4050	195	9	italy	italy	PROPN
dpc-4050	195	10	:	:	PUNCT
dpc-4050	195	11	a	a	DET
dpc-4050	195	12	5	5	NUM
dpc-4050	195	13	-	-	PUNCT
dpc-4050	195	14	year	year	NOUN
dpc-4050	195	15	observational	observational	ADJ
dpc-4050	195	16	study	study	NOUN
dpc-4050	195	17	from	from	ADP
dpc-4050	195	18	a	a	DET
dpc-4050	195	19	national	national	ADJ
dpc-4050	195	20	primary	primary	ADJ
dpc-4050	195	21	care	care	NOUN
dpc-4050	195	22	database	database	NOUN
dpc-4050	195	23	.	.	PUNCT
dpc-4050	196	1	eur	eur	PROPN
dpc-4050	196	2	j	j	PROPN
dpc-4050	196	3	dermatol	dermatol	NOUN
dpc-4050	196	4	.	.	PUNCT
dpc-4050	197	1	10	10	NUM
dpc-4050	197	2	original	original	ADJ
dpc-4050	197	3	article	article	NOUN
dpc-4050	197	4	|	|	ADV
dpc-4050	197	5	dermatol	dermatol	ADJ
dpc-4050	197	6	pract	pract	NOUN
dpc-4050	197	7	concept	concept	NOUN
dpc-4050	197	8	.	.	PUNCT
dpc-4050	198	1	2024;14(3):e2024166	2024;14(3):e2024166	NUM
dpc-4050	198	2	ixekizumab	ixekizumab	NOUN
dpc-4050	198	3	compared	compare	VERB
dpc-4050	198	4	to	to	PART
dpc-4050	198	5	etanercept	etanercept	VERB
dpc-4050	198	6	and	and	CCONJ
dpc-4050	198	7	placebo	placebo	NOUN
dpc-4050	198	8	in	in	ADP
dpc-4050	198	9	patients	patient	NOUN
dpc-4050	198	10	with	with	ADP
dpc-4050	198	11	moderate	moderate	ADJ
dpc-4050	198	12	-	-	PUNCT
dpc-4050	198	13	to	to	ADP
dpc-4050	198	14	-	-	PUNCT
dpc-4050	198	15	severe	severe	ADJ
dpc-4050	198	16	plaque	plaque	NOUN
dpc-4050	198	17	psoriasis	psoriasis	NOUN
dpc-4050	198	18	and	and	CCONJ
dpc-4050	198	19	non	non	ADJ
dpc-4050	198	20	-	-	ADJ
dpc-4050	198	21	pustular	pustular	ADJ
dpc-4050	198	22	palmoplantar	palmoplantar	NOUN
dpc-4050	198	23	involvement	involvement	NOUN
dpc-4050	198	24	:	:	PUNCT
dpc-4050	198	25	results	result	VERB
dpc-4050	198	26	from	from	ADP
dpc-4050	198	27	three	three	NUM
dpc-4050	198	28	phase	phase	NOUN
dpc-4050	198	29	3	3	NUM
dpc-4050	198	30	trials	trial	NOUN
dpc-4050	198	31	(	(	PUNCT
dpc-4050	198	32	uncover-1	uncover-1	PROPN
dpc-4050	198	33	,	,	PUNCT
dpc-4050	198	34	uncover-2	uncover-2	NUM
dpc-4050	198	35	and	and	CCONJ
dpc-4050	198	36	uncover-3	uncover-3	NUM
dpc-4050	198	37	)	)	PUNCT
dpc-4050	198	38	.	.	PUNCT
dpc-4050	199	1	10	10	NUM
dpc-4050	199	2	.	.	PUNCT
dpc-4050	199	3	megna	megna	PROPN
dpc-4050	199	4	m	m	PROPN
dpc-4050	199	5	,	,	PUNCT
dpc-4050	199	6	cinelli	cinelli	PROPN
dpc-4050	199	7	e	e	PROPN
dpc-4050	199	8	,	,	PUNCT
dpc-4050	199	9	balato	balato	VERB
dpc-4050	199	10	a	a	DET
dpc-4050	199	11	et	et	NOUN
dpc-4050	199	12	al	al	PROPN
dpc-4050	199	13	.	.	PROPN
dpc-4050	199	14	efficacy	efficacy	NOUN
dpc-4050	199	15	and	and	CCONJ
dpc-4050	199	16	safety	safety	NOUN
dpc-4050	199	17	of	of	ADP
dpc-4050	199	18	ixekizumab	ixekizumab	NOUN
dpc-4050	199	19	in	in	ADP
dpc-4050	199	20	a	a	DET
dpc-4050	199	21	group	group	NOUN
dpc-4050	199	22	of	of	ADP
dpc-4050	199	23	16	16	NUM
dpc-4050	199	24	elderly	elderly	ADJ
dpc-4050	199	25	patients	patient	NOUN
dpc-4050	199	26	with	with	ADP
dpc-4050	199	27	psoriasis	psoriasis	NOUN
dpc-4050	199	28	over	over	ADP
dpc-4050	199	29	a	a	DET
dpc-4050	199	30	1	1	NUM
dpc-4050	199	31	-	-	PUNCT
dpc-4050	199	32	year	year	NOUN
dpc-4050	199	33	period	period	NOUN
dpc-4050	199	34	.	.	PUNCT
dpc-4050	200	1	j	j	PROPN
dpc-4050	200	2	eur	eur	PROPN
dpc-4050	200	3	acad	acad	PROPN
dpc-4050	200	4	dermatol	dermatol	NOUN
dpc-4050	200	5	venereol	venereol	NOUN
dpc-4050	200	6	.	.	PUNCT
dpc-4050	201	1	2020	2020	NUM
dpc-4050	201	2	;	;	PUNCT
dpc-4050	201	3	34	34	NUM
dpc-4050	201	4	:	:	PUNCT
dpc-4050	201	5	e152–3	e152–3	PROPN
dpc-4050	201	6	.	.	PUNCT
dpc-4050	202	1	11	11	NUM
dpc-4050	202	2	.	.	PUNCT
dpc-4050	203	1	chiricozzi	chiricozzi	PROPN
dpc-4050	203	2	a	a	PROPN
dpc-4050	203	3	,	,	PUNCT
dpc-4050	203	4	pavlidis	pavlidi	NOUN
dpc-4050	203	5	a	a	PRON
dpc-4050	203	6	,	,	PUNCT
dpc-4050	203	7	  	  	SPACE
dpc-4050	203	8	dattola	dattola	PROPN
dpc-4050	203	9	a	a	PRON
dpc-4050	203	10	,	,	PUNCT
dpc-4050	203	11	et	et	PROPN
dpc-4050	203	12	al	al	PROPN
dpc-4050	203	13	.	.	PROPN
dpc-4050	203	14	efficacy	efficacy	NOUN
dpc-4050	203	15	and	and	CCONJ
dpc-4050	203	16	safety	safety	NOUN
dpc-4050	203	17	of	of	ADP
dpc-4050	203	18	infliximab	infliximab	NOUN
dpc-4050	203	19	in	in	ADP
dpc-4050	203	20	psoriatic	psoriatic	ADJ
dpc-4050	203	21	patients	patient	NOUN
dpc-4050	203	22	over	over	ADP
dpc-4050	203	23	the	the	DET
dpc-4050	203	24	age	age	NOUN
dpc-4050	203	25	of	of	ADP
dpc-4050	203	26	65	65	NUM
dpc-4050	203	27	.	.	PUNCT
dpc-4050	204	1	expert	expert	NOUN
dpc-4050	204	2	opin	opin	NOUN
dpc-4050	204	3	drug	drug	NOUN
dpc-4050	204	4	saf	saf	PROPN
dpc-4050	204	5	.	.	PROPN
dpc-4050	204	6	2016	2016	NUM
dpc-4050	204	7	nov;15(11):1459	nov;15(11):1459	NOUN
dpc-4050	204	8	-	-	PUNCT
dpc-4050	204	9	1462	1462	NUM
dpc-4050	204	10	.	.	PUNCT
dpc-4050	205	1	doi	doi	NOUN
dpc-4050	205	2	:	:	PUNCT
dpc-4050	205	3	10.1080	10.1080	NUM
dpc-4050	205	4	/14740338.2016.1226279	/14740338.2016.1226279	NOUN
dpc-4050	205	5	.	.	PUNCT
dpc-4050	206	1	epub	epub	PROPN
dpc-4050	206	2	2016	2016	NUM
dpc-4050	206	3	aug	aug	PROPN
dpc-4050	206	4	31	31	NUM
dpc-4050	206	5	.	.	PUNCT
dpc-4050	207	1	12	12	NUM
dpc-4050	207	2	.	.	PUNCT
dpc-4050	208	1	piaserico	piaserico	PROPN
dpc-4050	208	2	s	s	PART
dpc-4050	208	3	,	,	PUNCT
dpc-4050	208	4	conti	conti	PROPN
dpc-4050	208	5	a	a	X
dpc-4050	208	6	,	,	PUNCT
dpc-4050	208	7	lo	lo	PROPN
dpc-4050	208	8	console	console	NOUN
dpc-4050	208	9	f	f	PROPN
dpc-4050	208	10	et	et	PROPN
dpc-4050	208	11	al	al	PROPN
dpc-4050	208	12	.	.	PROPN
dpc-4050	208	13	efficacy	efficacy	NOUN
dpc-4050	208	14	and	and	CCONJ
dpc-4050	208	15	safety	safety	NOUN
dpc-4050	208	16	of	of	ADP
dpc-4050	208	17	systemic	systemic	ADJ
dpc-4050	208	18	treatments	treatment	NOUN
dpc-4050	208	19	for	for	ADP
dpc-4050	208	20	psoriasis	psoriasis	NOUN
dpc-4050	208	21	in	in	ADP
dpc-4050	208	22	elderly	elderly	ADJ
dpc-4050	208	23	patients	patient	NOUN
dpc-4050	208	24	.	.	PUNCT
dpc-4050	209	1	acta	acta	PROPN
dpc-4050	209	2	derm	derm	PROPN
dpc-4050	209	3	venereol	venereol	NOUN
dpc-4050	209	4	.	.	PUNCT
dpc-4050	210	1	2014	2014	NUM
dpc-4050	210	2	;	;	PUNCT
dpc-4050	210	3	94	94	NUM
dpc-4050	210	4	:	:	SYM
dpc-4050	210	5	293–7	293–7	NUM
dpc-4050	210	6	.	.	PUNCT
dpc-4050	211	1	13	13	NUM
dpc-4050	211	2	.	.	X
dpc-4050	212	1	ruggiero	ruggiero	PROPN
dpc-4050	212	2	a	a	DET
dpc-4050	212	3	,	,	PUNCT
dpc-4050	212	4	fabbrocini	fabbrocini	NOUN
dpc-4050	212	5	g	g	NOUN
dpc-4050	212	6	,	,	PUNCT
dpc-4050	212	7	cinelli	cinelli	PROPN
dpc-4050	212	8	e	e	PROPN
dpc-4050	212	9	,	,	PUNCT
dpc-4050	212	10	ocampo	ocampo	PROPN
dpc-4050	212	11	garza	garza	PROPN
dpc-4050	212	12	ss	ss	PROPN
dpc-4050	212	13	,	,	PUNCT
dpc-4050	212	14	camela	camela	ADP
dpc-4050	212	15	e	e	NOUN
dpc-4050	212	16	,	,	PUNCT
dpc-4050	212	17	 	 	SPACE
dpc-4050	212	18	megna	megna	PROPN
dpc-4050	212	19	m.	m.	NOUN
dpc-4050	212	20	anti	anti	PROPN
dpc-4050	212	21	-	-	ADJ
dpc-4050	212	22	interleukin-23	interleukin-23	ADJ
dpc-4050	212	23	for	for	ADP
dpc-4050	212	24	psoriasis	psoriasis	NOUN
dpc-4050	212	25	in	in	ADP
dpc-4050	212	26	elderly	elderly	ADJ
dpc-4050	212	27	patients	patient	NOUN
dpc-4050	212	28	:	:	PUNCT
dpc-4050	212	29	guselkumab	guselkumab	NOUN
dpc-4050	212	30	,	,	PUNCT
dpc-4050	212	31	risankizumab	risankizumab	NOUN
dpc-4050	212	32	and	and	CCONJ
dpc-4050	212	33	tildrakizumab	tildrakizumab	NOUN
dpc-4050	212	34	in	in	ADP
dpc-4050	212	35	real	real	ADJ
dpc-4050	212	36	-	-	PUNCT
dpc-4050	212	37	world	world	NOUN
dpc-4050	212	38	practice	practice	NOUN
dpc-4050	212	39	.	.	PUNCT
dpc-4050	213	1	clin	clin	PROPN
dpc-4050	213	2	exp	exp	NOUN
dpc-4050	213	3	dermatol	dermatol	NOUN
dpc-4050	213	4	.	.	PUNCT
dpc-4050	214	1	2022	2022	NUM
dpc-4050	214	2	mar;47(3):561	mar;47(3):561	PROPN
dpc-4050	214	3	-	-	PUNCT
dpc-4050	214	4	567	567	NUM
dpc-4050	214	5	.	.	PUNCT
dpc-4050	214	6	doi	doi	NOUN
dpc-4050	214	7	:	:	PUNCT
dpc-4050	214	8	10.1111	10.1111	NUM
dpc-4050	214	9	/	/	SYM
dpc-4050	214	10	ced.14979	ced.14979	NOUN
dpc-4050	214	11	.	.	PUNCT
dpc-4050	215	1	epub	epub	PROPN
dpc-4050	215	2	2021	2021	NUM
dpc-4050	215	3	nov	nov	NOUN
dpc-4050	215	4	17	17	NUM
dpc-4050	215	5	.	.	PUNCT
dpc-4050	216	1	14	14	NUM
dpc-4050	216	2	.	.	PUNCT
dpc-4050	216	3	esposito	esposito	PROPN
dpc-4050	216	4	m	m	PROPN
dpc-4050	216	5	,	,	PUNCT
dpc-4050	216	6	giunta	giunta	PROPN
dpc-4050	216	7	a	a	PROPN
dpc-4050	216	8	,	,	PUNCT
dpc-4050	216	9	mazzotta	mazzotta	NOUN
dpc-4050	216	10	a	a	PRON
dpc-4050	216	11	et	et	PROPN
dpc-4050	216	12	al	al	PROPN
dpc-4050	216	13	.	.	PROPN
dpc-4050	216	14	efficacy	efficacy	NOUN
dpc-4050	216	15	and	and	CCONJ
dpc-4050	216	16	safety	safety	NOUN
dpc-4050	216	17	of	of	ADP
dpc-4050	216	18	subcutaneous	subcutaneous	ADJ
dpc-4050	216	19	anti	anti	ADJ
dpc-4050	216	20	-	-	ADJ
dpc-4050	216	21	tumor	tumor	ADJ
dpc-4050	216	22	necrosis	necrosis	NOUN
dpc-4050	216	23	factor	factor	NOUN
dpc-4050	216	24	-	-	PUNCT
dpc-4050	216	25	alpha	alpha	NOUN
dpc-4050	216	26	agents	agent	NOUN
dpc-4050	216	27	,	,	PUNCT
dpc-4050	216	28	etanercept	etanercept	NOUN
dpc-4050	216	29	and	and	CCONJ
dpc-4050	216	30	adalimumab	adalimumab	NOUN
dpc-4050	216	31	,	,	PUNCT
dpc-4050	216	32	in	in	ADP
dpc-4050	216	33	elderly	elderly	ADJ
dpc-4050	216	34	patients	patient	NOUN
dpc-4050	216	35	affected	affect	VERB
dpc-4050	216	36	by	by	ADP
dpc-4050	216	37	psoriasis	psoriasis	NOUN
dpc-4050	216	38	and	and	CCONJ
dpc-4050	216	39	psoriatic	psoriatic	ADJ
dpc-4050	216	40	arthritis	arthritis	NOUN
dpc-4050	216	41	:	:	PUNCT
dpc-4050	216	42	an	an	DET
dpc-4050	216	43	observational	observational	ADJ
dpc-4050	216	44	long	long	ADJ
dpc-4050	216	45	-	-	PUNCT
dpc-4050	216	46	term	term	NOUN
dpc-4050	216	47	study	study	NOUN
dpc-4050	216	48	.	.	PUNCT
dpc-4050	217	1	dermatology	dermatology	NOUN
dpc-4050	217	2	2012	2012	NUM
dpc-4050	217	3	;	;	PUNCT
dpc-4050	217	4	225	225	NUM
dpc-4050	217	5	:	:	PUNCT
dpc-4050	217	6	312–19	312–19	NUM
dpc-4050	217	7	.	.	PUNCT
dpc-4050	217	8	15	15	NUM
dpc-4050	217	9	.	.	PUNCT
dpc-4050	218	1	megna	megna	PROPN
dpc-4050	218	2	m	m	PROPN
dpc-4050	218	3	,	,	PUNCT
dpc-4050	218	4	camela	camela	ADP
dpc-4050	218	5	e	e	PROPN
dpc-4050	218	6	,	,	PUNCT
dpc-4050	218	7	cinelli	cinelli	PROPN
dpc-4050	218	8	e	e	PROPN
dpc-4050	218	9	,	,	PUNCT
dpc-4050	218	10	fabbrocini	fabbrocini	PROPN
dpc-4050	218	11	g.	g.	PROPN
dpc-4050	218	12	real	real	ADJ
dpc-4050	218	13	-	-	PUNCT
dpc-4050	218	14	life	life	NOUN
dpc-4050	218	15	efficacy	efficacy	NOUN
dpc-4050	218	16	and	and	CCONJ
dpc-4050	218	17	safety	safety	NOUN
dpc-4050	218	18	of	of	ADP
dpc-4050	218	19	secukinumab	secukinumab	NOUN
dpc-4050	218	20	in	in	ADP
dpc-4050	218	21	elderly	elderly	ADJ
dpc-4050	218	22	patients	patient	NOUN
dpc-4050	218	23	with	with	ADP
dpc-4050	218	24	psoriasis	psoriasis	NOUN
dpc-4050	218	25	over	over	ADP
dpc-4050	218	26	a	a	DET
dpc-4050	218	27	2	2	NUM
dpc-4050	218	28	-	-	PUNCT
dpc-4050	218	29	year	year	NOUN
dpc-4050	218	30	period	period	NOUN
dpc-4050	218	31	.	.	PUNCT
dpc-4050	219	1	clin	clin	PROPN
dpc-4050	219	2	exp	exp	NOUN
dpc-4050	219	3	dermatol	dermatol	NOUN
dpc-4050	219	4	2020	2020	NUM
dpc-4050	219	5	;	;	PUNCT
dpc-4050	219	6	45	45	NUM
dpc-4050	219	7	:	:	PUNCT
dpc-4050	219	8	848–52	848–52	NUM
dpc-4050	219	9	.	.	PUNCT
dpc-4050	220	1	16	16	NUM
dpc-4050	220	2	.	.	PUNCT
dpc-4050	221	1	körber	körber	PROPN
dpc-4050	221	2	a	a	PROPN
dpc-4050	221	3	,	,	PUNCT
dpc-4050	221	4	papavassilis	papavassilis	PROPN
dpc-4050	221	5	c	c	X
dpc-4050	221	6	,	,	PUNCT
dpc-4050	221	7	bhosekar	bhosekar	NOUN
dpc-4050	221	8	v	v	NOUN
dpc-4050	221	9	,	,	PUNCT
dpc-4050	221	10	reinhardt	reinhardt	PROPN
dpc-4050	221	11	m.	m.	PROPN
dpc-4050	221	12	efficacy	efficacy	NOUN
dpc-4050	221	13	and	and	CCONJ
dpc-4050	221	14	safety	safety	NOUN
dpc-4050	221	15	of	of	ADP
dpc-4050	221	16	secukinumab	secukinumab	NOUN
dpc-4050	221	17	in	in	ADP
dpc-4050	221	18	elderly	elderly	ADJ
dpc-4050	221	19	subjects	subject	NOUN
dpc-4050	221	20	with	with	ADP
dpc-4050	221	21	moderate	moderate	ADJ
dpc-4050	221	22	to	to	ADP
dpc-4050	221	23	severe	severe	ADJ
dpc-4050	221	24	plaque	plaque	NOUN
dpc-4050	221	25	psoriasis	psoriasis	NOUN
dpc-4050	221	26	:	:	PUNCT
dpc-4050	221	27	a	a	DET
dpc-4050	221	28	pooled	pooled	ADJ
dpc-4050	221	29	analysis	analysis	NOUN
dpc-4050	221	30	of	of	ADP
dpc-4050	221	31	phase	phase	NOUN
dpc-4050	221	32	iii	iii	NUM
dpc-4050	221	33	studies	study	NOUN
dpc-4050	221	34	.	.	PUNCT
dpc-4050	221	35	 	 	SPACE
dpc-4050	222	1	drugs	drug	NOUN
dpc-4050	222	2	aging	age	VERB
dpc-4050	222	3	.	.	PUNCT
dpc-4050	223	1	2018;35(2):135	2018;35(2):135	NOUN
dpc-4050	223	2	-	-	PUNCT
dpc-4050	223	3	144	144	NUM
dpc-4050	223	4	.	.	PUNCT
dpc-4050	224	1	doi:10.1007	doi:10.1007	VERB
dpc-4050	224	2	/	/	SYM
dpc-4050	224	3	s40266	s40266	NOUN
dpc-4050	224	4	-	-	PUNCT
dpc-4050	224	5	018	018	NUM
dpc-4050	224	6	-	-	PUNCT
dpc-4050	224	7	0520	0520	NUM
dpc-4050	224	8	-	-	PUNCT
dpc-4050	224	9	z	z	NOUN
dpc-4050	224	10	17	17	NUM
dpc-4050	224	11	.	.	PUNCT
dpc-4050	225	1	eli	eli	PROPN
dpc-4050	225	2	lilly	lilly	PROPN
dpc-4050	225	3	&	&	CCONJ
dpc-4050	225	4	co.	co.	PROPN
dpc-4050	225	5	taltz	taltz	NOUN
dpc-4050	225	6	(	(	PUNCT
dpc-4050	225	7	ixekizumab	ixekizumab	NOUN
dpc-4050	225	8	)	)	PUNCT
dpc-4050	225	9	.	.	PUNCT
dpc-4050	226	1	summary	summary	NOUN
dpc-4050	226	2	of	of	ADP
dpc-4050	226	3	product	product	NOUN
dpc-4050	226	4	characteristics	characteristic	NOUN
dpc-4050	226	5	.	.	PUNCT
dpc-4050	227	1	data	datum	NOUN
dpc-4050	227	2	on	on	ADP
dpc-4050	227	3	file	file	NOUN
dpc-4050	227	4	.	.	PUNCT
dpc-4050	228	1	2016	2016	NUM
dpc-4050	228	2	.	.	PUNCT
dpc-4050	229	1	2010	2010	NUM
dpc-4050	229	2	sep	sep	PROPN
dpc-4050	229	3	-	-	PUNCT
dpc-4050	229	4	oct;20(5):593	oct;20(5):593	PROPN
dpc-4050	229	5	-	-	PUNCT
dpc-4050	229	6	8	8	NUM
dpc-4050	229	7	.	.	PUNCT
dpc-4050	229	8	doi	doi	NOUN
dpc-4050	229	9	:	:	PUNCT
dpc-4050	229	10	10.1684	10.1684	NUM
dpc-4050	229	11	/	/	SYM
dpc-4050	229	12	ejd.2010.1017	ejd.2010.1017	NUM
dpc-4050	229	13	.	.	PUNCT
dpc-4050	230	1	epub	epub	PROPN
dpc-4050	230	2	2010	2010	NUM
dpc-4050	230	3	jul	jul	PROPN
dpc-4050	230	4	7	7	NUM
dpc-4050	230	5	.	.	PUNCT
dpc-4050	231	1	pmid	pmid	NOUN
dpc-4050	231	2	:	:	PUNCT
dpc-4050	231	3	20605768	20605768	NUM
dpc-4050	231	4	3	3	NUM
dpc-4050	231	5	.	.	PUNCT
dpc-4050	231	6	davidovici	davidovici	PROPN
dpc-4050	231	7	bb	bb	PROPN
dpc-4050	231	8	,	,	PUNCT
dpc-4050	231	9	sattar	sattar	PROPN
dpc-4050	231	10	n	n	CCONJ
dpc-4050	231	11	,	,	PUNCT
dpc-4050	231	12	prinz	prinz	PROPN
dpc-4050	231	13	j	j	PROPN
dpc-4050	231	14	,	,	PUNCT
dpc-4050	231	15	et	et	PROPN
dpc-4050	231	16	al	al	PROPN
dpc-4050	231	17	.	.	PUNCT
dpc-4050	232	1	psoriasis	psoriasis	NOUN
dpc-4050	232	2	and	and	CCONJ
dpc-4050	232	3	systemic	systemic	ADJ
dpc-4050	232	4	inflammatory	inflammatory	ADJ
dpc-4050	232	5	diseases	disease	NOUN
dpc-4050	232	6	:	:	PUNCT
dpc-4050	232	7	potential	potential	ADJ
dpc-4050	232	8	mechanistic	mechanistic	ADJ
dpc-4050	232	9	links	link	NOUN
dpc-4050	232	10	between	between	ADP
dpc-4050	232	11	skin	skin	NOUN
dpc-4050	232	12	disease	disease	NOUN
dpc-4050	232	13	and	and	CCONJ
dpc-4050	232	14	co	co	ADJ
dpc-4050	232	15	-	-	ADJ
dpc-4050	232	16	morbid	morbid	ADJ
dpc-4050	232	17	conditions	condition	NOUN
dpc-4050	232	18	.	.	PUNCT
dpc-4050	233	1	j	j	PROPN
dpc-4050	233	2	invest	invest	VERB
dpc-4050	233	3	dermatol	dermatol	NOUN
dpc-4050	233	4	.	.	PUNCT
dpc-4050	234	1	2010	2010	NUM
dpc-4050	234	2	jul;130(7):1785	jul;130(7):1785	PROPN
dpc-4050	234	3	-	-	SYM
dpc-4050	234	4	96	96	NUM
dpc-4050	234	5	.	.	PUNCT
dpc-4050	235	1	doi	doi	NOUN
dpc-4050	235	2	:	:	PUNCT
dpc-4050	235	3	10.1038	10.1038	NUM
dpc-4050	235	4	/	/	SYM
dpc-4050	235	5	jid.2010.103	jid.2010.103	PROPN
dpc-4050	235	6	.	.	PUNCT
dpc-4050	236	1	epub	epub	PROPN
dpc-4050	236	2	2010	2010	NUM
dpc-4050	236	3	may	may	PROPN
dpc-4050	236	4	6	6	NUM
dpc-4050	236	5	.	.	PUNCT
dpc-4050	237	1	pmid	pmid	NOUN
dpc-4050	237	2	:	:	PUNCT
dpc-4050	237	3	20445552	20445552	NUM
dpc-4050	237	4	4	4	NUM
dpc-4050	237	5	.	.	PUNCT
dpc-4050	238	1	gisondi	gisondi	PROPN
dpc-4050	238	2	p	p	NOUN
dpc-4050	238	3	,	,	PUNCT
dpc-4050	238	4	del	del	PROPN
dpc-4050	238	5	giglio	giglio	PROPN
dpc-4050	238	6	m	m	PROPN
dpc-4050	238	7	,	,	PUNCT
dpc-4050	238	8	cozzi	cozzi	NOUN
dpc-4050	238	9	a	a	NOUN
dpc-4050	238	10	,	,	PUNCT
dpc-4050	238	11	girolomoni	girolomoni	ADJ
dpc-4050	238	12	g.	g.	NOUN
dpc-4050	238	13	psoriasis	psoriasis	NOUN
dpc-4050	238	14	,	,	PUNCT
dpc-4050	238	15	the	the	DET
dpc-4050	238	16	liver	liver	NOUN
dpc-4050	238	17	,	,	PUNCT
dpc-4050	238	18	and	and	CCONJ
dpc-4050	238	19	the	the	DET
dpc-4050	238	20	gastrointestinal	gastrointestinal	ADJ
dpc-4050	238	21	tract	tract	NOUN
dpc-4050	238	22	.	.	PUNCT
dpc-4050	239	1	dermatol	dermatol	NOUN
dpc-4050	239	2	ther	ther	ADV
dpc-4050	239	3	.	.	PUNCT
dpc-4050	240	1	2010	2010	NUM
dpc-4050	240	2	mar	mar	PROPN
dpc-4050	240	3	-	-	PUNCT
dpc-4050	240	4	apr;23(2):155	apr;23(2):155	NOUN
dpc-4050	240	5	-	-	PUNCT
dpc-4050	240	6	9	9	NUM
dpc-4050	240	7	.	.	PUNCT
dpc-4050	240	8	doi	doi	NOUN
dpc-4050	240	9	:	:	PUNCT
dpc-4050	240	10	10.1111	10.1111	NUM
dpc-4050	240	11	/	/	SYM
dpc-4050	240	12	j.1529	j.1529	NOUN
dpc-4050	240	13	-	-	PUNCT
dpc-4050	240	14	8019.2010.01310.x	8019.2010.01310.x	NUM
dpc-4050	240	15	.	.	PUNCT
dpc-4050	241	1	pmid	pmid	NOUN
dpc-4050	241	2	:	:	PUNCT
dpc-4050	241	3	20415823	20415823	NUM
dpc-4050	241	4	5	5	NUM
dpc-4050	241	5	.	.	PUNCT
dpc-4050	241	6	chiricozzi	chiricozzi	PROPN
dpc-4050	241	7	a	a	PROPN
dpc-4050	241	8	,	,	PUNCT
dpc-4050	241	9	zhang	zhang	PROPN
dpc-4050	241	10	s	s	PROPN
dpc-4050	241	11	,	,	PUNCT
dpc-4050	241	12	  	  	SPACE
dpc-4050	241	13	dattola	dattola	VERB
dpc-4050	241	14	a	a	PRON
dpc-4050	241	15	,	,	PUNCT
dpc-4050	241	16	gabellini	gabellini	NOUN
dpc-4050	241	17	m	m	PROPN
dpc-4050	241	18	,	,	PUNCT
dpc-4050	241	19	chimenti	chimenti	PROPN
dpc-4050	241	20	s	s	PROPN
dpc-4050	241	21	,	,	PUNCT
dpc-4050	241	22	nistico	nistico	NOUN
dpc-4050	241	23	sp	sp	NOUN
dpc-4050	241	24	.	.	NOUN
dpc-4050	241	25	role	role	NOUN
dpc-4050	241	26	of	of	ADP
dpc-4050	241	27	th17	th17	PROPN
dpc-4050	241	28	in	in	ADP
dpc-4050	241	29	the	the	DET
dpc-4050	241	30	pathogenesis	pathogenesis	NOUN
dpc-4050	241	31	of	of	ADP
dpc-4050	241	32	cutaneous	cutaneous	ADJ
dpc-4050	241	33	inflammatory	inflammatory	ADJ
dpc-4050	241	34	diseases	disease	NOUN
dpc-4050	241	35	.	.	PUNCT
dpc-4050	242	1	j	j	PROPN
dpc-4050	242	2	biol	biol	PROPN
dpc-4050	242	3	regul	regul	PROPN
dpc-4050	242	4	homeost	homeost	ADJ
dpc-4050	242	5	agents	agent	NOUN
dpc-4050	242	6	.	.	PUNCT
dpc-4050	243	1	2012	2012	NUM
dpc-4050	243	2	jul	jul	PROPN
dpc-4050	243	3	-	-	PUNCT
dpc-4050	243	4	sep	sep	PROPN
dpc-4050	243	5	;	;	PUNCT
dpc-4050	243	6	26(3):313	26(3):313	NUM
dpc-4050	243	7	-	-	SYM
dpc-4050	243	8	8	8	NUM
dpc-4050	243	9	.	.	NOUN
dpc-4050	243	10	6	6	NUM
dpc-4050	243	11	.	.	X
dpc-4050	244	1	dattola	dattola	PROPN
dpc-4050	244	2	a	a	PRON
dpc-4050	244	3	,	,	PUNCT
dpc-4050	244	4	silvestri	silvestri	PROPN
dpc-4050	244	5	m	m	PROPN
dpc-4050	244	6	,	,	PUNCT
dpc-4050	244	7	tamburi	tamburi	PROPN
dpc-4050	244	8	f	f	PROPN
dpc-4050	244	9	,	,	PUNCT
dpc-4050	244	10	amoruso	amoruso	PROPN
dpc-4050	244	11	gf	gf	PROPN
dpc-4050	244	12	,	,	PUNCT
dpc-4050	244	13	bennardo	bennardo	PROPN
dpc-4050	244	14	l	l	NOUN
dpc-4050	244	15	,	,	PUNCT
dpc-4050	244	16	nisticò	nisticò	PROPN
dpc-4050	244	17	sp	sp	PROPN
dpc-4050	244	18	.	.	PUNCT
dpc-4050	244	19	emerging	emerge	VERB
dpc-4050	244	20	role	role	NOUN
dpc-4050	244	21	of	of	ADP
dpc-4050	244	22	anti	anti	ADJ
dpc-4050	244	23	-	-	ADJ
dpc-4050	244	24	il23	il23	PROPN
dpc-4050	244	25	in	in	ADP
dpc-4050	244	26	the	the	DET
dpc-4050	244	27	treatment	treatment	NOUN
dpc-4050	244	28	of	of	ADP
dpc-4050	244	29	psoriasis	psoriasis	NOUN
dpc-4050	244	30	:	:	PUNCT
dpc-4050	244	31	when	when	SCONJ
dpc-4050	244	32	humanized	humanize	VERB
dpc-4050	244	33	is	be	AUX
dpc-4050	244	34	very	very	ADV
dpc-4050	244	35	promising	promising	ADJ
dpc-4050	244	36	.	.	PUNCT
dpc-4050	245	1	dermatol	dermatol	NOUN
dpc-4050	245	2	ther	ther	ADV
dpc-4050	245	3	.	.	PUNCT
dpc-4050	246	1	2020	2020	NUM
dpc-4050	246	2	nov;33(6):e14504	nov;33(6):e14504	NOUN
dpc-4050	246	3	.	.	PUNCT
dpc-4050	247	1	doi	doi	NOUN
dpc-4050	247	2	:	:	PUNCT
dpc-4050	247	3	10.1111	10.1111	NUM
dpc-4050	247	4	/	/	SYM
dpc-4050	247	5	dth.14504	dth.14504	PROPN
dpc-4050	247	6	.	.	PUNCT
dpc-4050	248	1	epub	epub	NOUN
dpc-4050	248	2	2020	2020	NUM
dpc-4050	248	3	nov	nov	PROPN
dpc-4050	248	4	10	10	NUM
dpc-4050	248	5	.	.	PUNCT
dpc-4050	249	1	pmid	pmid	NOUN
dpc-4050	249	2	:	:	PUNCT
dpc-4050	249	3	 	 	SPACE
dpc-4050	249	4	33141505	33141505	NUM
dpc-4050	249	5	7	7	NUM
dpc-4050	249	6	.	.	PUNCT
dpc-4050	250	1	lanna	lanna	PROPN
dpc-4050	250	2	c	c	PROPN
dpc-4050	250	3	,	,	PUNCT
dpc-4050	250	4	lambiase	lambiase	PROPN
dpc-4050	250	5	s	s	PROPN
dpc-4050	250	6	,	,	PUNCT
dpc-4050	250	7	gaeta	gaeta	PROPN
dpc-4050	250	8	shumak	shumak	PROPN
dpc-4050	250	9	r	r	PROPN
dpc-4050	250	10	,	,	PUNCT
dpc-4050	250	11	et	et	PROPN
dpc-4050	250	12	al	al	PROPN
dpc-4050	250	13	.	.	PUNCT
dpc-4050	251	1	why	why	SCONJ
dpc-4050	251	2	targeted	targeted	ADJ
dpc-4050	251	3	therapeutics	therapeutic	NOUN
dpc-4050	251	4	have	have	AUX
dpc-4050	251	5	provided	provide	VERB
dpc-4050	251	6	benefit	benefit	NOUN
dpc-4050	251	7	in	in	ADP
dpc-4050	251	8	psoriasis	psoriasis	NOUN
dpc-4050	251	9	:	:	PUNCT
dpc-4050	251	10	looking	look	VERB
dpc-4050	251	11	at	at	ADP
dpc-4050	251	12	il-17	il-17	NUM
dpc-4050	251	13	biology	biology	NOUN
dpc-4050	251	14	.	.	PUNCT
dpc-4050	252	1	expert	expert	NOUN
dpc-4050	252	2	rev	rev	PROPN
dpc-4050	252	3	clin	clin	PROPN
dpc-4050	252	4	pharmacol	pharmacol	PROPN
dpc-4050	252	5	.	.	PUNCT
dpc-4050	253	1	2022	2022	NUM
dpc-4050	253	2	oct;15(10	oct;15(10	NOUN
dpc-4050	253	3	):	):	PUNCT
dpc-4050	253	4	1209	1209	NUM
dpc-4050	253	5	-	-	SYM
dpc-4050	253	6	1224	1224	NUM
dpc-4050	253	7	.	.	PUNCT
dpc-4050	254	1	doi	doi	NOUN
dpc-4050	254	2	:	:	PUNCT
dpc-4050	254	3	10.1080/17512433.2022.2130758	10.1080/17512433.2022.2130758	NUM
dpc-4050	254	4	.	.	PUNCT
dpc-4050	255	1	epub	epub	VERB
dpc-4050	255	2	2022	2022	NUM
dpc-4050	255	3	oct	oct	NOUN
dpc-4050	255	4	8	8	NUM
dpc-4050	255	5	.	.	NOUN
dpc-4050	255	6	8	8	NUM
dpc-4050	255	7	.	.	PUNCT
dpc-4050	255	8	brembilla	brembilla	PROPN
dpc-4050	255	9	nc	nc	PROPN
dpc-4050	255	10	,	,	PUNCT
dpc-4050	255	11	boehncke	boehncke	PROPN
dpc-4050	255	12	wh	wh	VERB
dpc-4050	255	13	.	.	PUNCT
dpc-4050	256	1	revisiting	revisit	VERB
dpc-4050	256	2	the	the	DET
dpc-4050	256	3	interleukin	interleukin	NOUN
dpc-4050	256	4	17	17	NUM
dpc-4050	256	5	family	family	NOUN
dpc-4050	256	6	of	of	ADP
dpc-4050	256	7	cytokines	cytokine	NOUN
dpc-4050	256	8	in	in	ADP
dpc-4050	256	9	psoriasis	psoriasis	NOUN
dpc-4050	256	10	:	:	PUNCT
dpc-4050	256	11	pathogenesis	pathogenesis	NOUN
dpc-4050	256	12	and	and	CCONJ
dpc-4050	256	13	potential	potential	ADJ
dpc-4050	256	14	targets	target	NOUN
dpc-4050	256	15	for	for	ADP
dpc-4050	256	16	innovative	innovative	ADJ
dpc-4050	256	17	therapies	therapy	NOUN
dpc-4050	256	18	.	.	PUNCT
dpc-4050	257	1	front	front	ADJ
dpc-4050	257	2	immunol	immunol	NOUN
dpc-4050	257	3	.	.	PUNCT
dpc-4050	258	1	2023	2023	NUM
dpc-4050	258	2	may	may	AUX
dpc-4050	258	3	22	22	NUM
dpc-4050	258	4	;	;	PUNCT
dpc-4050	258	5	14:1186455	14:1186455	NUM
dpc-4050	258	6	.	.	PUNCT
dpc-4050	259	1	doi	doi	NOUN
dpc-4050	259	2	:	:	PUNCT
dpc-4050	259	3	10.3389	10.3389	NUM
dpc-4050	259	4	/	/	SYM
dpc-4050	259	5	fimmu.2023.1186455	fimmu.2023.1186455	PROPN
dpc-4050	259	6	.	.	PUNCT
dpc-4050	259	7	ecollection	ecollection	NOUN
dpc-4050	259	8	2023	2023	NUM
dpc-4050	259	9	.	.	PUNCT
dpc-4050	260	1	pmid	pmid	NOUN
dpc-4050	260	2	:	:	PUNCT
dpc-4050	260	3	37283755	37283755	NUM
dpc-4050	260	4	9	9	NUM
dpc-4050	260	5	.	.	PUNCT
dpc-4050	261	1	menter	menter	PROPN
dpc-4050	261	2	a	a	PROPN
dpc-4050	261	3	,	,	PUNCT
dpc-4050	261	4	warren	warren	PROPN
dpc-4050	261	5	rb	rb	PROPN
dpc-4050	261	6	,	,	PUNCT
dpc-4050	261	7	langley	langley	PROPN
dpc-4050	261	8	rg	rg	PROPN
dpc-4050	261	9	,	,	PUNCT
dpc-4050	261	10	et	et	PROPN
dpc-4050	261	11	al	al	PROPN
dpc-4050	261	12	.	.	PROPN
dpc-4050	262	1	j	j	PROPN
dpc-4050	262	2	eur	eur	PROPN
dpc-4050	262	3	acad	acad	PROPN
dpc-4050	262	4	dermatol	dermatol	NOUN
dpc-4050	262	5	venereol	venereol	NOUN
dpc-4050	262	6	.	.	PUNCT
dpc-4050	263	1	2017	2017	NUM
dpc-4050	263	2	oct;31(10):1686	oct;31(10):1686	NOUN
dpc-4050	263	3	-	-	SYM
dpc-4050	263	4	1692	1692	NUM
dpc-4050	263	5	.	.	PUNCT
dpc-4050	264	1	doi	doi	NOUN
dpc-4050	264	2	:	:	PUNCT
dpc-4050	264	3	10.1111/	10.1111/	NUM
dpc-4050	264	4	jdv.14237	jdv.14237	NUM
dpc-4050	264	5	.	.	PUNCT
dpc-4050	265	1	epub	epub	PROPN
dpc-4050	265	2	2017	2017	NUM
dpc-4050	265	3	apr	apr	NOUN
dpc-4050	265	4	26	26	NUM
dpc-4050	265	5	.	.	PUNCT
dpc-4050	266	1	pmid	pmid	NOUN
dpc-4050	266	2	:	:	PUNCT
dpc-4050	266	3	28322474	28322474	NUM
dpc-4050	266	4	.	.	PUNCT
dpc-4050	267	1	efficacy	efficacy	NOUN
dpc-4050	267	2	of	of	ADP